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4. ABSTRACT 
 
Colicins are a family of bacterial toxins, which kill Escherichia coli cells and other 
closely related species.  Their mode of action requires binding to an outer membrane 
receptor, translocation across the outer membrane and periplasm and cytotoxic action 
on a specific target.  Colicins usually kill cells either by attacking the bacterial RNA 
or DNA or by forming pores in the inner membrane of the cell.   Their cytotoxic 
activity can be inhibited by the high affinity binding of an immunity protein.   
For Group A colicins, translocation requires interaction between the N-terminal 
domain of the colicin and a series of membrane bound and periplasmic proteins called 
the Tol system (TolB, TolR, TolA, TolQ and Pal).   
 
Three residues of colicin E9 have previously been shown to be essential for an 
interaction with TolB.  This study suggests that these residues play differing roles in 
the interaction with TolB.  Other residues surrounding these previously identified 
residues are also shown to be involved in the interaction with TolB.   
 
In order to allow cytotoxicity, the immunity protein of colicins E3 and E9 must be lost 
on entry of the colicin to a target cell.  This work has demonstrated by Surface 
Plasmon Resonance and Atomic Force Microscopy that the affinity of colicins E3 and 
E9 for TolB is increased when the immunity protein is removed.  This observation has 
implications for the mechanism by which the immunity protein dissociates from the 
colicin.   
 
Finally this study has used Surface Plasmon Resonance to explore differences 
between pore-forming and enzymatic colicins in their interactions with Tol proteins.  
Although the pore-former colicin A interacts with TolR, TolA and TolB, the 
endonuclease colicins E3 and E9 were shown only to interact with TolB.  This 
suggests that pore-forming and endonuclease colicins use the Tol system in different 
ways in order to translocate across the periplasm.   
 
 1 
1. CHAPTER 1 - Introduction 
1.1. Discovery of colicins 
In 1925, the Belgian microbiologist, André Gratia, observed that certain strains of 
bacteria secrete proteins into the extracellular medium, killing non-producing strains 
(Gratia 1925).  These protein antibiotics (or bacteriocins) are now known as colicins 
when produced by Escherichia coli and Shigella and are active against strains of 
Escherichia coli and closely related species.   Over 20 colicins have now been 
identified (Pugsley 1984, Riley and Gordon 1992), ranging in size from 385 (Colicin 
N) to 626 (Colicin Ia) amino acids (Pugsley 1987, Wiener et al 1997).  Four 
mechanisms of colicin cytotoxicity have been identified: 
1. Formation of an ion-permeable channel in the inner membrane of the bacteria 
2. Non-specific degradation of cellular DNA 
3. Degradation of 16S rRNA or tRNA, inhibiting protein synthesis 
4. Inhibition of peptidoglycan synthesis.   
Colicins exert their effect through a one-hit mechanism at concentrations lower than 
0.1 nM, indicating that a single colicin molecule can kill a cell (Cramer et al 1983).   
1.2. Col plasmids 
Colicins are encoded on plasmids and these colicin-encoding plasmids can be divided 
into two groups ie small (~6 kb), high-copy-number plasmids, eg ColE1, or large 
(~150 kb), conjugative plasmids, eg ColB (Riley and Gordon 1992).  Col plasmids are 
found in approximately 30% of naturally occurring populations of Escherichia coli 
(Pugsley 1984, Riley and Gordon 1992) and provide host cells with the means to 
manipulate their environment and maximise their competitive advantage over other 
microbial populations.  Col plasmids contain the colicin structural gene (cxa, where x 
is the specific colicin eg caa encodes ColA), encoding the colicin protein; and a 
specific immunity gene (imm), encoding the immunity protein, which protects host 
cells against the cytotoxic activity of the colicin.  Except for colicin Ia, Ib, B and M, 
the colicin region contains a third gene, the lysis gene (kil), encoding the Bacteriocin 
Release Protein (BRP), to allow release of the colicin from the cell (van der Wal et al 
1995).   
 2 
The arrangement of colicin operons depends on the function of the encoded colicin 
(see Figure 1.1, Cavard and Oudega 1992).   The lysis gene for pore-forming colicins 
is separated from the structural gene by a large intercistronic region of approximately 
550 bp, containing the gene encoding the immunity protein on the opposite strand, 
which is therefore transcribed in the opposite direction (Lloubes et al 1996).  A 
transcription terminator (T1) is located immediately after the colicin structural gene 
and the immunity gene (see Figure 1.1).  For nuclease colicins, however, the lysis 
gene is located a few base pairs away from the immunity gene, with a transcription 
terminator (T1) located just after the immunity gene (Cavard and Oudega 1992, Chak 
and James 1985, James et al, 1996).   
 
Figure 1.1 Gene organisation in colicin operons.  The immunity gene is located between the 
colicin structural gene and the lysis gene and, for pore-forming colicins, is transcribed in the 
opposite direction.   T1 and T2 indicate the position of transcription terminator sites.   
 
1.3. Colicin expression 
Under normal conditions, colicins are only produced at a basal level due to expression 
of the structural gene (cxa) in only a small fraction of cells (Salles et al 1987).  The 
expression of colicins is induced during the SOS response (see Figure 1.2).  In most 
cells the LexA protein, a repressor of the SOS response genes of the cell (Witkin 
1976), represses transcription of cxa and the lysis gene (kil), although the immunity 
gene (imm) is continually expressed at low levels.  Footprinting experiments showed 
that LexA binds tightly (apparent Kd = 0.4 nM) to a 40 bp sequence containing two 
overlapping SOS boxes between the Pribnow box and the start codon of the cea gene 
(Ebina et al 1983a, Lu and Chak 1996).  Induction of the DNA-damage inducible SOS 
promoter, located proximal to cxa, results in cleavage of LexA by the RecA protease 
Pore-forming colicins 
Nuclease colicins 
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(Little et al 1980).  This allows enhanced expression of cxa and kil genes.  Expression 
of cea, the gene encoding colicin E1, occurs 20-30 minutes after induction of the SOS 
response (Salles et al 1987).  This lag time is not seen for other SOS response genes 
and could be due to the presence of two SOS boxes upstream of the start codon of the 
cea gene, allowing LexA to cooperatively bind to this regulatory region or the 
requirement for accumulation of an SOS-controlled factor in the cell before cea can 
be expressed (Salles et al 1987).   The delay could allow the cells to repair low levels 
of DNA damage without being killed.   
In addition to regulation by the SOS response, the expression of cea and kil genes is 
also regulated by catabolite repression, which is dependent on cAMP and the cAMP 
binding protein (CRP) (Ebina et al 1983b).  Transcription of cea is stimulated when 
cAMP and CRP are present and there are two binding sites for the cAMP-CRP 
complex near the cea promoter, although only one of these sites has been shown to be 
involved in the control of cea (Shirabe et al 1985, Salles and Weinstock 1989).  
Catabolite repression increases the delay in expression of cea following DNA 
damage, suggesting a potential role of the cAMP-CRP complex in removing tightly 
bound LexA from the cea regulatory region, making the promoter more accessible to 
RNA polymerase (Salles et al 1987).  Alternatively, the binding of CRP to the 
promoter region could affect the secondary structure of the DNA (Salles and 
Weinstock 1989).   
 
Figure 1.2  Production and release of endonuclease colicin proteins 
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1.4. Colicin Release 
Colicins are unlike other groups of proteins that are released into the extracellular 
medium by Gram-negative bacteria for several reasons.  Firstly they do not contain an 
N-terminal or internal signal sequence and their release relies on the expression of a 
single gene (encoding BRP).  They are also exported late after synthesis and are non-
specifically released with a subset of cytoplasmic and periplasmic proteins during a 
quasi-lysis state, causing cell death (Cavard and Oudega 1992, Suit and Luria, 1988).   
1.4.1. Bacteriocin Release Proteins 
BRPs are similar in nucleotide and amino acid sequences (Riley 1993, van der Wal 
1995) and are functionally interchangeable, shown by the secretion of colicin E2 by 
simultaneous expression of colicin E1, E3, E7, A or D gene clusters (Pugsley and 
Schwarz 1983), suggesting a common mode of action for the different BRPs.  
Therefore, although most of the work on BRPs has been concentrated on BRPs from 
colicin E1, A and cloacin DF13 (a bacteriocin from Klebsiella pneumoniae, closely 
related to colicins), it is reasonable to assume that BRPs from other colicins will 
function in a similar way.   
When the colicin operon is induced, a decrease in culture turbidity is observed, 
characteristic of the quasi-lysis state.  This decrease in turbidity, is caused by the 
activity of the BRP and its stable signal peptide (van der Wal et al 1995).     
BRPs are synthesised as precursor polypeptides, containing a signal sequence for the 
periplasm with a Leu-X-Y-Cys sequence around the signal peptide cleavage site, 
where X is Ala, Val or Ser and Y is Ala or Gly (Cavard et al 1992).  The cysteine in 
this sequence is acylated, before the precursor protein is processed by signal peptidase 
II, producing a stable signal peptide and the BRP of approximately 30 amino acids.  
The amino group of the acylated cysteine residue of the BRP is then modified by a 
fatty acid residue (Cavard et al 1987, Cavard et al 1992).   The mature lipoproteins, 
are predominantly localised in the outer membrane, with the exception of colicin N, 
where the BRP is localised only in the outer membrane (Pugsley, 1988).   
1.4.2. Activation of outer-membrane phospholipase A 
BRPs have been shown to activate phospholipase A of the outer membrane (Cavard et 
al 1987, Pugsley and Schwartz 1984) by dimerisation (Snijder et al 1999, Dekker et al 
1999).  Changes in phospholipid content release were measured and the major 
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changes were a decrease in phosphatidylethanolamine (PE) and an increase in 
lysophosphatidylethanolamine (lysoPE) and free fatty acid content, indicative of the 
action of a phospholipase (Pugsley and Schwartz 1984).  Cells containing a mutation 
in the pldAI  gene, encoding phospholipase A, were shown to be much less proficient 
at release of both colicins E1 and A and also showed no quasi-lysis (Pugsley and 
Schwartz 1984, Cavard et al 1987).  Therefore, both BRP and phospholipase A seem 
to be necessary for efficient colicin release.  However, it has been observed that in 
pldA1 mutants, the BRP is degraded by the DegP protease (Cavard et al 1989) and 
therefore, the BRP may not reach sufficient levels to enable colicin release and lysis, 
which could mean that the lack of colicin release in these mutants is an artefact.  
Colicin A has also been shown to affect the integrity of the outer membrane, 
independently of phospholipase A (Howard et al 1991).   
1.4.3. Mechanism of colicin release 
Several mechanisms for how the BRP causes release of colicins into the extracellular 
medium have been suggested.   
The first model proposes that activation of the phospholipase by BRP may cause 
changes in the lipid composition of the outer membrane to enable leakage of the 
colicin and other proteins into the extracellular medium.  The BRP itself would 
therefore be involved in transferring the colicin across the inner membrane and 
activating phospholipase A (Pugsley and Schwartz 1984).   
An alternative model has been proposed, involving the stable signal peptide produced 
by cleavage of the immature BRP by signal peptidase II (Luirink et al 1986, Luirink 
et al 1991).  The signal peptide has been shown to be stable and disrupt the 
cytoplasmic membrane (Cavard 1997, van der Wal et al 1995, Luirink et al 1991).  
The BRP of cloacin DF13, with its signal peptide replaced with the signal sequence of 
the murein-lipoprotein, was unable to release the cloacin but still caused lysis (Luirink 
et al 1991), indicating that the signal peptide plays a significant role in the release of 
colicins.  Thin section electron micrographs show that colicins accumulate 
exclusively in the cytoplasm (Cavard et al 1981, Luirink et al 1991), indicating that 
colicins move in a one-step process from the cytoplasm to the extracellular medium.  
Therefore it has been proposed that the BRP, the stable signal peptide and 
phospholipase A co-operate to form trans-envelope pores through which the colicin 
and other proteins would pass (Luirink et al 1991, Cavard and Oudega 1992, van der 
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Wal et al 1995).  Recent work with high molecular-mass forms of colicin A in cells 
with a BRP gene deletion, showed that colicin A appeared to be able to reach the 
outer membrane without the help of BRP.  Colicin A was shown to interact with 
phospholipase A in the outer membrane.  Phospholipase A forms a 12-stranded β-
barrel, which spans the membrane (Snijder et al 1999), and therefore it is possible that 
phospholipase A may facilitate transport of colicin A across the outer membrane, with 
the help of BRP (Cavard 2002).   
Colicins Ia, Ib, B and M appear to have no lysis-like protein and as yet it is unclear 
how these colicins are released from the cell (Riley 1993, Thum 1988).   
1.5. Immunity proteins 
Cells that produce a specific colicin are immune to the action of the colicin they 
produce (Fredericq 1957).  This immunity is conferred by an immunity protein, the 
product of the imm gene. 
1.5.1. Expression of the imm gene 
Most Col plasmids contain a single imm gene, under the control of constitutive 
promoters within the 3’ end of the colicin gene (Soong et al 1994).  However, three 
colicins have been identified that have more than one immunity gene.  Colicins E3 
and E6 contain a second imm gene 5’ to the kil gene, encoding an immunity protein 
with sequence similarity to the colicin E8 immunity protein (Im8) (Chak and James 
1984).  Both immunity proteins have their own promoters, independent of the colicin 
structural gene (Chak and James 1985) and are therefore constitutively expressed 
under normal conditions.  The colicin E9 plasmid also has a second imm gene, similar 
to the sequence of Im5 (James et al 1987).     
In pore-forming colicin operons, the imm gene is present in the reverse orientation to 
the kil and cxa genes.  This potentially provides several advantages (Zhang et al 
1988).  Firstly, the imm gene can be constitutively expressed, without the 
simultaneous expression of the kil gene, preventing the deleterious effects of 
expression of BRP under normal conditions and protecting the cell from any 
exogenous colicin produced by the same strain.  Western blot analysis has 
demonstrated that under normal conditions the amount of Im7 is at least 20 times 
greater than the amount of colicin E7 and BRP (Hsieh et al 1997).  Therefore, there is 
more than enough immunity protein available to protect cells from exogenous or 
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endogenous colicin, produced by basal level expression of the colicin operon.  
Secondly, the imm RNA inhibits transcription of the kil gene and therefore 
transcription of the imm gene allows transcription of the kil gene to be delayed whilst 
large amounts of colicin structural protein are produced, before protein synthesis is 
inhibited by the BRP.  It may also allow inhibition of colicin synthesis, during periods 
of derepression eg during plasmid replication.   
1.5.2. Putative RNase activity of immunity proteins 
Studies with Im7 have suggested a role for the dimeric form of Im7 in controlling 
translational expression of the ColE7 operon by exerting a specific RNase activity 
(Hsieh et al 1997, Chang et al 2002).  The putative active site for this RNase activity 
is at the interface of the two Im7 molecules.  If induction of the SOS response 
promoter only lasts for a short time, Im7 could keep the level of translation of the 
BRP below toxic levels, by cleaving the RNA within the imm RNA, leading to 
uncoupling of translational expression of the kil gene.  However, if the SOS response 
induction lasts for 100 minutes, the amount of dimeric Im7 would not be sufficient to 
cleave the significantly increased numbers of transcripts and would be unable to keep 
the translation of the BRP below the lethal dose, causing quasi-lysis (Chang et al 
2002).  Therefore the lag time, observed after induction of the SOS response, could 
reflect the time taken for the colicin mRNA to overpower the RNase activity of the 
dimeric immunity protein.  However, analytical ultracentrifugation experiments 
demonstrated that Im7 only ever exists as a monomer (Dennis et al 1998) and 
therefore the functional significance of the dimeric form of Im7 observed in the 
crystallography is questionable.   
1.5.3. Sequences of immunity genes 
Immunity proteins are more variable in sequence than the kil and cxa structural genes.  
Many immunity proteins show no detectable sequence similarity.  However, E2, E8 
and E9 immunity sequences are similar at 54-97 % of their residues (Riley 1993).   
Immunity proteins have a high affinity for the C-terminus of the colicin protein, 
although the mechanism of action of the immunity protein is dependent on the 
cytotoxic activity of the colicin.   
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1.5.4. Immunity proteins for endonuclease colicins 
Before release into the extracellular medium, endonuclease colicins form a complex 
with a specific immunity protein, which neutralises the activity of the colicin.   
The immunity protein must be lost on entering a target cell but how and where this 
occurs is as yet uncertain.  Free colicin E9 has the same bactericidal activity as colicin 
E9 bound to Im9 (Schaller and Nomura 1976, Wallis et al 1992a) and it would 
therefore appear that the immunity protein is not required for receptor binding or 
translocation of colicin E9.  However, removal of Im3 from colicin E3 leads to 
substantial loss of bactericidal activity indicating that, in addition to providing 
immunity to colicin E3 producing cells, Im3 may also stabilise colicin E3 on entering 
susceptible cells (Walker et al 2003).   
1.5.4.1. Affinity of colicin-immunity protein interactions 
The requirement for denaturation to separate the immunity protein from the 
endonuclease domain of a colicin, first indicated that the interaction between the two 
proteins must be strong (Jakes and Zinder 1974, Schaller and Nomura 1976).  This 
was substantiated when it was shown that the equilibrium dissociation constant (Kd) 
for the colicin E9-Im9 complex was 9.3 x 10-17 M in conditions of low ionic strength 
(Wallis et al 1995a).  This is one of the highest affinity protein-protein interactions 
known.  The Kd for the interaction between the DNase domain of colicin E9 and Im9 
was found to be 7.2 x 10-17 M, a value very similar to that for the full-length colicin 
and therefore it is assumed that the immunity protein only makes energetically 
important contacts with the DNase domain of the colicin (Wallis et al 1995a).    This 
is supported by NMR studies which show a lack of chemical shift perturbation of the 
translocation domain when Im9 is added to colicin E9 (Collins et al 2002).  However, 
the interaction between full-length colicin E3 and Im3 is stronger than the interaction 
between the RNase domain of colicin E3 and Im3 (Kd = 10-14 M and 10-12 M 
respectively) (Walker et al 2003).  The crystal structure of the full-length colicin E3-
Im3 complex shows that the increased affinity of the full-length colicin E3 for Im3 is 
due to an interaction of Im3 with the N-terminal translocation domain of the colicin 
(Soelaiman et al 2001). 
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1.5.4.2. Kinetics of the colicin-immunity protein complex 
Formation of the colicin E9-Im9 complex was shown, by stopped flow fluorescence, 
to proceed by a two-step process (Wallis et al 1995a).  The initial rate of association 
(k1) was shown to be 4 x 109 M-1s-1 in buffer of low ionic strength and hence the 
association is essentially diffusion-controlled.  This rate of association is comparable 
to the rate of association observed for the colicin E3 rRNase domain and Im3         
(108 M-1s-1, Walker et al 2003).   
The first step in the association between colicin and immunity protein is highly 
dependent on salt concentration, consistent with the highly acidic nature of the 
immunity protein (pI ~4.5) and the highly basic nature of the endonuclease domain of 
the colicin (pI >10.5).  Therefore, electrostatic interactions probably pre-orient the 
two proteins before collision, minimising the time for effective complex formation to 
occur (Wallis et al 1995a, Kleanthous et al 1998, Walker et al 2003, Li et al 2004).   
The second step in the association between colicin E9 and Im9 involves a relatively 
slow (6.8 s-1) conformational change in the DNase domain of the colicin (Wallis et al 
1995a).     
The dissociation rate constant (koff) has been estimated, by radioactive exchange 
kinetics, to be 3.7 x 10-7 s-1.  This is inconsistent with the kinetics of colicin action, as 
colicins start to kill cells within minutes, and therefore the dissociation rate for the 
colicin-immunity protein complex must be increased by at least four orders of 
magnitude on entering a susceptible cell (Kleanthous et al 1998).  The immunity 
protein of the RNase toxin, cloacin DF13, active against Enterobacter cloacae, 
Klebsiella edwardsii  and E. coli, has been shown by immunological detection to be 
released into the culture medium on binding of the cloacin to its receptor (Krone et al 
1986).  Therefore it has been suggested that the magnitude of the interaction between 
the colicin and its immunity protein may be overcome by partial or complete 
unfolding of the colicin on binding to its receptor (Wallis et al 1995a).  An alternative 
mechanism has been proposed for the dissociation of Im3 from colicin E3 (Walker et 
al 2003).  In this mechanism receptor binding would trigger translocation of the N-
terminal translocation domain of the colicin into the periplasm.  The interaction 
between the translocation domain and TolB would cause contacts between the 
translocation domain of the colicin and Im3 to be lost, weakening the colicin E3-Im3 
interaction and increasing the dissociation of the immunity protein from the colicin.   
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The association and dissociation kinetics for the colicin E2-Im2 interaction are very 
similar to those of the colicin E9-Im9 interaction indicating that high affinity binding 
is a common feature of colicin-immunity protein complexes (Li et al 2004).   
1.5.4.3. Structures of immunity protein-colicin complexes 
Determination of structures for three colicin endonuclease domains bound to their 
corresponding immunity proteins has provided insights into how immunity proteins 
protect bacteria from the cytotoxic activity of endonuclease colicins.  The structures 
of the DNase domain of colicins E7 in complex with Im7 (at 2.3 Ǻ resolution, Ko et 
al 1999) and E9 in complex with Im9 (at 2.05 Ǻ and 1.7 Ǻ resolution, Kleanthous et 
al 1999, Kühlmann et al 2000) have been determined as well as the structure of the 
RNase domain of colicin E3 in complex with Im3 (at 2.4 Ǻ resolution, Carr et al 
2000b).  The structure of full-length colicin E3 in complex with Im3 has also been 
determined (Soelaiman et al 2001) and the structure of the RNase domain in this full-
length structure is very similar to the isolated RNase domain.  Structural comparison 
of the RNase and DNase domains reveals few similarities, the DNase domains are αβ 
proteins (Ko et al 1999, Kleanthous et al 1999) whereas the RNase domain is 
composed predominantly of β sheet (Carr et al 2000b, Soelaiman et al 2001).  The 
immunity proteins for the RNase and DNase domains are also structurally unrelated.  
The DNase immunity proteins are distorted four-helix bundles (Osborne et al 1996, 
Chak et al 1996) and the rRNase immunity proteins are predominantly β sheet 
proteins (Li et al 1999).  A property that is shared between the DNase and RNase 
complexes however, is the charge complementarity resulting from the basic nature of 
the endonuclease domain and the acidic nature of the immunity protein.   
The colicin E9 DNase-Im9 complex shows that the complex consists of a 
hydrophobic core, formed mainly by aromatic residues from the DNase and Im9. 
Multiple hydrogen bonds and salt bridges surround this core.  The structure of the 
DNase domain of colicin E7 in complex with Im7 show that there are 2.17 hydrogen 
bonds per 100 Å2 formed between colicin E7 and Im7, substantially more than the 
average calculated for enzyme-inhibitor complexes (1.37 hydrogen bonds per 100 Å2, 
Jones and Thornton 1996).  This, in conjunction with the fact that many of the 
hydrogen bonds involve charged donor and acceptor groups, is likely to contribute to 
the high affinity of the interaction (Ko et al 1999).   
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The structure of the colicin E3 RNase-Im3 complex shows that an N-terminal helix of 
the RNase domain wraps around the exposed face of the four-stranded β-sheet of Im3 
(Kolade et al 2002).  There is a much greater loss of surface area on binding of the 
colicin E3 RNase domain to Im3 compared to binding of colicin E9 or E7 DNase 
domains to their respective immunity proteins (2554 Å 2 compared to 1575 Å 2 and 
1473 Å 2 respectively).  There is a high degree of surface complementarity, which 
may contribute to the high affinity of the interaction (Kolade et al 2002).  This high 
degree of surface complementarity is indicative of a conformational change on 
formation of the RNase domain-immunity protein complex but so far no structure of 
the free RNase is available to confirm this.   
1.5.4.4. Mechanism of inhibition 
Unlike many enzyme inhibitors, the immunity protein does not bind directly at the 
active site (Kleanthous et al 1999, Kühlmann et al 2000).  The structure of the DNase 
domain of colicin E9 in complex with Im9, shows that Im9 binds in a cleft on the 
DNase domain, formed by a short helix, an extended strand and two loops spanning 
residues 72-98, adjacent to the active site (Kühlmann et al 2000).   
Two mechanisms of inhibition by endonuclease immunity proteins have been put 
forward based on structural and functional studies (Kleanthous and Walker 2001).  
Firstly, the immunity protein could cause conformational changes in the protein 
backbone of the endonuclease domain causing allosteric inhibition.  Secondly, the 
immunity protein could sterically hinder the nucleic acid binding site.   
Steric hindrance 
There are now several pieces of evidence suggesting that the immunity protein 
hinders the nucleic acid binding site.   
Docking of the active site of colicin E3 onto the cleavage site on 16S RNA, within the 
30S ribosomal subunit, indicates that, although the immunity protein does not 
sterically hinder the approach of the endonuclease domain to the ribosome, many 
negatively charged residues of the immunity protein point towards the 30S rRNA 
backbone, resulting in strong electrostatic repulsion (Zarivach et al 2002).   
Modelling of B-form DNA into the active site of the DNase domain of colicin E9 
show that the N-terminal end of helix II and the adjoining loop of Im9 forms an 
“electrostatic elbow”, which could hinder access of the DNA to the DNase domain by 
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steric and electrostatic repulsion, approximately one helical turn from the active site 
(Kleanthous et al 1999).  The crystal structure of an inactive mutant of the colicin E9 
DNase domain (H575A) in complex with a short single stranded DNA ligand, 
indicates that the immunity protein sequesters residues critical to the binding of an 
extended DNA substrate (Kolade et al 2002).  Residues D499 and D502 interact with 
a purine ring in the DNA and Y531 forms a hydrogen bond with a phosphate group of 
the DNA.  These residues are all involved in direct interactions with Im9 in the colicin 
E9 DNase-Im9 complex.   
These observations are consistent with the second model of inhibition ie steric 
hindrance and this is supported by the fact that the structure of unbound colicin E9 
and E7 DNase domains are very similar to the structures of the respective colicin 
DNase-Im complexes, indicating that the structure of the DNase domain is unaltered 
by the binding of the immunity protein, arguing against allosteric inhibition (Cheng et 
al 2002, Kolade et al 2002).   
Allosteric inhibition 
However, NMR has shown the existence of at least two conformational states of 
unbound colicin E9 that interconvert slowly (Whittaker et al 1998).  The rate of 
conversion is comparable to the conformational change in the DNase domain of 
colicin E9 on binding of Im9 seen in stopped-flow fluorescence experiments (Wallis 
et al 1995a, van den Bremer et al 2004).  These observations suggest that Im9 could 
stabilise an inactive conformation of colicin E9, acting as an allosteric inhibitor.   
1.5.4.5. Specificity of immunity proteins 
The structure of the DNase domain of colicin E9 bound to Im9 shows that residues 
23-56, ie helix II and helix III, of Im9 are involved in binding to the DNase domain 
(Kühlmann et al 2000).  The use of Im8 and Im9 gene fusions allowed the specificity-
determining region of Im9 to be localised to residues 16-43 (Wallis et al 1992 b).  The 
structure of Im9, determined by NMR shows that these residues encompass helix I 
and helix II of a four-helix bundle (Osborne et al 1996).   
When helix II of Im2 is replaced with helix II of Im9, the chimeric immunity protein 
binds almost as tightly to the colicin E9 DNase domain as wild-type Im9, indicating 
that helix II is the main specificity-determinant of Im9 (Li et al 1997).  The difference 
in binding affinity is due to internal packing interactions between helix I and helix II 
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of Im9.  A similar observation was made when helix II of Im7 was replaced with the 
corresponding helix of Im8 (Lu et al 1999).  The mutated Im7 then provided cells 
with partial immunity to colicin E8.   
Five residues out of fifteen vary between helix II of Im2 and helix II of Im9.  These 
five variable residues in Im2 were mutated to the corresponding residue in Im9 in turn 
and the mutants were assayed for biological activity towards colicin E2 and colicin E9 
(Li et al 1998).  Three residues in helix II of Im2 cause a change in specificity, D33, 
N34 and R38.  N34 had also been recognised as an important specificity determinant 
by mutagenesis of residues in Im9 to the corresponding residue in Im8 (Wallis et al 
1992b).  When all three of these residues in Im2 are mutated to the corresponding 
residues in Im9, the mutant immunity protein behaves exactly the same as Im9, 
indicating that the specificity of Im2 and Im9 for colicin E9 is controlled by these 
three residues alone, with residue D33 playing the most significant role (Li et al 
1998).   Unlike Im9 where several residues appear to be contributing to specificity, 
only residue D33 makes a major contribution to specificity in Im2 (Li et al 2004).  It 
has been speculated that this residue may form a salt bridge with a basic residue in the 
colicin E2 DNase domain (Li et al 2004).   
Site directed mutagenesis has identified residues D31, D35 and E39, in the loop 1-
helix II region as specificity determining residues in Im7, and D31 is the most critical 
of the three residues (Lu et al 1999).  A sequence alignment shows that in Im2, Im7, 
Im8 and Im9, residue 31 is a negatively charged residue, which may play an important 
role in an electrostatic or steric interaction (Lu et al 1999).  Loop 1 in Im7 contains an 
insertion of one residue to Im9 (Dennis et al 1998), therefore residues D35 and E39 in 
Im7 correspond to residues N34 and R38 in Im9.  It would therefore seem that the 
equivalent residues in Im7 and Im9 are important in determining specificity.   
1.5.4.6. Dual recognition 
Alanine scanning mutagenesis and stopped flow fluorescence has shown that 
approximately two thirds of the colicin E9 DNase and colicin E2 DNase binding free 
energy is derived from five conserved residues of helix III of the immunity protein 
(Wallis et al 1998, Li et al 2004).  Helix II residues provide approximately one third 
of the binding energy (Wallis et al 1998).  Therefore, the conserved residues of helix 
III are the main contributors to the binding energy and the variable residues of helix II 
govern specificity as well as making a small contribution to binding energy (Wallis et 
 14 
al 1998).  On the basis of this data, a dual recognition model has been proposed.  In 
this model, if helix II of the immunity protein is able to make favourable interactions 
ie with its cognate colicin, then helix III of the immunity protein interacts with the 
colicin to allow maximal binding.  However, if the interactions of helix II with the 
colicin are wrong, the residues of this helix do not dock properly and the colicin-
immunity protein interaction is much weaker (Kleanthous et al 1998).  For example, 
if a non-cognate immunity protein binds to the colicin E9 DNase, despite the 
conserved residues of helix III docking onto the DNase, insertion of hydrophilic 
residues from helix II into inappropriate hydrophobic binding sites, could destabilise 
the complex (Kleanthous et al 1998). 
The structures of Im7 and Im9 and the E9 DNase-Im9 and E7 DNase-Im7 complexes 
have provided a molecular rationale for the dual-recognition mechanism 
Comparison of the crystal structure of Im7 with the NMR structure of Im9 (Osborne 
et al 1996, Dennis et al 1998, Chak et al 1996) shows that although both proteins 
adopt similar four-helix bundle structures, there are subtle structural differences, the 
most significant being the position of a tyrosine residue (Y56 in Im7 and Y55 in Im9) 
in helix III (Dennis et al 1998).  In Im9, the residue extends into the solvent, whereas 
in Im7 it folds back onto the helix.   
Structural superposition of the crystal structure of Im7 bound to the colicin E7 DNase 
domain and the structure of Im9 bound to the colicin E9 DNase domain shows that 
the immunity proteins are displaced relative to one another due to a 19º rigid-body 
rotation (Kühlmann et al 2000).  The axis for this rotation is formed by two tyrosine 
residues, Y54 and Y55 in Im9 (see Figure 1.3).  The rotation does not significantly 
alter the position of the tyrosine residues but does affect the position of helix II 
relative to the DNase.  Conserved residues of helix III of Im9 interact with the DNase 
backbone via hydrogen bonds and hydrophobic interactions, whilst the rotation 
around the two tyrosine residues in helix III, causes different regions of helix II to be 
presented to the DNase so that the variable residues form different interactions: 
predominantly hydrophobic in the case of colicin E9 DNase-Im9 and charged in the 
case of colicin E7 DNase-Im7 (Kühlmann et al 2000).   
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Figure 1.3  Comparison of the DNase-Im interfaces showing the relationship 
between the conserved tyrosine residues of the immunity proteins, Im9 (left) and Im7 (right) and 
specificity residues of the immunity proteins and DNase domains [from Kühlmann et al 2000].  
Immunity protein residues are shaded light, DNase residues are shaded dark.  Y54 presents a key 
specificity residue of the DNase to specificity residues of the immunity protein.  Immunity protein 
amino acid residues are numbered according to the Im9 sequence.   
 
1.5.5. Immunity proteins for pore-forming colicins 
On the basis of homology, immunity proteins for pore-forming colicins have been 
classified into two groups: type A, including ImA, ImB, ImN and ImU and type E, 
including ImE1, Im5, ImK, Im10, ImIa and ImIb (Duché 2002).  The immunity 
proteins for pore-forming colicins are 11-18 kDa in size (Lazdunski et al 1988). 
As with immunity proteins for endonuclease colicins, the immunity proteins are 
highly specific and only provide full protection against one pore-forming colicin 
(Song and Cramer 1991).  However, ImA has been shown to provide cells with partial 
protection against colicin B, when encoded on a high-copy-number plasmid (Géli and 
Lazdunski 1992).  Cells producing the specific immunity protein are approximately 
105 times more resistant to the colicin compared to cells that lack the immunity 
protein (Cramer et al 1995).   
1.5.5.1. Location of immunity proteins for pore-forming 
colicins 
In contrast to immunity proteins for endonuclease colicins, immunity proteins for 
pore-forming colicins are not released with the colicin but are localised to the 
cytoplasmic membrane of producing cells.  This has been shown by several methods, 
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including topology analysis of ImA, ImE1, ImU and Im5 fusion proteins (Song and 
Cramer 1991, Duché 2002), immunological detection of ImA (Géli et al 1988) and 
detergent extraction of ImE1 (Bishop et al 1985).   
1.5.5.2. Topology of immunity proteins for pore-forming 
colicins 
Topology analysis of ImA and ImU has indicated that these proteins have four 
transmembrane helices, with the N- and C- termini located in the cytoplasm, whereas 
ImE1 and Im5 are shorter, consisting of three transmembrane helices, with the N-
terminus in the cytoplasm and the C-terminus in the periplasm (Géli et al 1989, Song 
and Cramer 1991, Pilsl and Braun 1995a, Pilsl et al 1998).   
1.5.5.3. Mechanism of action of immunity proteins for 
pore-forming colicins 
The transmembrane helices of immunity proteins have been shown to be important in 
their activity (Zhang and Cramer 193) and the hydrophobic hairpins of colicin E1 and 
colicin A have been shown to be important for immunity recognition (Bénédetti et al 
1991a, Espesset et al 1994).  Therefore, it has been proposed that the hydrophobic 
helices of the immunity protein and the hydrophobic hairpin of the colicin pore-
forming domain interact when their transmembrane regions are exposed to each other, 
on insertion of the colicin into the cytoplasmic membrane, neutralising the pore-
forming ability of the colicin (Zhang and Cramer 1993, Cramer et al 1995, Espesset et 
al 1996).  Colicin E1 immunity protein has been shown to be able to interact with the 
pore-forming domain of the colicin upon voltage-gating, which places helix VI of the 
pore-forming domain in a transmembrane orientation, enabling it to interact with the 
transmembrane helices of ImE1 (Lindeburg and Cramer 2001).     
Pore-forming immunity proteins are able to protect a cell against colicin 
concentrations 104 – 107 times greater than those required to kill a non-immune cell 
(Cramer et al 1983).  However, only approximately 100 immunity protein molecules 
are present in the inner membrane.  This is possible because the diffusion rate 
constant in the membrane of 10-9 – 10-10 cm2s-1 means that the probability of an 
interaction between the colicin and the immunity protein is high, as the immunity 
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protein can travel through the membrane at least 500 nm in 10 seconds (Song and 
Cramer 1991).   
1.6. Classification of colicins 
Colicins can be classified in several ways (see Table 1.1).  Firstly, they can be 
classified according to the cell surface receptor to which they bind eg E colicins bind 
to BtuB, the vitamin B12 receptor.  Following receptor-binding, colicins enter the 
periplasm by one of two routes, known as the Ton and Tol pathways, involving 
periplasmic and inner membrane proteins.  Colicins can be split into two groups 
according to the translocation pathway they utilise to enter the susceptible cell.  Group 
A are inactive against strains containing lesions in the tolA gene, whilst group B are 
inactive against bacteria carrying mutations in the tonB gene. 
Once they have crossed the outer membrane, colicins can begin their cytotoxic 
activity.  Several cytotoxic activities have been attributed to colicins.  For example 
colicins A, E1 and N cause depolarisation of the cell by the formation of voltage-
gated ion channels in the inner membrane.  Colicin M inhibits peptidoglycan 
synthesis causing lysis of susceptible bacteria.  Other colicins take the form of 
endonucleases, cleaving the bacterial DNA (colicins E2, E7, E8 and E9), ribosomal 
RNA (colicins E3 and E6) or transfer RNA (colicin E5).  
Table 1.1  Classification of colicins (adapted from Lazzaroni et al 2002, Lazdunski et al 
2000) 
Colicin Group Receptor Translocation system Cytotoxic activity 
A A BtuB OmpF, TolABQR Pore-forming 
B B FepA TonB, ExbBD Pore-forming  
D B FepA TonB, ExbBD Inhibition of protein 
synthesis 
E1 A BtuB TolCAQ Pore forming 
E2, E7, E8, E9 A BtuB OmpF, TolABQR DNase 
E3, E4, E6 A BtuB OmpF, TolABQR 16s rRNase 
E5 A BtuB OmpF, TolABQR Anticodon tRNase 
K A Tsx OmpF, OmpA, TolABQR Pore-forming 
M B FhuA TonB, ExbBD Inhibition of murein 
& LPS synthesis 
N A OmpF OmpF, TolAQR Pore-forming 
U A OmpA OmpF, LPS, TolABQR Pore-forming 
1a, 1b B Cir TonB, ExbBD Pore-forming 
28b A OmpA OmpF, LPS, TolABQR Pore-forming 
DF13 A IutA TolAQR 16s rRNase 
Col5, Col10 B Tsx TolC, TonB, ExbBD Pore-forming 
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1.7. Colicin structures 
In general, colicins can be divided into 3 domains on the basis of function, a C-
terminal cytotoxic domain, an N-terminal translocation (T) domain and a receptor-
binding (R) domain.   
 
Figure 1.4  General structure of a colicin, consisting of an N-terminal translocation 
(T) domain, a receptor-binding (R) domain and a C-terminal cytotoxic (C) domain.   
 
 
Figure 1.5  Crystal structures of colicins N, Ia and E3 (from Zakharov and Cramer 
2002).  The receptor binding domains of colicins Ia and E3 are formed by long helical hairpins, at 
the top of which sit the translocation domains and cytotoxic domains.  The first 66 residues of 
colicin N, the first 83 residues of colicin E3 and the first 22 residues of colicin Ia are missing in 
the crystal structures.    
 
 
 T domain                                    R domain                C domain N C 
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Figure 1.6  The crystal structure of colicin B (Hilsenbeck et al 2004).  No electron 
density was detected for residues 1-10 and 29-43 (dotted line).  In contrast to the full-length 
structures of other colicins, which have clearly delineated cytotoxic, translocation and receptor-
binding domains, colicin B is dumbbell shaped with the intertwined receptor-binding and 
translocation domains forming one end of the dumbbell (top half) and the pore-forming domain 
forming the other end (bottom half).  The two ends of the dumbbell are held together by one long 
74 Å α-helix. 
 
The only published structures of full-length colicins to date, shown in Figure 1.5 and 
Figure 1.6, are the structures of the endonuclease colicin E3 (Soelaiman et al 2001) 
and the pore-forming colicins Ia (Wiener et al 1997), N (Vetter et al 1998) and B 
(Hilsenbeck et al 2004).  Generally, these structures concur with the above domain 
organisation, although the structural and functional definitions of the domains, at 
times, overlap.  Colicin E1 and colicin 10 also contain a fourth domain between the 
translocation domain and the receptor binding domain, involved in binding to TolC 
(Pilsl and Braun 1995b).   
1.8. Receptor-binding 
The first step for a colicin entering a susceptible cell is to bind to an outer membrane 
receptor.  Colicin receptors are usually involved in the uptake of ligands into the cell 
and have been parasitized by colicins as part of the colicin killing pathway. 
1.8.1. Colicin Receptors 
Several colicin receptors have been identified, including the vitamin B12 receptor, 
BtuB (Di Masi 1976, James et al 1996), the siderophore receptors, FepA and FhuA 
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(Ferguson and Deisenhofer 2002, Locher et al 1998), and the porins, Tsx (Bradley 
and Howard 1992, Pilsl and Braun 1995b), OmpA (Pilsl and Braun, 1995c) and 
OmpF (Bourdineaud et al 1990, Cowan et al 1992).  It has been proposed that these 
receptors act as gated channels, whereby binding of the ligand opens a channel, 
through which the ligand may pass (Lazdunski et al 1998).   
1.8.1.1. FepA 
The structure of FepA, the receptor for colicins B and D, shows that this receptor 
consists of a 22-stranded β-barrel and an N-terminal plug domain (Buchanan et al 
1999).  The region involved in ligand recognition was predicted to lie in the large 
extracellular loops of the β-barrel domain, as complete removal of the N-terminal 
plug domain did not affect the ability of FepA to bind to colicins B and deletion of 
loops 7 or 8, rendered FepA unable to bind colicin B (Newton et al 1999, Scott et al 
2001, Barnard et al 2001).  However, recent work has shown that the genetic 
backgrounds used for these FepA deletions could allow interprotein complementation, 
such that the plug domain of the inactive chromosomally encoded FepA would insert 
into the empty β-barrel of the plasmid-encoded FepA (Vakharia and Postle 2002).  
Therefore, the work has been repeated in a strain in which the chromosomally 
encoded FepA does not contain the plug domain so that this complementation would 
not be possible.  In this strain, constructs with deletions of the plug domain did not 
retain sensitivity to colicin B, indicating that the N-terminal plug domain is important 
in binding of colicins (Vakharia and Postle 2002).   
The plug domain is firmly anchored to the β-barrel domain, with extensive hydrogen 
bonding between the two domains, indicating that a large amount of energy would be 
required to remove the plug from the barrel and it is proposed that instead of removal 
of the plug, a conformational rearrangement would allow the natural ligand, ferric 
enterobactin (716 Da), to pass through the channel (Buchanan et al 1999).  However, 
this does not explain how the much larger colicin B (58 kDa) or colicin D (75 kDa) 
molecules could use this transporter to cross the outer membrane.   The affinities of 
colicins B and D (10-7 M) for FepA are much weaker than the affinity of ferric 
enterobactin (10-10 M) (Payne et al 1997, Scott et al 2001).  This is likely to be due to 
the lack of shape complementarity between the receptor-binding domain of the colicin 
and the binding pocket of FepA (Cao and Klebba 2002).  However, as colicin-
producing cells are protected from the cytotoxic action of the colicin, and they can 
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therefore produce the toxin in a high local concentration, and as the concentration of 
the natural ligand is usually low, it is likely that this difference in affinity is overcome 
to allow adequate binding of colicin to FepA (Cao and Klebba 2002).  The biphasic 
kinetics for binding of ferric enterobactin and colicins to FepA, indicate that a 
conformational change may occur on binding (Payne et al 1997).  Mutagenesis 
experiments have shown that although some residues of FepA are important in 
binding both ferric enterobactin and colicins, other residues are important specifically 
to either colicins or ferric enterobactin eg residues R286 and R316 are important to 
both colicins and ferric enterobactin but residue E319 is only important to ferric 
enterobactin binding and residue G549 is only important to colicin binding (Newton 
et al 1997, Cao and Klebba 2002).  The larger surface area of colicins due to their 
greater mass than ferric enterobactin makes it likely that although the binding sites for 
ferric enterobactin and colicins may overlap, colicins will interact with a greater 
number of residues on the receptor than enterobactin (Newton et al 1997).   
1.8.1.2. FhuA 
FhuA, the receptor for colicin M, also consists of a β-barrel, which is obstructed by an 
N-terminal plug domain (Locher et al 1998).  The barrel domain was suggested to be 
involved in binding colicin M, as complete removal of the plug domain did not affect 
binding of colicin M (Scott et al 2001) but as was the case for FepA, this was shown 
to be due to complementation of the empty β-barrel of the plasmid-encoded FhuA 
with the plug domain of the inactive chromosomally encoded FhuA (Braun et al 
2003).  In a mutant with the chromosomally encoded fhuA gene deleted, deletion of 
the plug domain resulted in the inability of FhuA to bind colicin M, indicating that the 
plug domain is involved in binding colicins.  On binding of the ferrichrome ligand, it 
had been proposed that this plug could be removed from the barrel, allowing the 
ligand to pass through the barrel.  The crystal structure of FhuA shows that the plug 
obstructs the entire channel lumen and tightly fits in the wall of the barrel, which is 
inconsistent with a complete removal of the plug upon ligand binding (Locher et al 
1998).  Removal of the plug would be unnecessary for the translocation of 
ferrichrome across the membrane, due to the small size (740 Da) of this ligand and it 
is proposed that more subtle conformational changes could allow translocation of 
ferrichrome.  However, colicin M is a much larger (29 kDa) ligand and therefore if 
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this ligand were to pass through the barrel of FhuA, it is likely that the plug would 
have to be removed.    
1.8.1.3. BtuB 
The receptor used by the E colicins is BtuB, the vitamin B12 receptor (see Table 1.1).    
The mature 66 kDa protein is produced from cleavage of a 20 amino acid signal 
sequence (Heller and Kadner 1985).  The protein is a minor component of the outer 
membrane, with approximately 200 copies present per cell (James et al 1996).   
The crystal structures of wild-type BtuB, BtuB with bound calcium and BtuB with 
bound calcium and bound vitamin B12 have been determined (Chimento et al 2003, 
see Figure 1.7).  The basic structure of BtuB is very similar to FepA and FhuA and 
consists of an N-terminal plug domain inserted in a 22-stranded β-barrel.  In the 
presence of calcium, extracellular loops connecting β-strands 3-4 and 5-6 of the barrel 
domain become partially ordered and it has been suggested that calcium serves to 
order these loops, exposing the high-affinity substrate-binding site.   This is consistent 
with the 50-100 fold reduction in binding affinity for vitamin B12 when calcium is 
removed from BtuB (Bradbeer et al 1996).   
The vitamin B12 binding site is formed by two loops of the plug domain, and two 
loops connecting strands 5-6 (one of the loops ordered by the addition of calcium) and 
7-8 in the barrel domain (Chimento 2003).  The substrate also makes additional 
interactions with other loops of the barrel domain.  The largest structural change that 
occurs, on binding to vitamin B12, is the movement of Cα carbons in a loop of the 
plug domain by up to 6 Å.  Other smaller conformational changes occur in the barrel 
domain (Chimento 2003).   
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Figure 1.7 Crystal structures of BtuB a) in the absence of calcium ions and vitamin B12 and 
b) in the presence of calcium ions and vitamin B12 (from Chimento et al 2003).  Structures on the 
left depict the molecule with extracellular loops pointing up and periplasmic loops pointing 
down.  Structures on the right show the molecule looking down the extracellular face.  The plug 
domain is depicted in purple and the barrel domain is coloured green.  Extracellular loops that 
are disordered in the apo-BtuB structure (a) become fully ordered in the Ca2+-vitamin B12-BtuB 
structure (b).   
1.8.2. Receptor-binding domains of colicins 
Despite utilising different outer membrane receptors (see Table 1.1), the receptor-
binding domains of colicins E3 and Ia are structurally similar, both consisting of a 
coiled coil, 160 Å in length in the case of colicin Ia and 100 Å for colicin E3 (Wiener 
et al 1997, Soelaiman et al 2001).  The length of the coiled coil of colicin Ia was 
suggested to allow the colicin to span the periplasmic space, which has an 
approximate width of 150 Å (Wiener et al 1997), but the coiled coil of colicin E3 is 
too short to allow this.  The helical regions of both colicins Ia and E3 are Alacoils, 
such that an alanine is present at every seventh position.  The minimum receptor-
binding domain of colicin E9 has been shown to consist of residues 343-418 (Penfold 
et al 2000) and forms a helical hairpin structure (Boetzel et al 2003).  This 76-residue 
minimal receptor-binding domain protects cells in an in vivo biological protection 
 b) 
a) 
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assay at least as efficiently as the full-length colicin (Penfold et al 2000).  The region 
is identical in sequence to the corresponding region of colicin E3.  NMR has shown 
that the minimum receptor-binding domain has slowly interchanging conformers and 
a flexible inter-helix loop (Boetzel et al 2003).  It has been proposed that the flexible 
loop may act as a hinge to allow unwinding of the helical hairpin upon receptor-
binding, allowing access of the translocation domain to the periplasm (Boetzel et al 
2003).  This is supported by the loss of activity of colicin mutants with disulphide 
bridges near the middle or the top of the receptor-binding domain of colicin E9 
(Penfold et al 2004).   
In contrast to the receptor-binding domains of colicins E3 and Ia, the receptor-binding 
domain of colicin N consists of a six-stranded antiparallel β-sheet wrapped around a 
63 Å long α-helix of the pore-forming domain (Vetter et al 1998).   
The function of residues 419-448, between the minimum receptor-binding domain 
and the DNase domain of colicin E9 is as yet unknown.  This region has been termed 
the ‘linker region’ and forms the upper part of the coiled coil of colicin E3 (James et 
al 2002).  It has been suggested that this region could bridge the periplasmic space to 
assist delivery of the endonuclease domain to the cytoplasm, although the region is 
too short (~50 Å) unless the translocation of the colicin occurs at zones of adhesion, 
which would bring the outer and inner membranes into closer proximity (James et al 
2002).   It has been suggested that colicins may preferentially bind to newly 
synthesised BtuB molecules, present at adhesion sites and radioactively labelled 
colicin A has also been show to associate with adhesion sites (Penfold et al 2000, 
Guihard et al 1994).   
The receptor binding domain of colicin B is difficult to distinguish from the 
translocation domain as the two domains are intertwined at one end of the dumbbell 
structure (Hilsenbeck et al 2004, see Figure 1.6).  Amino acids 262-282 of colicin B 
show significant sequence homology to the two β-strands in the receptor-binding 
domain of colicin Ia, indicating that these residues could be involved in receptor-
binding.  Amino acids 1-291 of colicin B also share significant sequence similarity 
with the same region in colicin D.  These two colicins use the same receptor, FepA, 
and therefore these residues are likely to be used in receptor-binding (Hilsenbeck et al 
2004).  There is also similarity between residues 130-291 of colicins B, D, E2, E3, 
E6, E7 and E9 and this region was recently proposed to be the receptor-binding 
domain of all these colicins (Hilsenbeck et al 2004).   Based on this sequence 
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similarity, it was recently suggested that residues 343-418 could be involved in 
binding to OmpF, rather than BtuB, supported by the fact that colicins B and D, which 
do not bind to OmpF, do not contain sequences homologous to residues 343-418 in 
colicin E9 (Hilsenbeck et al 2004).  However this suggestion ignores substantial 
evidence supporting the involvement of residues 343-418 of colicin E9 in binding to 
BtuB, ie the structure of BtuB bound to the residues 313-447 of the colicin E3 
receptor-binding domain (Kurisu et al 2003), the demonstration that a 34-residue 
peptide binds to BtuB with nanomolar affinity (Mohanty et al 2003) and the 
demonstration that the isolated residues 343-418 of colicin E9 compete with vitamin 
B12 for binding to BtuB (Penfold et al 2000).     
1.8.3. Crossing the outer membrane 
The mechanism by which colicins, once bound to their receptor, traverse the outer 
membrane, once bound to their receptor, is still unknown.  Two hypotheses have been 
put forward in an attempt to explain the mechanism although there is currently a lack 
of evidence to support either hypothesis (Cao and Klebba 2002).   
1.8.3.1. The “Nail” Hypothesis  
This hypothesis suggests that binding of the tip of the helical hairpin of the colicin 
receptor-binding domain to its receptor allows the colicin to penetrate the membrane 
by passing through the β-barrel of the receptor.  However, this hypothesis raises 
several questions such as where the energy to drive the colicin through the barrel 
would come from and whether the diameter of the β-barrel of the receptors is large 
enough to accommodate the colicin in the folded or unfolded state.  Although it is 
possible that the hairpin of the receptor-binding domain could fit into the barrel of the 
receptor, the translocation and cytotoxic domains are too large to pass through any 
known outer membrane channels unless they are in a denatured state (Cao and Klebba 
2002).   
1.8.3.2. Denaturation of colicins 
There is some evidence available to suggest that at least partial denaturation of 
colicins may occur on binding to the outer membrane receptor.  Denaturation of 
colicin A by urea has been shown to decrease the time taken by the cytotoxic domain 
to depolarise the inner membrane, shown by the decreased lag time for onset of the 
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efflux of cytoplasmic potassium (Bourdineaud  et al 1990, Bénédetti et al 1992).  
Binding of colicin A to bacterial cells was also shown to increase the susceptibility of 
site-directed disulphide bonds in the colicin to DTT, in a similar manner to 
denaturation of colicin A using urea, again indicating that denaturation of the colicin 
occurs on binding to a cell surface receptor, which may promote its entry into the cell 
(Duché et al 1994).  However, disulphide bonds in the pore-forming domain of 
colicin A did not prevent translocation, although they did slow it down, indicating that 
extensive unfolding of the pore-forming domain does not occur (Duché et al 1994).  
Isothermal titration calorimetry data for the binding of colicin N to OmpF indicates 
that a structural rearrangement occurs on formation of the OmpF-colicin N complex 
(Evans et al 1996).   
It has been suggested that proteins can become less ordered on approaching a 
membrane due to a local increase in pH and in the dielectric constant (Bychkova et al 
1996).  Unfolding of the colicin would also increase the length of the colicin, allowing 
the cytotoxic domain to reach the cytoplasmic membrane, with the receptor-binding 
domain still bound to its outer-membrane receptor.  Addition of trypsin to cells treated 
with colicin A causes membrane depolarization to be halted (Bénédetti et al 1992).  
As trypsin cannot access the periplasm or cytoplasmic membrane, it would appear 
that part of the colicin is still accessible to the external medium even after the pore-
forming domain has inserted into the cytoplasmic membrane.  Bacteria treated with 
colicin E2 can also be rescued by trypsin after they have begun their cytotoxic 
activity, indicating that endonuclease colicins also span the cell envelope whilst 
exerting their cytotoxicity (Nose and Mizuno 1968, Beppu et al 1972).  A colicin A 
mutant, with a disulphide bond connecting two helices in the pore-forming domain, 
disabling its pore-forming activity, has been shown to prevent the potassium efflux 
caused by various group A colicins, when the functional colicins are added at various 
times following addition of the colicin A disulphide mutant (Duché 1995).  The 
mutant was unable to prevent the cytotoxic action of group B colicins, which use 
different import machinery.  Despite the lack of pore-forming activity, the mutant 
should still be able to efficiently translocate across the outer membrane, indicating 
that even once the colicin mutant had been translocated; it still remained in contact 
with its receptor and the translocation machinery.     
 27 
1.8.3.3. Translocation at a distant site 
The alternative hypothesis proposes that the cytotoxic domain could translocate across 
the membrane at a second site, away from the initial binding site (Cao and Klebba 
2002).  This seems plausible for colicins E3 and Ia as their extended structures would 
allow binding of the cytotoxic domain away from the binding site for the receptor-
binding domain.  Proteins, lipids or a “membrane island” containing an unusual mix 
of proteins and lipid have all been implicated as possible secondary sites for 
translocation (Cao and Klebba 2002).    
Colicin N is much shorter and therefore this restricts the identity of the entry site for 
the cytotoxic domain, unless colicin N does not use a secondary site and simply 
translocates across the outer membrane through its primary receptor, OmpF.   This is 
possible as no other outer membrane protein has been identified that is required for 
translocation of colicin N.  A model of binding of colicin N to its receptor, OmpF, has 
been proposed in which the receptor-binding domain sits like a plug above the pore of 
OmpF with positively charged residues in a solvent-exposed cleft of the receptor-
binding domain interacting with negatively charged loops of OmpF (Vetter et al 
1998).  The pore-forming and translocation domains of colicin N are predicted to be 
involved in interacting with OmpF as the binding affinity of the receptor-binding 
domain alone for OmpF is much weaker than the full-length colicin (Evans et al 
1996).  The translocation domain needs to reach the periplasm and three routes were 
put forward as to how this could occur (Vetter et al 1998).  Firstly, the translocation 
domain could move along the outside of the porin barrel but the requirement for direct 
interactions with the lipid bilayer is energetically unfeasible.  Secondly, the 
monomers of OmpF could destabilise allowing the translocation domain to pass 
through the middle of the trimer, but OmpF is very stable.  Thirdly, the domain could 
move through the pore of one of the monomers of OmpF.  The translocation domain 
of colicin N is absent in the crystal structure and has a glycine/ proline/ serine/ 
asparagine-rich sequence, indicating that it is not likely to contain defined secondary 
structure.  The absence of regular secondary structure in the translocation domain 
makes it more plausible that this domain could thread through the porin.  Therefore, 
the third possibility is the most likely and it is proposed that residues from the pore-
forming domain interact with the outer rim of OmpF and the translocation domain 
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threads through the pore of OmpF to interact with Tol proteins in the periplasm 
(Vetter et al 1998).   
1.8.4. A colicin translocon? 
Recently a structure of BtuB bound to residues 313-447 of the receptor binding 
domain of colicin E3 (R135) has been solved at a resolution of 2.75 Å (Kurisu et al 
2003).  This structure shows that only the tip of the helical hairpin of the receptor-
binding domain of colicin E3 is involved in binding to BtuB.  24 % of R135 and 6.3 
% of BtuB become buried on formation of the complex (Kurisu et al 2003).  27 
residues of R135 (between residues I369-T402), and 29 residues of BtuB (mostly at 
the top of the plug domain) are involved in the BtuB-R135 complex.  There are small 
conformational changes in the plug domain of BtuB, but these cannot account for 
translocation of the colicin (Kurisu et al 2003).  Competition assays show that 
exogenous vitamin B12 can protect cells against colicin cytotoxicity and therefore it 
was predicted that colicins would bind to the same binding site on BtuB as vitamin 
B12 (Cavard 1994).  The receptor binding domain of colicin E9 has also been shown 
to inhibit the growth of E.coli 113/3 cells that are dependent on the addition of 
vitamin B12 (Penfold et al 2000).  The crystal structure shows that the binding site for 
R135 on BtuB overlaps with the binding site of vitamin B12 by five residues but the 
other eight residues involved in vitamin B12 binding are not involved in binding R135 
and overall vitamin B12 is more deeply buried in BtuB than R135.  No calcium was 
detected in the BtuB-R135 structure, in contrast to the BtuB-vitamin B12 structure 
(Chimento et al 2003).     
Binding of R135 causes ordering of loops 5-6 and 7-8 of BtuB and alters the position 
of loop 19-20 and 3-4.  Ordering of loop 5-6 in FepA caused by binding of colicin B 
has also been shown by electron spin resonance spectroscopy (Jiang et al 1997).  The 
first ten residues at the N-terminus and nine residues at the C-terminus of R135 are 
disordered in the R135-BtuB complex, leading to the Cα displacement of residues of 
R135, which increases with increasing distance from the hairpin tip.  It is proposed 
that this partial unfolding of the hairpin could trigger unfolding of the rest of the 
colicin (Kurisu et al 2003).   
The R135-BtuB structure prompted the proposal that instead of the colicin directly 
translocating through BtuB, this receptor is used to concentrate the colicin on the 
surface, where it can then “fish” for a secondary receptor.  The translocation domain 
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would bind to this secondary receptor, forming a translocon (see Figure 1.8).  If the 
cytotoxic domain or translocation domain passes through the porin, whilst the 
receptor-binding domain is still attached to its receptor, this indicates a potential role 
for the “linker region” of colicin E9 mentioned earlier, as a spacer between the 
receptor-binding domain and the translocation domain.  A long helix of the 
translocation domain of colicin Ia has no obvious function and has also been 
suggested to act as a spacer (Wiener et al 1997).  Colicin A mutants with residues 98-
108 or 154-172 deleted are still active, and it has been suggested that these regions 
could act as spacers (Bouveret et al 1998, Journet et al 2001).   
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Figure 1.8   Proposed model for the formation of a colicin translocon (Kurisu et al 
2003).  The receptor-binding domain (red) is bound to BtuB (barrel domain in green, plug 
domain in orange) and the positions of the translocation domain (blue), cytotoxic domain 
(magenta) and immunity protein (yellow) are extrapolated from the structure of the R135-BtuB 
complex.  The model suggests that binding of the receptor-binding domain of colicin E3 to BtuB, 
concentrates the colicin on the cell surface.  The extended coiled coil of the receptor-binding 
domain would then allow the colicin to scan along the cell surface for an OmpF trimer (grey) and 
the disordered region of the translocation domain of colicin E3 would interact with OmpF.   The 
translocation domain would then thread through the OmpF channel where it could interact with 
the Tol translocation system.   
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1.8.4.1. OmpF 
The putative secondary receptor in the proposed colicin translocon is OmpF, as the E-
colicins, except colicin E1, and colicin A have all been shown to require OmpF for 
translocation (Dover et al 2000).  OmpF is a non-selective trimeric porin, each 
monomer consisting of a 16-stranded β-barrel with large loops between each β-strand 
(see Figure 1.9).  The traverse loop (L3) of OmpF constricts the monomer pore 
diameter to 7 x 11 Å about half way down the β-barrel (Cowan et al 1992).  The wide 
cross-section of the pore is sufficient for insertion of an unfolded polypeptide and the 
porin is present in a high density (~105 molecules per cell) on the cell surface 
(Nikaido and Vaara 1987).  The N-terminal residues of the translocation domains of 
colicins Ia, B and E3 are unresolved in the crystal structures, implying a low degree of 
secondary structure and a high degree of flexibility (Wiener et al 1997, Soelaimain et 
al 2001, Hilsenbeck et al 2004).  It is proposed that this disordered region of the 
translocation domain would thread through the OmpF pore.  Due to the unfolded 
nature of this domain, the threading through OmpF is not predicted to require a large 
energy input (Kurisu et al 2003).   
Kurisu et al (2003) support their hypothesis by demonstrating that OmpF channels in 
planar bilayers could be occluded by addition of colicin E3 (Kurisu et al 2003).  This 
occlusion only occured when colicin E3 was applied to the trans-side of the bilayer, 
likely to be analogous to the extracellular side of the outer membrane.  No occlusion 
occurred when colicin E1, which does not require OmpF for translocation, was added 
to the bilayer (Kurisu et al 2003).   
However, the exact role of OmpF in the translocation process is still debateable.  The 
absence of OmpF in the cell has very little effect on binding of the receptor-binding 
domain of colicin E9 to cells and would therefore appear not to act as a co-receptor 
(Penfold et al 2000).   Pre-incubation of colicin E9 with OmpF has been shown to 
enhance protection to cells afforded by pre-incubation of colicin E9 with BtuB, 
although any interaction between OmpF and the BtuB-colicin E9 is predicted to be 
weak and transient, as no tertiary complex could be detected using gel filtration and 
chemical cross-linking (Law et al 2003).  The pore-forming domains of colicin N and 
colicin B have been shown to interact with OmpF, although the formation of these 
complexes depends on the presence of detergent or lipopolysaccharide, and therefore 
the biological significance of these complexes remains questionable (Dover et al 
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2000).  Cells with a G119D mutation in OmpF causing this residue of loop L3 to 
protrude into the lumen of the channel, dividing it into two sections of reduced 
diameter, are resistant to colicin N (Jeanteur et al 1994).  As this mutation had no 
effects on the rest of the structure, it was concluded that colicin N normally passes 
through OmpF and that this mutation prevents colicin from entering the porin channel 
(Jeanteur et al 1994).  However, an alternative explanation is that exposed loops, 
involved in binding colicin N are affected, preventing binding of colicin N to OmpF.  
Mutation of OmpF at residues G119 or G120 to bulkier residues has also been shown 
to dramatically affect the activity of colicin A, indicating that loop L3 also has a role 
in recognising and/or transporting colicin A (Bredin et al 2003).  Residues D113 and 
D121 were also found to be important for the activity of colicins A and N.  However, 
residue D113 was found to play a more prominent role in colicin A activity, whereas 
residue D121 was more important for colicin N activity.  This indicates that there may 
be differences in the uptake of the two colicins with colicin N interacting with 
residues located at the top of L3 and colicin A using residues further down and on the 
other side of L3 (Bredin et al 2003).   
In an attempt to discover whether colicins do translocate across the outer membrane 
by passing through OmpF, genetically engineered disulfide bonds were used to tether 
loop L3 of the porin to the barrel wall at various postions (Bainbridge et al 1998).  
This loop must undergo a conformational change to allow enough space for 
translocation of a polypeptide chain.  Potassium efflux and fluorescence 
depolarisation assays were used to show that out of five disulfide pairs, only the 
E117C-D312C pair caused resistance to colicin N, but not to colicin A.  This was 
predicted to be due to impaired binding of colicin N to OmpF and indicated that 
although small conformational changes at the tip of L3 may occur, a large 
conformational change in L3 to allow a polypeptide chain to pass through the pore is 
unlikely to occur and therefore colicins N and A do not appear to move through the 
OmpF pore.  However, this conclusion has been questioned for several reasons (Cao 
and Klebba 2002).  Firstly, the crystal structure of OmpF shows that the L3 loop does 
block the pore but in solution this loop is likely to be far more flexible.  Secondly, the 
mutations E117C-D312C and D107C (a single mutation which affected colicin 
sensitivity) are beyond the reach of the colicin N binding domain as it is too large to 
enter the porin channels and therefore it is possible that rather than interfere with 
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binding of the colicin as proposed by Bainbridge et al (1998), these mutations may 
slow down the rate of colicin “threading” through the pore (Cao and Klebba 2002).   
 
If colicins do use two different outer membrane proteins to traverse the outer 
membrane, the two proteins must be within a certain distance of one another, 
suggesting that co-localisation may occur.  It has been suggested that translocation 
across the outer membrane could be dependent on membrane fluidity, as it is 
dependent on temperature (Bourdineaud et al 1990).  This could potentially be a 
consequence of the requirement for OmpF and BtuB to be in close proximity in the 
membrane.   
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Figure 1.9  Three-dimensional structure of OmpF (from Delcour 2003) 
A.  A side view of an OmpF monomer; β-strands are shown as a gray ribbon, and α-helices as red 
cylinders; extracellular loops L2, L3, L4 and L6 are labelled.  
B. A cross section of an OmpF monomer, viewed from the extracellular side. Residues labelled 
are K16, R42, R82, D113, E117, G119 and R132. D113, E117 and G119 form part of loop L3. 
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1.8.4.2. TolC 
The existence of a fourth domain in colicin E1 which has been shown to bind to TolC, 
indicates that colicin E1, rather than using OmpF as a translocator, uses TolC.  
Although no direct interaction has been observed between OmpF and endonuclease 
colicins, a region in the translocation domain of colicin E1 has been shown to interact 
with TolC.  
TolC is a homotrimer, comprising a 40 Å long β-barrel that spans the outer membrane 
and a unique 100 Å long α-helical barrel projecting into the periplasm (Koronakis et 
al 2000).  Unlike other outer membrane proteins, which form one 16- or 18- stranded 
barrel per monomer, eg OmpF, in TolC, each monomer contributes 4 β-strands to 
form a single 12-stranded β-barrel (see Figure 1.10).  This gives TolC a much greater 
cross-sectional area (960 Å) than other outer-membrane proteins, fifteen times that of 
OmpF.  TolC does not contain the common loop that constricts the channel of other 
channel-forming proteins ie L3 in OmpF and does not contain a plug domain, found 
in iron transporters.  However, the conductance of TolC remains low, probably 
because the diameter of the channel narrows towards the periplasmic end of the 
protein (Andersen et al 2001).  TolC is known to be involved in export of large 
proteins (~170 kDa) from the periplasm into the extracellular medium so this narrow 
opening must extend to allow passage of these large proteins.  This implies that TolC 
could allow translocation of colicin E1 across the outer membrane in the opposite 
direction ie from the extracellular medium into the periplasm (Zakharov and Cramer 
2002).     
 
If OmpF and TolC allow translocation of the colicin across the outer membrane, this 
contradicts the traditional view that the three separate domains of a colicin function in 
three separate compartments of the cell ie the receptor-binding domain functions at 
the outer membrane, the translocation domain allows translocation across the 
periplasm and the cytotoxic domain is involved at the cytoplasmic membrane and, for 
endonuclease colicins, the cytoplasm.   
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Figure 1.10 The crystal structure of TolC (from Andersen et al 2002).  TolC is 140 Ǻ in 
length and is comprised of a 40 Å long β-barrel domain spanning the outer membrane (OM) and 
a 100 Å long -helical domain, which projects across the periplasmic space. One monomer is 
shown in colour.  Each monomer contributes 4 strands to the 12-stranded β-barrel domain.   
 
1.9. Translocation 
Colicins can be divided into two groups, based on the mechanism of translocation 
from the outer membrane to the inner membrane (Davies and Reeves 1975a, b).  
Group A colicins eg colicins A, E1, E3, E9 (see Table 1.1) are inactive against cells 
containing lesions in the tola gene and therefore use the Tol (“Tolerant”) import 
system, whereas group B colicins eg colicins B,D, Ia, M are inactive against cells 
carrying a tonb mutation and therefore use the Ton system (Nomura and Witten 1967, 
Webster 1991).  The domain organisation is similar for Ton- and Tol-dependent 
colicins and some components of the two translocation systems are homologous.  
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Therefore it is likely that translocation of both types of colicins occurs via a similar 
mechanism (James et al 2002).   
1.9.1. The Tol translocation system 
The Tol system consists of five proteins, TolQ, TolR, TolA, TolB and the 
peptidoglycan-associated lipoprotein (Pal).   
The genes involved in the Tol pathway are clustered at 17 minutes on the E.coli 
chromosome (Lazdunski et al 2000).  They are organised in 2 operons (Vianney et al 
1996): 
i) ybgc, tolA, tolQ and tolR under the control of promoter P1 
ii) tolB, pal and ybgf under the control of the strong promoter, PB and P1 
ybgc and ybgf mutants do not cause a tol phenotype and the functions of YbgC and 
YbgF proteins are unknown (Lazdunski et al 1998).   
The nucleotide sequences of the tol genes have been determined and a number of 
mutations in the tol genes have been isolated that render bacteria insensitive to certain 
colicins, without affecting binding of the colicins to their specific receptors (Webster 
1991).  Experiments with these tol mutations have shown that the tol gene products 
required for translocation differ for specific colicins.  For example, Tol A, B, Q and R 
are required to translocate the enzymatic colicins, E2-E9, whereas only Tol C, A and 
Q are required to translocate the pore-forming colicin E1.   
The protein products of tol Q, R, A and B have been identified and correspond to the 
sizes predicted from the DNA sequences (Webster 1991).  Figure 1.11 shows the 
structure or predicted structures and cellular locations of proteins in the Tol system.   
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Figure 1.11 Components of the Tol/Pal translocation cellular import pathway for Group A 
colicins 
1.9.1.1. Involvement of Tol proteins in translocation of 
colicins 
Although the transport of colicins across the periplasm is still poorly understood, 
there are now many studies that show interaction of group A colicins with Tol 
proteins is necessary for translocation.   
The first demonstration of a correlation between the translocation of group A colicins 
and colicin binding to a Tol protein came from analysis of in vitro binding of over-
expressed Tol proteins to colicins by Western blotting (Bénédetti et al 1991b).  The 
Tol-dependent colicins, colicins A and E1, interacted with TolA but colicin B, a Ton-
dependent colicin, did not.  The isolated translocation domain of colicin A was the 
only region shown to be involved in interacting with TolA.  This was confirmed by 
surface plasmon resonance experiments and the interaction was shown to have a Kd of 
0.2 µM.  The N-terminal of colicin E1 was shown by the same technique to bind to 
TolA with a Kd of 0.6 µM (Derouiche et al 1997). 
Another study reported that when cells were treated with colicin A, the amount of Tol 
proteins in the membrane fraction, defined as contact sites between the inner and 
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outer membranes, doubled (Guihard et al 1994).  This suggested that colicins recruit 
Tol proteins for translocation.   
The Tol-dependent colicins contain a consensus pentapeptide sequence, 
DG(T/S)G(S/W) close to the N-terminus, originally called the TolA box (Pilsl and 
Braun 1995b).  Site-directed mutagenesis experiments were used to show that 
although mutation of the two glycine residues to alanine did not affect the biological 
activity of colicin E9, mutation of any of the other three residues completely 
abolished cytotoxic activity in vivo.  The D35A, S37A and W39A mutants retained 
their ability to bind to BtuB and exhibited DNase activity in vitro, signifying a role for 
these residues in translocation (Garinot-Schneider et al 1997).  In vivo and in vitro 
cross-linking experiments demonstrated an interaction between the N-terminal 325 
residues of colicin E3 and TolB, which was abolished if the serine residue at position 
37 in the putative TolA box was mutated to phenylalanine (Bouveret et al 1997).  
Therefore, although the pentapeptide sequence identified is involved in colicin-Tol 
interactions, it is the TolB protein with which it interacts, rather than the TolA 
protein, and hence it was designated the TolB box.   
The interaction between the translocation domain of colicin E9 and TolB has also 
been demonstrated using the yeast two-hybrid system (Carr et al 2000a).  Mutation of 
the TolB box residues of the T domain of colicin E9 to alanine confirmed that it was 
the protein interaction between the TolB box and TolB that gave rise to the positive 
yeast two-hybrid interaction.   
The entry of a hybrid toxin, consisting of the first 372 amino acids of the attachment 
(gene III) protein of the bacteriophage f1 fused to the RNase domain of E3, was 
shown to not only be dependent on the products of tolA, tolQ and tolR, which are 
required for both phage f1 infection and colicin entry but also on the TolB protein, 
which is required for colicin E3 killing but not for phage f1 infection (Jakes et al 
1988).  This suggests that the toxin may be using the F pilus to bind to the outer 
membrane with pilus retraction bringing the toxin to the cell membrane but that the 
enzymatic portion then reaches the cytoplasm via TolB and the Tol system rather then 
the pathway normally used by f1.   
NMR and crystal structures (Wiener et al 1997, Soelaiman et al 2001, Collins et al 
2002) suggest that the translocation domains of colicins are relatively unstructured 
and it is not yet known how Tol proteins are able to specifically recognise and bind to 
regions of this unstructured domain.   
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1.9.1.2. TolB 
TolB is a periplasmic protein of 408 residues, resulting from cleavage of its 21-
residue signal sequence (Isnard et al 1994).  It is mainly found in the periplasm but a 
small amount is also found associated with the outer membrane (Isnard et al 1994).  
By sequence homology, TolB is a member of the tryptophan-aspartate (W-D) repeat 
protein family. This protein family has a diverse range of cellular functions including 
transmembrane signalling, transcription and mRNA modification and several 
members of the family form multiprotein complexes, sometimes interacting through 
their W-D repeat regions (Neer et al 1994).   Two different groups have determined 
the crystal structure of TolB to 2 Å resolution (Carr et al 2000a) and 1.95 Å resolution 
(Abergel et al 1999).  The two structures show that the overall fold of the protein 
comprises a 131-residue N-terminal domain consisting of a 5-stranded mixed β-sheet 
that sandwiches two major α-helices against a C-terminal 6-bladed β-propeller (see 
Figure 1.12).  Each blade of the propeller consists of twisted β-sheets that are radially 
arranged around a central tunnel.   
Interaction of TolB with colicins 
β-propeller proteins usually use their central tunnel or the entrance to the tunnel to 
coordinate a ligand or to carry out a catalytic function that is preserved by the 
structural rigidity of the propellers.  It has therefore been proposed that the 
translocation domains of colicins interact with the β-propeller domain (Carr et al 
2000a).   However, this has been questioned, as deletions and insertions in the β-
propeller domain of TolB do not affect the interaction with colicins, whereas an 
insertion into the N-terminal domain of TolB caused a reduction in the ability of 
colicins to penetrate into the bacteria (Abergel et al 2000).   
As well as interacting with colicins, TolB has been shown to interact with the 
peptidoglycan associated lipoprotein (Pal), Lpp and OmpA (Wallburger et al 2002, 
Bouveret et al 1995, see section 1.9.1.3).   
TolB dimersation 
Yeast two-hybrid studies and in vitro cross-linking experiments have indicated that 
TolB dimerises (Wallburger et al 2002, Dubuisson et al 2002).  This dimerisation 
appears to occur through the N-terminal domain, as the isolated N-terminal domain 
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has been shown to have the capacity to dimerise and multimerise, possibly due to the 
adoption of different conformations, exposing different cross-linking sites.  The 
physiological relevance of the dimerisation remains unclear as it was not detected in 
the determination of the crystal structure or in previous in vitro and in vivo studies 
(Carr et al 2000a, Abergel et al 1999, Bouveret et al 1995, 1998).    
 
Figure 1.12  The crystal structure of TolB looking down the central barrel of the β-
propeller domain.  Six repeated sequence motifs produce the six propellers of the domain (Carr 
et al 2000a).   
TolB box 
The conserved pentapeptide sequence, DG(T/S)G(S/W), near the N-terminus of 
several Group A colicins, found to be important for interaction of colicins with TolB, 
has been designated the TolB box.   
Mutation of residues D35, S37 or W39 to A in colicin E9, which abolishes cytotoxic 
activity of the colicin, has also been shown to abolish binding of the colicin to TolB 
by yeast-two hybrid screening (Carr et al 2000a).  Mutation of either of the two 
glycine residues to alanine in colicin E9, had no effect on biological activity or on its 
interaction with TolB (Carr et al 2000a).  Mutation to alanine of two serine residues 
(S34 and S40), flanking the TolB box, did not abolish biological activity, but the 
zones of growth inhibition caused by these mutants were hazy and slower to form 
than those zones formed by the wild-type colicin protein (Garinot-Schneider et al 
1997).  Mutation of S37 to F in colicin E3 also abolished binding of this colicin to 
TolB (Bouveret et al 1997).   
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The region of colicin A involved in binding to TolB, has been narrowed down to 
residues 7-20, by mutagenesis (Journet et al 2001).  A pentapeptide sequence, very 
similar to that of colicin E9 ie DGTGW, occurs at residues 11-15.  However, other 
residues downstream of residue 15 are predicted to be involved in binding to TolB, as 
a colicin A mutant with residues 16-30 deleted, does not interact with TolB (Bouveret 
et al 1998).  Another colicin A mutant with residues 21-29 deleted does interact with 
TolB indicating that residues between 15-20 are also involved in binding to TolB 
(Bouveret et al 1998).   
Colicin K has no well conserved TolB box, despite being dependent on TolB for 
translocation.  The suggested TolB box, contains an alanine residue at the fifth 
position.  This fifth position in colicin E9 is a tryptophan residue, which when 
mutated to alanine abolishes binding to TolB (Carr et al 2000a).  This indicates that, if 
the TolB box for colicin K has been identified correctly, colicin K may interact with a 
different region of TolB, compared to other TolB-dependent colicins.   
1.9.1.3. Pal 
Pal is a 152 amino acid lipoprotein with a serine residue at position +2, which results 
in its localisation in the outer membrane via an N-terminal lipid moiety (Mizuno 
1979).   Residues 94 to 114 form an amphipathic helix, which contains a 
peptidoglycan recognition sequence that interacts with peptidoglycan (Koebnik et al 
1995, Bouveret et al 1999, Cascales and Lloubes 2004).   
Pal has been shown to form dimers in vitro and in vivo, probably via its C-terminal 
residues, independent of Tol proteins, Lpp and OmpA (Cascales et al 2002, Cascales 
and Lloubes 2004).   
TolB-Pal interaction 
In vivo cross-linking and immunoprecipitation experiments first indicated that TolB 
interacts with Pal (Bouveret et al 1995).   
Insertion of two residues in the β-propeller domain of TolB, abolished the interaction 
of TolB with Pal, and reduced the interaction with OmpA, indicating that the β-
propeller domain may be involved in binding to Pal and OmpA (Abergel et al 1999).  
Suppressor genetics also identified the C-terminal β-propeller domain of TolB as 
important for the interaction with Pal (Ray et al 2000).   
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Mutagenesis studies have limited the region of Pal that interacts with TolB to residues 
89-104 and 126-130 (Clavel et al 1998).  A peptide comprising residues 89-130 of Pal 
is able to interact with TolB and with peptidoglycan (Bouveret et al 1999).  However, 
the peptide is unable to bind to both the peptidoglycan and TolB at the same time in 
vivo, which is consistent with the region involved in binding to TolB overlapping with 
the binding site for peptidoglycan.  Dimerisation of Pal is not required for the 
interaction with TolB (Cascales and Lloubes 2004).   
Role of the TolB-Pal interaction in colicin translocation 
Binding of colicin E3 to TolB prevents the interaction of TolB with Pal and point 
mutations have been identified in Pal that render cells insensitive to colicins 
(Bouveret et al 1997, Clavel et al 1998).  Therefore, although a pal null mutant is 
equally sensitive to colicins as wild-type cells (Bouveret et al 1995), there is evidence 
to suggest that Pal is, at least indirectly, involved in colicin translocation.  It has been 
suggested that the varying associations of Pal with TolB and peptidoglycan may play 
a role in the crossing of colicins across the peptidoglycan layer (Bouveret et al 1997).  
Alternatively TolB could act as a shuttle between Pal at the outer membrane and 
TolQRA at the inner membrane (Bouveret et al 1999).   
Pal interaction with Lpp and OmpA 
TolB and Pal can be cross-linked with outer-membrane proteins, OmpA and Lpp 
(Clavel et al 1998, Cascales et al 2002).  The OmpA binding sequence of Pal has been 
localised to residues 44-61 (Cascales and Lloubes 2004).  It was necessary for TolB to 
be associated with Pal in order for TolB to interact with these two proteins.  It has 
therefore been suggested that TolB and Pal are part of a multiprotein complex that 
links the peptidoglycan to the outer membrane (Clavel et al 1998).   
1.9.1.4. TolA 
TolA is a 44 kDa membrane protein, which can be divided into three domains, 
although no crystal structure of the full-length protein is yet available (Webster 1991).  
Domain I, consisting of the N-terminal 47 amino acids, contains a 21 amino acid 
hydrophobic segment, anchoring the protein in the inner membrane (Webster 1991).  
This domain has been shown by formaldehyde crosslinking to interact with TolR and 
TolQ (Derouiche et al 1995).   
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Secondary structure predictions and circular dichroism measurements indicate that the 
central domain II is mainly α-helical (Levengood et al 1991, Derouiche et al 1999).  
This domain is separated from domain I by five glycine residues and from domain III 
by three glycine residues.  Secondary structure prediction indicates that domain II 
lacks turns and analytical ultracentrifugation indicates that the domain is elongated 
(Derouiche et al 1999).  A single helix formed by this region would be approximately 
35 nm, enabling the protein to span the periplasm.  However, this single helix is 
unlikely to form, as hydrophobic sequences in the domain would make the purified 
domain insoluble when exposed to hydrophilic solvents, whereas the purified domain 
was actually found to be soluble (Derouiche et al 1999).  Molecular modeling of 
domain II, suggests that the domain could consist of a three-stranded coiled coil 
structure and this has been suggested to act to tether the anchoring domain I to the 
functional domain III (Webster et al 1991).   
A crystal structure of domain III of TolA is now available, in complex with domain I 
of the phage minor coat gene 3 protein (Lubkowski et al 1999).  Domain III of TolA 
is a novel fold consisting of three antiparallel β strands with four helical motifs.   
NMR studies have shown that interaction with colicin A induces a significant 
structural change in domain III of TolA, involving an increase in flexibility of the 
domain (Deprez et al 2002).  It has been suggested that this increase in flexibility 
could disrupt the interaction of TolA with Pal, contributing to the disruption of the 
Tol/Pal system, allowing translocation of colicin A (Deprez et al 2002).   
Interaction of TolA with colicins 
TolA interacts with colicins A and E1.  TolA with a deletion in domain III was unable 
to interact with colicins A and E1 in vivo (Bénédetti et al 1991b).  In vitro studies 
with purified proteins and yeast-two hybrid experiments confirmed that it is the C-
terminus of TolA that interacts with colicins A and E1 (Derouiche et al 1997, 
Wallburger et al 2002).  A mutational analysis of the α-helical domain II of TolA, 
indicated that although cells containing a tolA gene with almost the entirety of domain 
II deleted, had a decreased sensitivity to colicins A, E3 and N, there was very little 
change in their sensitivity to colicin E1 (Schendel et al 1997).  Colicin E1 also 
requires lower levels of TolA compared to other TolA-dependent colicins.  It was 
therefore concluded that colicin E1 interacts with TolA in a different manner to other 
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colicins.  It has been proposed that colicin E1 is able to locate domain III of TolA 
more easily than other colicins due to its dependence on TolC, which may be located 
at adhesion zones, where other Tol proteins are concentrated (Guihard et al 1994, 
Journet et al 1999).  This is in contrast to the OmpF-dependent colicins, such as E3 
and A, which may require a longer TolA molecule to bridge the periplasm, as OmpF 
is unlikely to be particularly concentrated at adhesion zones (Schendel et al 1997).  
This hypothesis is supported by evidence suggesting that TolA II interacts with outer 
membrane proteins such as the OmpF, PhoE and LamB porins, indicating that the 
TolA–OmpF interaction could be lost if domain II of TolA is deleted (Derouiche et al 
1996).   
TolA-TolB interaction 
A strong interaction between TolB and domain III of TolA has been shown by yeast 
two hybrid studies and cross-linking experiments (Wallburger et al 2002).  A 
suppressor mutation in the N-terminal region of TolB (D120N) was able to restore the 
wild-type phenotype to a tolA mutant, indicating that the N-terminal domain of TolB 
interacts with the C-terminal domain of TolA (Dubuisson et al 2002).   
Although the N-terminal domain of TolB was sufficient to allow interaction with 
TolA in the yeast-two hybrid work, the C-terminal domain strengthened the 
interaction, possibly by stabilising the structure of the N-terminal domain (Wallburger 
et al 2002).  It is therefore possible that TolB links the outer and inner membranes by 
simultaneously interacting with Pal and TolA.   
The physiological relevance of the TolB-TolA interaction was shown by using cells 
with a Y345H V409E mutation in TolA, which had been shown to abolish the 
interaction, without affecting the interaction between TolA and colicin A (Wallburger 
et al 2002).  The mutant cells presented a tol phenotype, with an envelope integrity 
defect and an increased tolerance to colicins A and E3.  The mutation had no effect on 
sensitivity to colicin E1, which does not require TolB for translocation.  This indicates 
that the TolB-TolA interaction is important for uptake of TolB-dependent colicins and 
for the maintenance of cell-envelope integrity.   
TolA-Pal interaction  
In vivo cross-linking and immunoprecipitation experiments have shown that the C-
terminal domain III of TolA forms a complex with Pal (Cascales et al 2000).  
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Analysis of these experiments with respect to cell energisation, shows that the TolQ 
and TolR activate TolA in a proton motive force (pmf) dependent manner, which 
drives the C-terminal domain of TolA to interact with Pal (Cascales et al 2001).  As 
Pal is anchored to the outer membrane and TolA to the inner membrane, the TolA-Pal 
interaction forms a link between the inner and outer membranes.   
The region of Pal involved in binding to TolA has been localised to the 30 C-terminal 
residues of Pal ie residues 123-152 and an SYGK motif has been suggested to 
represent a “TolA” box in Pal (Cascales and Lloubes 2004).  Similar motifs have been 
shown to be present in the regions of colicins A and N, involved in the colicin-TolA 
interaction and therefore it has been speculated that these colicins could displace the 
TolA-Pal interaction, disrupting membrane integrity and hence allowing colicins to 
move across the membrane (Cascales and Lloubes 2004).   
It is not yet known whether TolA can interact with Pal and TolB at the same time.   
TolA box 
The region of colicin A involved in binding to TolA has been shown to lie between 
residues 32-107 (Bouveret et al 1998).  The sequence of this region with other 
colicins only shows similarity to one other colicin, colicin K (Pilsl and Braun 1995c).  
Residues 50-84 of colicin A and 62-97 of colicin K have been proposed as TolA 
boxes (Bouveret et al 1998).  However, colicin A with residues 85-172 deleted, does 
not bind to TolA (Bouveret et al 1998).  Further mutagenesis studies have narrowed 
the region of colicin A involved in binding to TolA to residues 52-97 (Journet et al 
2001).   
Mutation of residues between H57 and I64 to alanine was shown by ITC and 
fluorescence binding assays to reduce binding of colicin N to TolA, indicating that the 
colicin N TolA box lies within this region (Raggett et al 1998).  The Y62A mutation 
completely abolished binding of colicin N to TolA, indicating that this tyrosine 
residue is essential for binding.  Residues W44 and W46 of colicin N were shown by 
an enhancement in tryptophan fluorescence to be completely buried on binding to 
TolA, indicating that these residues are also involved in binding to TolA, such that a 
region of at least 20 residues is involved in the binding of colicin N to TolA (Raggett 
et al 1998).  Further mutagenesis studies have mapped the full TolA box of colicin N 
to residues 44-66 (Gokce et al 2000).  All residues between D54 and F66, except S58 
and S61 were found to be required for the TolA interaction.  Residues 40-90 fused to 
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GST showed full binding to TolA in an SPR experiment, whereas residues 48-90 
fused to GST did not bind to TolA, indicating that residues upstream of N40 are not 
required for TolA binding but that residues between N40 and N48 are involved in 
TolA binding (Gokce et al 2000).   No region in other colicins has been found that is 
similar to the colicin N TolA box, again indicating that different group A colicins may 
bind to TolA in a variety of ways.   
1.9.1.5. TolR 
TolR is a 142-residue inner-membrane protein, which can be divided into three 
domains.  Domain I, consisting of the N-terminal 43 residues, spans the inner 
membrane once (Muller et al 1993).  Domain II is located in the periplasm and 
appears to be involved in homo-dimerisation (Journet et al 1999).  The C-terminal 
domain III, extending from residues 117-142, has been proposed to form an 
amphipathic α-helix, which could interact with proteins, eg TolQ, TolA, in the 
cytoplasmic membrane (Lazzaroni et al 1995, Journet et al 1999).  TolRII-III and 
TolRI-II proteins are unable to complement tolR cells indicating that domains I and 
III are involved in TolR function and therefore the interactions between TolR and 
TolQ and TolA are likely to be important for TolR function (Journet et al 1999).   
Overproduction of TolRII in the bacterial periplasm, induces tolerance to colicin A, 
indicating that this domain is involved in interacting with colicin A (Journet et al 
1999).  In vivo and in vitro cross-linking studies have now confirmed that it is domain 
II of TolR that interacts with colicins A and E3 (Journet et al 2001).   
The interaction between TolR and colicin A has only been detected using 
formaldehyde cross-linking.  No interaction could be detected using a yeast two-
hybrid screen or spectrofluorometric analysis, suggesting that the interaction between 
TolR and colicin A is weak and transient and may be dependent on other factors in 
vivo (Journet et al 2001).   
TolRII cannot interact with TolA alone but the N-terminal domain of colicin A cross-
linked to TolRII can interact with TolA at the same time to form a TolRII-colicin A-
TolA ternary complex (Journet et al 2001).   
TolR box 
Deletion mutants in the colicin A N-terminal domain were used to localise the region 
of colicin A that is involved in binding to TolR (Journet et al 2001).  Colicin A with 
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residues 2-9 deleted could not be cross-linked to TolR, whereas colicin A proteins 
with residues 2-6 or residues 15-30 deleted were able to interact with TolR.  This 
indicates that residues 7-14 are involved in the interaction with TolR (Journet et al 
2001).   The sequence in this putative TolR box region is not well conserved with 
other colicins, except for the presence of several glycine residues.  The region 
overlaps with the TolB box of colicin A (residues 11-15), consistent with the fact that 
all colicins requiring TolB for translocation, also require TolR.  This indicates that the 
interaction between colicins and TolB and TolR is unlikely to be simultaneous, 
although the colicin-TolB and colicin-TolR interactions are probably closely linked 
(Journet et al 2001).   
1.9.1.6. TolQ 
TolQ consists of 230 residues and is an integral cytoplasmic membrane protein, 
predicted to span the membrane three times (Kampfenkel and Braun 1993).  The N-
terminus and a small loop are located in the periplasm and the C-terminus and a large 
loop, following the first transmembrane region, are situated in the cytoplasm 
(Vianney et al 1994).  Mutational analysis has indicated that the transmembrane 
regions and parts of the cytoplasmic loop are important for TolQ activity 
(Kampfenkel and Braun 1993, Vianney et al 1994).  The sequences of the predicted 
transmembrane regions are also highly conserved, again indicating that these regions 
may be important in the function of TolQ.   
1.9.1.7. TolQ-TolR-TolA interactions 
Biochemical and genetic studies have shown that TolR, TolQ and TolA interact 
together in the cytoplasmic membrane.  However it is as yet unknown if these 
interactions are simultaneous as no trimeric TolQ-TolR-TolA complex has ever been 
detected (Journet et al 1999).   
TolR-TolQ 
A mutation in the third transmembrane region of TolQ induced tolerance to colicin A 
but not colicin E1 (Vianney et al 1994).  TolQ is required for uptake of both of these 
colicins, but TolR is only required for uptake for colicin A, indicating that this 
mutation was affecting the interaction between TolQ and TolR.  This was confirmed 
by the discovery of suppressor mutations in TolR that restored colicin sensitivity to 
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the tolQ mutant (Lazzaroni et al 1995).  Four out of five of these suppressor mutations 
were located in the transmembrane helix of TolR, indicating that the third 
transmembrane domain of TolQ interacts with the transmembrane region of TolR.  
This was confirmed with cross-linking experiments (Journet et al 1999).  The fifth 
suppressor mutant was located at the C-terminus of TolR in the region predicted to 
consist of an amphiphilic helix.  It has been proposed that this C-terminal helix of 
TolR interacts with TolQ and TolA in the cytoplasmic membrane (Lazzaroni et al 
1995, Journet et al 1999).   
A complex between a TolR dimer and TolQ has been detected, indicating that at least 
one molecule of the TolR dimer can interact with TolQ (Journet et al 1999).   
TolR-TolA 
Cross-linking experiments have shown that the N-terminal transmembrane domain of 
TolR interacts with the N-terminal transmembrane domain of TolA (Derouiche et al 
1995).  No complex between a TolR dimer and TolA could be detected in cross-
linking studies (Journet et al 1999).   
As mentioned above, it has been proposed that the C-terminal domain of TolR also 
plays a role in the TolR-TolA interaction, consistent with the observation that TolR 
domain III partially co-fractionates with membranes (Journet et al 1999).   
TolQ-TolA 
Mutation of the N-terminal region of TolA, resulted in disruption in the interaction 
with TolQ or TolR (Germon et al 1998).  Suppressor mutations, which restored the 
activity of tolA mutants were found to be located in the first transmembrane region of 
TolQ, indicating that the TolA N-terminal domain interacts with the first TolQ 
transmembrane region (Germon et al 1998).   
1.9.1.8. Ybgc and YbgF 
The roles of the other two genes in the tol-pal operon is less clear.  ybgc encodes a 
cytoplasmic protein with an unknown function (Vianney et al 1996).  Bacteria with an 
insertion in the ybgc gene remained sensitive to colicins E1 and E3 (Sun and Webster 
1987).   
ybgf encodes a 29 kDa periplasmic protein but inactivation of this gene does not 
induce a tol phenotype.  The protein does not interact with TolB or Pal in cross-
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linking studies but has been shown to interact with TolAII-III (Vianney et al 1996, 
Wallburger et al 2002).  The interaction between YbgF and TolA is predicted to occur 
through coiled coil regions of TolAII and of YbgF (Wallburger et al 2002).   
1.9.1.9. Stoichiometry of Tol-Pal proteins 
The stoichiometry of the Tol-Pal proteins is not well defined, as the expression levels 
have not been simultaneously measured in a given strain.  It has been estimated, by 
using an inactive colicin A mutant in competition experiments, that there are 1000 
translocation sites per cell (Duché et al 1995).   
It is estimated from Western blotting that TolA is present at approximately 800 copies 
per cell and there are 2000-3000 copies of TolR (Levengood 1991, Muller et al 1993).  
This is consistent with radioactive labeling experiments, which suggest that the 
TolA:TolR ratio is 1:2 (Guihard et al 1994).  These experiments also suggest that 
TolQ is about three times as abundant as TolR (Guihard et al 1994).  Pal has been 
found to be present in large excess over the TolA protein and it is predicted that there 
are 10,000 to 30,000 copies of Pal per cell (Cascales et al 2000, Lloubès et al 2001).  
This greater amount of Pal protein per cell is consistent with the tolb/pal operon being 
under the control of the P1 promoter and the strong promoter, PB, whereas the 
tola/q/r operon is only under the control of P1.   
It is not yet known whether the Tol system is dependent on formation of stable 
complexes of defined stoichiometry or on more subtle transient interactions between 
different protein partners.   
A model has been proposed in which four TolQ and two TolR proteins interact with 
one TolA molecule in the inner membrane (Cascales et al 2001).   
1.9.1.10. Function of the Tol system 
Sensitivity of tol mutants to dyes and detergents and their tendency to release 
periplasmic proteins into the medium indicates that the membrane permeability of tol 
mutants is altered, and it has therefore been proposed that the Tol system maintains 
outer membrane integrity (Lazzaroni et al 1989).  The tol phenotype is very similar to 
the lpp phenotype and as Lpp is covalently associated with peptidoglycan, it has been 
suggested that the Tol system could link the outer and inner membranes to 
peptidoglycan (Lloubes et al 2001).  This is supported by the identification of the 
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TolA-Pal and TolB-Pal interactions and the interaction of TolB and Pal with OmpA 
and Lpp (Clavel et al 1998, Cascales et al 2002).   
The interaction of TolA and TolB with porin trimers (Derouiche et al 1996, Rigal et 
al 1997, Clavel et al 1998, Dover et al 2000) suggests that these proteins could be 
involved in the assembly of porins.  This is supported by the reduction in the amount 
of OmpF and LamB in tol mutants (Lazdunski et al 1998).  Tol proteins could also 
regulate LPS translocation or assembly as tol mutants can have a decreased LPS 
content and TolA is required for the surface expression of O-antigen and LPS 
(Lazzaroni et al 1999, Gaspar et al 2000).  The Tol-Pal proteins might help porin 
trimer-LPS complexes with a molecular weight greater than 50 kDa, the cut-off point 
for translocation across the peptidoglycan layer, to cross the peptidoglycan layer 
(Clavel et al 1998).  The Tol-Pal apparatus assists in the transport of newly 
synthesized outer membrane components by bringing inner and outer membranes into 
close proximity via the TolA-Pal or TolA-TolB interactions (Cascales et al 2004).   
Studies showing that TolQ and TolR can transduce energy to TolA, dependent on the 
proton motive force, suggest that TolQRA could act as an ion potential-driven 
molecular motor (Cascales et al 2000).  TolQ and TolR are homologous to the MotA 
and MotB components of the flagellar motor.  An ion pore could be formed by the last 
two transmembrane helices of TolQ and the TolR transmembrane helix and possibly 
the C-terminal domain of TolR.  By analogy with models of the MotA-MotB motor, 
the ion conductance would be regulated by changes in relationship between TolQ and 
TolR (Cascales et al 2001).  The natural function of the ion potential created could be 
to export cell envelope components with colicins parasitising the system to be 
imported across the cell envelope.   
1.9.1.11. Current model for Tol-dependent translocation of 
colicins 
Once a colicin has bound to its receptor, the translocation domain may move through 
the outer membrane via a second outer membrane protein, possibly requiring 
unfolding of the translocation domain.  As TolB associates with Pal, linking it to the 
outer membrane, it is likely that the colicin translocation domain first interacts with 
TolB.  The interaction between TolB and the colicin, would displace the TolB-Pal 
interaction and Pal may then interact with the peptidoglycan (Lazdunski et al 2000).  
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The colicin then interacts with TolR and TolA, either separately or at the same time, 
possibly allowing further unfolding of the colicin polypeptide chain (Journet et al 
2001, Lazdunski et al 2000).  It is not yet known how these interactions could allow 
the C-terminal cytotoxic domain of the colicin to enter the periplasm.  It has been 
suggested that interaction of this domain with phospholipids could induce a slow 
conformational change into a “molten globule” state, allowing movement of the 
domain across the outer membrane (Lazdunski et al 2000).  Recent work with the 
colicin E9 DNase domain indicates that the structure and stability of the domain is 
altered on interaction of the domain with phospholipids vesicles, suggesting that a 
destabilising protein-lipid complex is the first step for translocation of the cytotoxic 
domain of colicins across the outer membrane (Mosbahi et al 2004).   
 
The differing requirements for Tol proteins between colicins, indicates that a single 
model is insufficient for translocation of all Tol-dependent colicins.  The lack of 
conservation of TolA and TolR boxes in different colicins also points towards several 
mechanisms of Tol-dependent translocation.   
 
It has been suggested that colicin translocation occurs by Brownian ratcheting, where 
the movement of the colicin across the periplasm would occur by simple diffusion 
with interactions of the colicin with Tol proteins, preventing the colicin from moving 
backwards (Journet et al 2001).  This would require each interaction between the 
colicin and a Tol protein to have a higher affinity than the previous interaction.   
This model cannot account for movement of the colicin from the outer membrane to 
the periplasm as the Kd for interaction of the colicin with its receptor is of nanomolar 
affinity, whereas the Kd for interaction with Tol proteins is of micromolar affinity 
(Bradbeer et al 1986, Journet et al 2001).  A potential discrepancy with the model is 
that the affinity of the interaction between TolR and colicin A appears weaker than 
the affinity of the interaction between TolB and colicin A, although the affinity 
constant of the TolR-colicin A interaction has not yet been determined (Journet et al 
2001).  This is inconsistent with the Brownian ratcheting model if colicin A interacts 
with TolB first.   
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1.9.2. The Ton translocation system 
The Ton system is composed of proteins ExbB, ExbD and TonB, which form a 
complex in the inner membrane (Lazdunski et al 1998).  The tonB gene is located at 
28 min on the E.coli chromosome and the exbB and exbD genes form an operon at 65 
min (Lazdunski et al 1998).  The physiological role of the Ton system is transduction 
of energy from the pmf of the cytoplasmic membrane into the periplasm (Larsen et al 
2001).   
1.9.2.1. Arrangement of the Ton system 
TonB and ExbD are anchored by their N-terminal end to the cytoplasmic membrane 
and extend into the periplasm (Postle and Skare 1988, Kampfenkel and Braun 1992).  
ExbB is an integral cytoplasmic membrane protein with three transmembrane 
segments (Fischer et al 1989).  ExbB, ExbD and TonB form a complex in the inner 
membrane via their transmembrane regions with ExbB at the centre of the complex 
(Lazdunski et al 1998).  However, the stoichiometry may not be 1:1:1 as TonB may 
dimerise, and ExbB is thought to be expressed in greater quantities than ExbD and 
TonB (Chang et al 2001, Fischer et al 1989).   
1.9.2.2. Similarities of the Ton and Tol systems 
ExbB and ExbD are functionally and structurally homologous to TolQ and TolR 
respectively and it is thought that TolQR can complete the role of ExbBD and vice 
versa (Eick-Helmerich and Braun 1989, Braun and Hermann 1993).  However, TolA 
and TonB are not interchangeable although when the N-terminal transmembrane 
region of TolA was exchanged with the same region of TonB, the mutated protein 
exhibited TonB activity, consistent with the sequence similarity observed in this 
region (Braun and Hermann 1993).   
1.9.2.3. TonB box 
The N-terminal domain of TonB interacts with outer membrane receptors (Brewer et 
al 1990).   
TonB dependent receptors contain a conserved sequence at their N-terminus, termed 
the TonB box and consisting of five residues (D/ETXXV, Postle 1999).  Disulphide 
and formaldehyde cross-linking has shown that the TonB boxes of BtuB, FepA and 
FhuA are in close proximity to TonB (Skare et al 1993, Moeck et al 1997, Cadieux 
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and Kadner 1999).  The crystal structure of BtuB shows that the TonB box is located 
in the plug domain and that the TonB box shifts in position, on binding of vitamin B12 
(Chimento et al 2003).  This supports the hypothesis that the interaction of TonB with 
the TonB box is involved in the removal of the ligand from the binding site of the 
receptor (Cadieux et al 2000).   
The TonB box has been identified in a number of different colicins, suggesting that 
Ton-dependent colicins could interact with TonB in a similar way to the Ton-
dependent receptors (Wiener et al 1997).  Mutagenesis studies have shown that 
colicin M requires the TonB box of FhuA as well as its own TonB box for uptake 
(Schöffler and Braun 1989).  Therefore, the receptor TonB box-TonB interaction may 
induce the conformational change required for the colicin to enter the periplasm and 
then the colicin may interact with TonB independently.   
1.9.2.4.  Model for Ton-dependent translocation of colicins 
Two models have been proposed to explain how TonB energy transduction can cause 
translocation.   
The propeller model (Chang et al 2001) proposes that TonB remains associated with 
the cytoplasmic membrane with a rotation of its carboxy terminus, initiated by ExbB, 
ExbD and the pmf.  When this propeller of TonB binds to the TonB-dependent 
receptor, the rotary motion causes the receptor to release its ligand into the periplasm.  
This model was based on the observation that the carboxy-terminal domain of TonB 
is a rigid, strand-exchanged dimer, likened to a propeller, but there is currently very 
little data to support the model (Postle and Kadner 2003).   
The shuttle model (Letain and Postle 1997, see Figure 1.13) proposes that TonB starts 
in a complex with ExbB and ExbD in an unenergised state.  ExbB and ExbD then use 
the cytoplasmic membrane pmf to convert TonB into an energised state.  The C-
terminal domain of TonB would then contact the outer membrane, whilst remaining in 
contact with the cytoplasmic membrane.  This then causes the N-terminal domain of 
TonB to be released from ExbB and ExbD so it could interact with a Ton-dependent 
receptor in the outer membrane.  This interaction would cause release of 
conformationally stored potential energy from TonB and release of the ligand from 
the receptor into the periplasm.  Current evidence, including the localisation of TonB 
at both the outer and cytoplasmic membranes and in soluble intermediate forms, 
supports this shuttling model (Postle and Kadner 2003).   
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Figure 1.13 The shuttle model for translocation of a ligand across the periplasm via TonB-
dependent energy transduction (from Postle and Kadner 2003).    1. TonB is associated with 
ExbD and ExbB at the cytoplasmic membrane.  2.  ExbB, ExbD use the cyptoplasmic membrane 
pmf to energise TonB.  3. TonB associates with the outer membrane, initially with non-
transporter proteins such as Lpp.  The binding of ligand to FepA induces a conformational 
change allowing the receptor to interact with TonB causing a release of conformationally stored 
potential energy and release of ligand into the periplasm. 4.  The energetically uncharged TonB 
then shuttles back to the cytoplasmic membrane.   
 
It is as yet unknown whether colicins could use a similar mode of translocation to the 
natural ligands of Ton-dependent receptors.  A model for the translocation of colicin 
Ia has been proposed, based on the crystal structure of this colicin (Wiener et al 
1997).  In this model, the TonB box in the translocation domain of the colicin 
competes with the TonB box of Cir, the Ton-dependent receptor for colicin Ia, for 
binding to TonB.  The displacement of TonB from the receptor, allows colicin Ia to 
move across the outer membrane, into the periplasm (see Figure 1.14).  
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Figure 1.14 Proposed mechanism for translocation of Ton-dependent colicins (adapted from 
Wiener et al 1997).  On binding of the receptor-binding domain of the colicin to the Ton-
dependent receptor, the TonB box of the colicin competes with the TonB box of the receptor for 
binding to TonB.  This would then allow the cytotoxic portion of the colicin to enter the 
periplasm and move towards the cytoplasmic membrane.  
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1.9.3. Translocation of endonuclease colicins across the 
cytoplasmic membrane 
As the DNA and RNA targets for endonuclease colicins are located in the cytoplasm, 
endonuclease colicins must not only traverse the outer membrane and periplasm, but 
must also translocate across the cytoplasmic membrane.   
1.9.3.1. Proteolytic processing 
Only the cytotoxic domain of the colicin needs to enter the cytoplasm and it has 
therefore been suggested that this domain is cleaved from the rest of the colicin (de 
Zamaroczy et al 2001).  The peptidase, LepB, has been proposed to perform this 
cleavage for colicin D, as incubation of colicin D with cell extracts containing 
overexpressed LepB, results in the production of a 10 kDa fragment corresponding to 
the RNase domain (de Zamaroczy et al 2001).  This cleavage is prevented by the 
presence of ImD.  However, purified LepB is not sufficient to cleave the colicin, 
suggesting that other proteins are involved.  LepB had no effect on other 
endonuclease colicins, indicating that this effect is specific for colicin D (de 
Zamaroczy et al 2001).   
The production of a fragment of colicin E3, corresponding to the translocation and 
receptor binding domains has also been detected, indicating that colicin E3 is also 
susceptible to proteolytic cleavage, but the smaller fragment, corresponding to the 
RNase domain, has not yet been identified (de Zamaroczy and Buckingham 2002).  
This production of the fragment was not dependent on LepB indicating that another 
peptidase is responsible for the cleavage.  The proposed cleavage site is located at the 
C-terminus of the receptor-binding domain of colicin E3 (residues 424-446) and this 
region is conserved in all nuclease colicins but not in pore-forming colicins (de 
Zamaroczy and Buckingham 2002).   
Processing of the nuclease domain of colicin E7 has also been reported (Liao et al 
2001).  Target cells, endogenously expressing his-tagged Im7 and treated with a 
colicin E7-Im7 complex were found to contain a polypeptide, slightly larger than the 
DNase domain of colicin E7, which was able to bind Im7.  It has been proposed that 
the difference in size is because the putative cleavage site is upstream of the 
“minimal” DNase domain (de Zamaroczy and Buckingham 2002).  However, the 
processing step took eight hours in vitro and one and a half hours in vivo, and required 
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a much higher concentration of colicin than the concentration needed for killing of 
sensitive cells (Liao et al 2001).  Therefore the biological significance of these results 
remains uncertain.    
1.9.3.2. Formation of channels 
The cytotoxic domain of colicin E9 shows channel-forming activity in planar lipid 
bilayers (Mosbahi et al 2002).  This channel-forming activity is abolished by the 
presence of Im9.  The channels formed are different to those formed by pore-forming 
colicins as they are not voltage gated and have much shorter lifetimes (Mosbahi et al 
2002).  Unlike pore-forming colicins, the formation of channels in the inner 
membrane by the DNase colicins does not directly cause cell death, as a colicin E9 
DNase active site mutant (H575A) is not cytotoxic despite being able to form 
channels (Mosbahi et al 2002).  The DNase domains of colicins E2, E7 and E8 also 
showed channel-forming activity, but the channels varied in size and gating behaviour 
(Mosbahi et al 2002).  Therefore, the formation of channels appears to be the 
mechanism by which DNase colicins traverse the inner membrane.   
No channel-forming activity could be detected for RNase colicins, indicating that 
their mechanism of translocation across the inner membrane may differ to that of the 
DNase colicins (Mosbahi et al 2002).     
1.10. Cytotoxicity 
1.10.1. Pore-formers 
The cytotoxicity of pore-forming colicins, results from the formation of ion-
permeable channels formed in the inner membrane of the susceptible cell, by the C-
terminal pore-forming domain of the colicin (Dankert et al 1982).  Several models 
have been proposed to explain the formation of the channel, but none are readily 
accepted (Lakey et al 1993, van der Goot 1991, Zakharov and Cramer 2002).   
The initial interaction of the cytotoxic domain with the membrane is predicted to be 
electrostatic, as pore-forming colicins require an acidic pH for binding to artifical 
membrane vesicles (Davidson et al 1995, Zakharov and Cramer 2002).  A group of 
positive charges on the surface of the domain is predicted to orient the domain on the 
membrane surface (Elkins et al 1997).  Once the cytotoxic domain has bound to the 
membrane, it then unfolds, possibly via a molten globule intermediate, allowing 
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extension of the helices and insertion into the membrane (van der Goot et al 1991, 
Cramer et al 1995, Zakharov and Cramer 2002).  The requirement for partial 
unfolding of the pore-forming domain, as it moves from the aqueous to the membrane 
phase, has been inferred from the onset of channel activity and the decrease in 
structure, as monitored by CD, as a function of pH (Schendel and Cramer 1995).   
1.10.1.1. Structures of pore-forming domains 
The structures of the pore-forming domains of colicins A (Parker et al 1989), E1 
(Elkins et al 1997), N (Vetter et al 1998), B (Hilsenbeck et al 2004) and Ia (Wiener et 
al 1997) show that they consist of a bundle of eight amphipathic helices burying two 
hydrophobic helices.  The average length of the helices is 13 residues, but 
approximately 17-20 residues are required to span the membrane bilayer (Elkins et al 
1997, Zakharov and Cramer 2002).  However, the α-helical content of colicin E1 
increases by ~25 % on pore formation, which may cause a sufficient extension to 
allow the helices to span the membrane (Elkins et al 1997, Zakharov et al 1998). 
The two longest helices (the hydrophobic helices, 8 and 9) form a hydrophobic helical 
hairpin at the core of the domain, which is predicted to provide a membrane anchor 
after the initial interaction of the protein with the membrane bilayer (Zakharov and 
Cramer 2002).   
1.10.1.2. Nature of the channel 
The cytotoxic domain of the pore-forming colicin remains tightly bound to the 
membrane once it has inserted into the membrane (Kd ~ 2-3 nM, Heymann et al 
1996).  From the permeability of the channel formed by colicin E1 to various probes, 
the diameter of the channel formed by colicin E1 has been estimated to be 9 Ǻ at the 
narrowest part (Bullock et al 1992).  However, if the elongated shape of these probes 
is taken into account, the channel could be as small as 4-5 Ǻ (Cramer et al 1995).  The 
size of the channel formed varies according to the colicin.   
The channel activity of colicin A has been measured by analysing the kinetics of 
potassium efflux induced by the colicin (Bourdineaud et al 1990).  The channels 
formed in vivo were shown to be voltage and pH dependent.  After addition of colicin, 
the membrane potential drops to -85mV and the channel closes if the potential 
increases above this value (Bourdineaud et al 1990).  The channel will re-open again 
if the cell regains polarisation (Bourdineaud et al 1990).  The gating voltage, ie the 
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voltage at which 50 % of channels are activated, varies for different colicins 
(Bénédetti and Géli 1996).  The gating voltage for full-length colicins is pH 
dependent but the gating voltage for the pore-forming domain is not pH dependent.  
This indicates that regions other than the pore-forming domain regulate channel 
behaviour (Bénédetti and Géli 1996).   
The channel allows movement of monovalent ions (Na+, K+ and Cl-) with a single 
channel conductance of > 106 ions channel-1 second-1, which is sufficient to allow a 
single colicin pore to depolarise the membrane (Bénédetti and Géli 1996, Bullock et 
al 1983).  The depolarisation causes inhibition of active transport and depletion of 
intracellular ATP, potassium and phosphate, leading to cell death (Elkins et al 1997).   
1.10.2. Endonucleases 
1.10.2.1. DNases 
The DNase colicins E2, E7, E8 and E9 cleave the host chromosomal DNA.  They 
share a high sequence identity in their receptor binding and translocation domains but 
are only ~70-80 % identical in their DNase domains.  X-ray crystallography and 
activity assays have localized the DNase domain of colicin E9 to residues 449-582 
(Kleanthous et al 1999, Pommer et al 1998).   
Structures of DNase domains 
Structures of the DNase domains of colicins E7 and E9 with their respective 
immunity proteins have recently been determined (Ko et al 1999, Kleanthous et al 
1999).  The crystal structure for the E9 DNase-Im9 complex at 2.05Å resolution 
shows the DNase domain consists of a central core of β-sheet surrounded by α-helices 
(Kleanthous et al 1999).  The C-terminal 32 amino acid residues show sequence 
identity to the HNH family of homing endonucleases (Shub et al 1994). The HNH 
motif resembles a distorted zinc finger and forms the core of the DNase active site 
(Pommer et al 1999).  This is supported by site-directed mutagenesis experiments, 
which were used to identify putative active site residues in the DNase domain of 
colicin E9 (Garinot-Schneider et al 1996).    Three single site mutations were 
identified which completely destroyed the toxic action of the colicin, R544A, E548A 
and H575A.  All three residues are highly conserved amongst the DNase colicins 
suggesting that these residues are involved either in maintaining the overall fold or in 
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the mechanism of the enzyme (Kleanthous et al 1999).  A nickel ion is bound in the 
crystal structure, and NMR has confirmed that this ion is coordinated by three 
histidine side chains and a phosphate molecule (Hannan et al 2000).   
The crystal structure of the colicin E7-Im7 complex at 2.3 Å resolution shows the 
DNase domain is a novel αβ protein with a Zn2+ ion bound to 3 histidine residues and 
a water molecule and contains a zinc finger motif  (Ko et al 1999).  The three 
catalytically important residues identified by site-directed mutagenesis of colicin E9 
are conserved in colicin E7 and are located near the Zn2+ ion.   
Colicin E9 has been shown to share sequence homology with CAD enzymes ie 
DNases involved in degradation of chromatin during the terminal stages of apoptosis 
(Walker et al 2002).  The similarity is supported by mutagenesis experiments.  H263 
in mouse CAD, equivalent to H103 in the colicin E9 DNase domain, is predicted to 
activate the hydrolytic water molecule.  H308 of mouse CAD, equivalent to H127 in 
the colicin E9 DNase, is suggested to be the Mg2+ binding residue.  The CAD 
enzymological properties are analogous to those of the colicin E9 DNase and 
therefore it is speculated that colicin DNases and CADs cleave DNA by the same 
mechanism, which is an interesting possibility given that both enzymes are involved 
in the degradation of chromosomal DNA, leading to cell death (Walker et al 2002).   
Specificity of colicin E9 DNase 
The colicin E9 DNase has been shown to preferentially nick double-stranded DNA at 
thymine bases, producing 3’-hydroxy and 5’-phosphate termini and it is suggested 
that a DNase monomer binds to the phosphate backbone of each strand (Pommer et al 
2001).  The DNase does not cleave mononucleotide phosphoryl esters or dinucleotide 
substrates.  The DNase also cleaves single-stranded DNA, but the presence of a 
transition metal is required (Pommer et al 2001).   
The metal ion 
The role of the metal ion bound to the DNase domain is still debateable and it has 
been suggested that it may play a catalytic or structural role.     
The metal-bound water molecule may serve as a nucleophilic hydroxide ion that 
attacks the phosphate atom (Ko et al 1999).  A cleft near the three catalytically 
important residues, formed by a central β-sheet and the α-helices layered next to it, is 
the proposed binding site for the DNA substrate (Ko et al 1999).  Work with the 
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DNase domain of colicin E7 has shown that although zinc ions are not required for 
binding of the domain to DNA, the metal ion is required for hydrolysis of DNA, 
further suggesting that the metal ion is involved in DNA hydrolysis (Ku et al 2002). 
Ordinarily the metal ion in the zinc finger motif would be tetrahedrally coordinated 
with four protein ligands.  However, in the DNase domain of colicins E9 and E7, the 
fourth ligand is either a phosphate molecule or a water molecule respectively.  This 
could reduce the affinity of the protein for the metal ion, allowing removal of the 
metal ion at some point during translocation to allow partial unfolding (Pommer et al 
1999).  Therefore, the metal ion could play another role in stabilising the DNase 
domain in the extracellular environment.   
Although zinc or nickel have been identified in the crystal structures of colicin E7 and 
E9, enzymological characterisation of the colicin E9 DNase domain showed that it 
can use a number of metal ions to cleave DNA, the identity of which governs whether 
the enzyme produces single or double strand breaks (Pommer et al 1998).   
Although zinc can be used for hydrolysis of DNA by colicin E7, zinc does not support 
hydrolysis of any DNA substrate by colicin E9 (Pommer et al 2001).  The 
physiological metal ion for colicin E9 has been shown to be magnesium, which allows 
the formation of double-strand breaks in the DNA (Walker et al 2002).   
1.10.2.2. RNases 
The cytotoxic domains of the RNase colicins display a greater sequence conservation 
(~80-90%) than that for DNase colicins.   
Colicin E3, E4, E5 and E6 kill cells by inactivating the protein biosynthetic 
machinery (Nomura and Witten 1967).     
rRNases 
Colicin E3 is a 58 kDa ribonuclease that cleaves 16S ribosomal RNA (rRNA) at the 
49th phosphodiester bond from the 3’ end (Bowman et al 1971).  This bond is at a 
critical position near where interactions of the A site tRNA and the mRNA on the 
ribosome occur (Cate et al 1999).  The crystal structure of the cytotoxic domain of 
colicin E3 in complex with its immunity protein has been solved to 2.4Å resolution 
revealing a highly twisted central antiparallel β-sheet elaborated with a short N-
terminal helix (Carr et al 2000b, Soelaiman et al 2001).  This fold is significantly 
different to that of other ribonucleases.  Sequence and structural analysis combined 
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with molecular modelling and mutagenesis has revealed a putative active site within 
the toxin containing a His-Glu catalytic pair (Soelaiman et al 2001, Walker et al 
2004).   
Docking of the crystal structure of the RNase domain of colicin E3 onto the crystal 
structure of the 30S ribosomal subunit, has lead to the proposal of a catalytic 
mechanism with residues E517, H513 and D510 making up the catalytic triad 
(Zarivach et al 2002).  Residue R545 is likely to stabilise the negatively charged 
penta-coordinated cyclic phosphate atom transition state.  Alanine mutagenesis 
confirmed the importance of residue H513 and E517 as the acid-base pair in catalysis 
(Walker et al 2004).   
A comparison of the sequences of the C-terminal domains of colicins E4 and E6 with 
colicin E3 shows that colicins E4 and E6 are E3 homologs and also cleave the 16S 
rRNA.  However, the C-terminal region of E5 exhibits no sequence similarity to 
colicin E3.   
tRNases 
Examination of colicin E5 activity in vitro and in vivo demonstrated that the target of 
colicin E5 is not ribosomes, as in the case of colicin E3, but tRNA for tyrosine, 
histidine, asparagine and aspartate.  These tRNAs all contain the guanine analog, 
queuine, at the wobble position of each anticodon, although the sequence with an 
unmodified guanine instead of queuine is also sensitive to the colicin (Ogawa et al 
1999, Masaki and Ogawa 2002).  Colicin E5 hydrolyses these tRNAs on the 3’ side of 
this nucleotide.  Colicin D has also been shown to act as a tRNase, cleaving arginine 
tRNAs (Masaki and Ogawa 2002).  The tRNase activity of colicin D has been 
localised to the C-terminal 91 residues (de Zamaroczy et al 2001).   
1.10.3. Inhibition of peptidoglycan biosynthesis 
Colicin M is unique amongst colicins, as it causes lysis of cells.  It has been shown to 
inhibit synthesis of peptidoglycan and LPS by inhibiting the bactoprenyl-P carrier 
lipid, interfering with the recycling of bactoprenyl phosphate from bactoprenyl 
pyrophosphate (Harkness and Braun 1989).    
 64 
1.11. Project Aims 
The broad aim of this research project is to investigate the mechanism by which the 
cytotoxic domain of colicins is delivered to its cellular target.  Colicins range between 
30 and 90 kDa in size and in order to reach their cytotoxic target, they must traverse 
the formidable barriers of the outer membrane and periplasm, and, in the case of 
endonuclease colicins, the inner membrane.   
In order to achieve this unique event in prokaryotic biology, colicins have parasitised 
multiprotein systems used by cells to perform important biological functions such as 
porins (eg OmpF, OmpA), siderophore receptors (eg FhuA, FepA), the vitamin B12 
receptor, BtuB, and the Ton and Tol systems.  Therefore, colicins provide an excellent 
model to study the transport of polypeptides into cells.   
A full understanding of this process requires knowledge of binding of the colicin to its 
outer-membrane receptor and interactions between the colicin and proteins of the Ton 
or Tol systems, in the periplasm, involved in translocation.   
This thesis concentrates on characterisation of the interactions between Group A 
colicins and proteins of the Tol system.  To achieve this, the techniques of surface 
plasmon resonance and atomic force microscopy have been employed.   
The best characterised of the colicin-Tol protein interactions is the interaction 
between endonuclease colicins and TolB and the initial part of this study concentrates 
on this interaction.   
The study is then extended to investigate differences between pore-forming and 
endonuclease colicins in their interactions with three Tol proteins, TolB, TolR and 
TolA.   
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2. CHAPTER 2 – Materials and Methods 
2.1. Bacterial Strains and Media 
Bacterial cultures were grown in LB broth or on LB agar plates.  Selection of 
recombinant clones was on media supplemented with ampicillin or kanamycin (100 
g ml -1 final concentration).  Isopropyl-β-D-thiogalactopyranoside (IPTG) was added 
to a final concentration of 1mM to induce expression of T7 RNA polymerase in λ 
(DE3) lysogenic cultures.  Strains used are listed in Table 2.1. 
Bacterial strains were stored in 20 % glycerol at -20 ºC.   
Table 2.1 List of strains used throughout this thesis, with their relevant genotypes and 
source. 
E.COLI  STRAIN RELEVANT GENOTYPES SOURCE 
DH5α LacZDM15 recA1 Invitrogen 
ER2566 LacZ::T7 λ (DE3) New England Biolabs 
JM83 ∆(lac-proAB), Φ90dlacZ∆M15  
BL21 (DE3) araB::T7 Invitrogen 
2.2. Plasmids and Plasmid Isolation 
pET21a, pET21d and pET30c (Studier and Moffat 1986; Novagen, see Figure 2.1 and 
Figure 2.2) were used for cloning and expression of target genes.  Expression was 
under the control of strong bacteriophage T7 transcription and translation signals.  
Reverse PCR primers were designed to remove the stop codon of the target gene 
during cloning to allow incorporation of a six histidine (His6) tag at the C-terminus of 
the encoded protein.  This tag enables rapid purification of the protein using nickel 
affinity chromatography (Garinot-Schneider et al 1996).   
Colicin E9 mutants were produced using pNP69 (Christopher Penfold) as a template.  
pNP69 is a pET21a-based plasmid, based on pCS4 (Garinot-Schneider et al 1997), 
expressing colicin E9 and its immunity protein mutated to contain the following 
restriction sites in the colicin E9 gene: EcoRV 490-95, SacI 988-93, NcoI 342-347.  
The colicin E9 and immunity protein genes were cloned into the vector using NdeI 
and XhoI restriction sites.  The sequence of pNP69 is shown in Figure 2.3.   
Plasmid extractions were completed using the Wizard SV Miniprep kit (Promega, WI) 
as directed by the manufacturer’s instructions.   
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Figure 2.1 The Vector Map of pET21a (Novagen). pET21d differs slightly from pET21a. 
pET21d is 5440 bp as 2 bp have been removed after the BamHI site (position 198). Additionally, 
the NdeI site of pET21a is replaced with an NcoI site in pET21d resulting in a net 1 bp loss at 
position 238. 
 
Figure 2.2 The Vector Map of pET30a (Novagen). pET30c differs from pET30a as 1 bp has 
been added after the BamHI site (position 198).  This removes the C-terminal his-tag.   
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M  S  G  G  D  G  R  G  H  N  T  G  A  H  S  T  S  G  N  I   
atgagcggtggggatggacgcggccataacacgggcgcgcatagcacaagtggtaacatt 
 
N  G  G  P  T  G  I  G  V  S  G  G  A  S  D  G  S  G  W  S  
aatggtggcccgaccgggattggtgtaagtggtggtgcttctgatggttcaggatggagt 
        
S  E  N  N  P  W  G  G  G  S  G  S  G  I  H  W  G  G  G  S  
tcggaaaataacccgtggggtggtggttccggtagcggcattcactggggaggtggctcc 
 
G  R  G  N  G  G  G  N  G  N  S  G  G  G  S  G  T  G  G  N  
ggtcgtggtaatggcgggggtaatggcaattccggtggtggctcgggaacaggcggtaat 
 
L  S  A  V  A  A  P  V  A  F  G  F  P  A  L  S  T  P  G  A  
ttgtcagcagtagctgcgccagtggcatttggttttccggctctttccactccaggagct 
 
G  G  L  A  V  S  I  S  A  S  E  L  S  A  A  I  A  G  I  I  
ggcggtctggctgtcagtatttctgcaagcgaattatcggcagctattgctggtattatt 
 
A  K  L  K  K  V  N  L  K  F  T  P  F  G  V  V  L  S  S  L  
gctaaattaaaaaaagtaaatcttaaattcactccttttggggttgtcttatcttcatta 
 
I  P  S  E  I  A  K  D  D  P  N  M  M  S  K  I  V  T  S  L  
attccgtcggaaatagcgaaagatgaccccaatatgatgtcaaagattgtgacgtcatta 
 
P  A  D  D  I  T  E  S  P  V  S  S  L  P  L  D  K  A  T  V  
cccgcagatgatatcactgaatcacctgtcagttcattacctctcgataaggcaacagta 
    EcoRV 
D  N  V  N  V  R  V  V  D  V  K  D  E  R  Q  N  I  S  V  V  
aacgtaaatgttcgtgttgttgatgatgtaaaagacgaacgacagaatatttcggttgtt 
 
S  G  V  P  M  S  V  P  V  V  D  A  K  P  T  E  R  P  G  V  
tcaggtgttccgatgagtgttccggtggttgatgcaaaacctaccgaacgtccaggtgtt 
 
F  T  A  S  I  P  G  A  P  V  L  N  I  S  V  N  D  S  T  P  
tttacggcatcaattccaggtgcacctgttctgaatatttcagttaatgacagtacgcca 
 
A  V  Q  T  L  S  P  G  V  T  N  N  T  D  K  D  V  R  P  A  
gcagtacagacattaagcccaggtgttacaaataatactgataaggatgttcgcccggca 
 
G  F  T  Q  G  G  N  T  R  D  A  V  I  R  F  P  K  D  S  G  
ggatttactcagggtggtaataccagggatgcagttattcgattcccgaaggacagcggt 
 
H  N  A  V  Y  V  S  V  S  D  V  L  S  P  D  Q  V  K  Q  R  
cataatgccgtatatgtttcagtgagtgatgttcttagtcctgaccaggtaaaacaacgt 
 
Q  D  E  E  N  R  R  Q  Q  E  W  D  A  T  H  P  V  E  A  A  
caggatgaagaaaatcgccgtcagcaggaatgggatgctacgcatccggttgaagcggct 
 
E  R  N  Y  E  R  A  R  A  E  L  N  Q  A  N  E  D  V  A  R  
gagcgaaattatgaacgcgcgcgtgcagagctcaatcaggcaaatgaagatgttgccaga 
        SacI 
N  Q  E  R  Q  A  K  A  V  Q  V  Y  N  S  R  K  S  E  L  D  
aatcaggagcgacaggctaaagctgttcaggtttataattcgcgtaaaagcgaacttgat 
 
A  A  N  K  T  L  A  D  A  I  A  E  I  K  Q  F  N  R  F  A  
gcagcgaataaaactcttgctgatgcaatagctgaaataaaacaatttaatcgatttgcc 
 
H  D  P  M  A  G  G  H  R  M  W  Q  M  A  G  L  K  A  Q  R  
catgacccaatggctggcggtcacagaatgtggcaaatggccgggcttaaagctcagcgg 
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A  Q  T  D  V  N  N  K  Q  A  A  F  D  A  A  A  K  E  K  S  
gcgcagacggatgtaaataataagcaggctgcatttgatgctgctgcaaaagagaagtca 
 
D  A  D  A  A  L  S  A  A  Q  E  R  R  K  Q  K  E  N  K  E  
gatgctgatgctgcattaagtgccgcgcaggagcgccgcaaacagaaggaaaataaagaa 
 
K  D  A  K  D  K  L  P  M  E  S  K  R  N  K  P  G  K  A  T  
aaggacgctaaggataaattagccatggagagtaaacggaataagccagggaaggcgaca 
        NcoI 
G  K  G  K  P  V  G  D  K  W  L  D  D  A  G  K  D  S  G  A  
ggtaaaggtaaaccagttggtgataaatggctggatgatgcaggtaaagattcaggagcg 
 
P  I  P  D  R  I  A  D  K  L  R  D  K  E  F  K  S  F  D  D  
ccaattccagatcgcattgctgataagttgcgtgataaagaatttaaaagcttcgacgat 
 
F  R  K  A  V  W  E  E  V  S  K  D  P  E  L  S  K  N  L  N  
tttcggaaggctgtatgggaagaggtgtcgaaagatcctgagcttagtaaaaatttaaac 
 
P  S  N  K  S  S  V  S  K  G  Y  S  P  F  T  P  K  N  Q  Q  
Ccaagcaataagtctagtgtttcaaaaggttattctccgtttactccaaagaatcaacag 
 
V  G  G  R  K V  Y  E  L  H  H   D  K  P  I  S  Q  G  G  E  
Gtcggagggagaaaagtctatgaacttcatcatgacaagccaattagtcaaggtggtgag 
 
V  Y  D  M  D  N  I  R  V  T  T  P  K  R  H  I  D  I  H  R  
Gtttatgacatggataatatccgagtgactacacctaagcgacatatcgatattcaccga 
 
G  K  -   M  E  L  K  H  S  I  S  D  Y  T  E  A  E  F  L  
Ggtaagtaaaatggaactgaagcatagcattagtgattatacagaagctgaattttta 
 
Q  L  V  T  T  I  C  N  A  D  T  S  S  E  E  E  L  V  K  L  
caacttgtaacaacaatttgtaatgcggacacttccagtgaagaagaactggttaaattg 
 
V  T  H  F  E  E  M  T  E  H  P  S  G  S  D  L  I  Y  Y  P  
gttacacactttgaggaaatgactgagcaccctagtggtagtgatttaatatattaccca 
 
K  E  G  D  D  D  S  P  S  G  I  V  N  T  V  K  Q  W  R  A  
aaagaaggtgatgatgactcaccttcaggtattgtaaacacagtaaaacaatggcgagcc 
 
A  N  G  K  S  G  F  K  Q  G  L  E  H  H  H  H  H  H  
gctaacggtaagtcaggatttaaacagggcctcgagcaccaccaccaccaccac  
     XhoI            
 
Figure 2.3 The sequence of colicin E9 and Im9 DNA and protein from pNP69.  The 
nucleotide sequence is shown in black lower case with restriction sites indicated in green.  The 
amino acid translation is shown in blue for colicin E9 and red for Im9.  – indicates a stop codon.  
The TolB box is highlighted in purple.   
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2.3. Plasmid Restriction, Ligation, Transformation and 
Electrophoresis 
Endonuclease digestion of plasmid DNA, ligation of DNA fragments, transformation 
of competent E. coli cells and agarose gel electrophoresis were completed as detailed 
by Sambrook et al (1989).   
2.4. Extraction of DNA from Agarose Gels 
Extraction of DNA from agarose gels was completed using the QIAEX II kit (Qiagen) 
as directed by the manufacturer’s instructions.   
2.5. Polymerase Chain Reaction (PCR) 
PCR was completed using an Eppendorf Mastercycler Personal.  PWO polymerase 
(Roche, Penzberg, Germany) was used in all reactions.   
Standard PCR reactions consisted of 30 cycles of 92 ºC for 30 seconds, 55 ºC for 30 
seconds, 72 ºC for 30 seconds.   
Second stage PCR reactions, used for site-directed mutagenesis, consisted of 30 
cycles of 92 ºC for 30 seconds, 62 ºC for 60 seconds, 72 ºC for 60 seconds.   
Details of primers used are shown in Table 2.2.   
Primer 
ID 
Sequence (5’ – 3’)  Use  
SR1 GTTATTTTCCGCACTCCATCC Mutates S41 to A in ColE9 
SR2 CCACGGGTTAGCTTCCGAACT Mutates N43 to A in ColE9 
SR3 CCACGGGGCATTTTCCGAACT Mutates N44 to A in ColE9 
H52 GCTCGAGGCCCTGTTTAAATCCTG Inserts an XhoI site instead of the stop codon of Im9 
T7 
promoter TAATACGACTCACTATAGGG 
Cloning & sequencing from 
pET vectors 
T7 
terminator CTAGTTATTGCTCAGCGGTGG 
Cloning & sequencing from 
pET vectors 
DW22 ACCATGGAACTGAAGCATAGC Inserts an NcoI site instead of the start codon of Im9 
W78 GCTCGAGCCAATCACCATCACGATAAT Replaces the stop codon of Im3 
with an XhoI site 
Z4 GCATATGAGCGGTGGCGATGGACGCGGC Introduces an NdeI site at the 
start of ColE3 
Table 2.2  List of sequences and uses of primers  
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2.6. Site-Directed Mutagenesis 
SDM was completed in a two-step PCR method (Sarkar and Sommer 1990).  A 
mutagenic primer was designed with a minimum of 6 complementary bases either 
side of the mutation.  This was used with the T7 promoter primer to complete the first 
stage PCR reaction using the standard PCR protocol.  The first stage PCR product 
was then purified from an agarose gel (Section 2.4) and used in a second stage PCR 
reaction with primer H52.   
2.7. DNA Sequencing 
DNA sequencing reactions were completed using a BigDye Terminator kit (PE 
Applied Biosystems) in an Eppendorf Mastercycler Personal.  The reaction involved 
25 cycles of 96 ºC for 10 seconds, 50 ºC for 5 seconds and 60 ºC for four minutes.  
The DNA was then ethanol precipitated and reactions were run on a Prism 310 
Genetic Analyzer (ABI) by sequencing technician, Sue Bainbridge, of the Division of 
Immunology, University of Nottingham.   
2.8. Protein expression 
4 ml of an overnight LB broth culture of E.coli BL21 cells or ER2566 cells, 
transformed with the relevant plasmid, in LB broth, was used to inoculate 400 ml LB 
broth.  When an OD600nm of 0.6 was reached, the cells were induced by addition of 
IPTG to 1 mM.  After two hours of induction the cells were harvested by 
centrifugation at 8000 g for 10 minutes in a Beckman Avanti J-20 centrifuge.   
2.9. Colicin Production Stab Test 
An LB agar plate supplemented with 100 g ml-1 ampicillin was inoculated with 
E.coli BL21 cells, transformed with the test and control plasmids.  The cultures were 
incubated at 37 ºC for 16 hours.  The cells were lysed by exposure of the plate to 
chloroform for ten minutes.  100 l of an overnight E.coli JM83 culture transformed 
with pET21a was added to 5 ml 0.7 % w/v molten non-nutrient agar.  The agar was 
then poured over the plate and allowed to set.  The plate was incubated overnight at 
37 ºC.  Cells producing active colicin produce a clear zone, where growth of the JM83 
culture is inhibited.    
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2.10. Colicin Production Spot Test 
5ml of 0.7% w/v molten non-nutrient agar was inoculated with 100 l E.coli JM83 
(pET21a) and was poured onto an LB agar plate supplemented with 100 g ml-1 
ampicillin.  The purified colicin proteins were serially diluted in potassium phosphate 
buffer and 2 l of the diluted proteins were spotted onto the agar and allowed to dry.  
The plate was incubated for 16 hours at 37 ºC.  The minimum concentration in a 10-
fold dilution series that produced a clear zone in the sensitive lawn, termed the titre, 
was determined. 
2.11. Luminescence Reporter Assay 
This assay makes use of an SOS-inducible chromosomal lux operon to detect DNA 
damage induced by colicin E9 in reporter cells (Mireille Vankemmelbeke unpublished 
results, Davidov et al 2000).  All assays were performed in a microtitre plate 
luminometer (Lucy 1, Anthos Labtech, Salzburg, Austria) at 37 ºC.  The luminometer, 
plates and media were pre-warmed to 37 ºC, to prevent induction of a stress response 
due to cooling.  An overnight culture of E.coli DPD1718, containing a fusion of the 
E.coli recA promoter region to the Photorhabdus luminescens luxCDABE reporter 
integrated into the lacZ locus of E.coli DPD1692, was diluted 1:50 and grown for 
three hours at 37 ºC in the presence of 30 g ml-1 chloramphenicol, until reaching an 
OD of 0.3-0.4.  The cells were then diluted 1:2 in 100 l total volume in black 96-well 
optical bottom microtitre plates (Nunc, www.nuncbrand.com) and 4 l of the wild-
type or mutant colicin was added.  Induction of luminescence was followed over a 
period of 90 minutes, with readings taken every 600 seconds.  Cell density was also 
monitored by measuring OD at 492 nm.   
The ratio of relative luminescence units (RLU) over OD492nm values were used to 
calculate gamma values at a time point of 50 minutes, using Equation 2-1.   
 
γ = 
Lcontrol
Lsample - Lcontrol
 
Equation 2-1 Equation to calculate gamma values, where L = RLU/OD492nm 
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2.12.  SDS-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
SDS-PAGE was completed using a mini gel system (Atto).  Stacking (6 %) and 
resolving (12 or 16 %) gels were prepared as described in Sambrook et al 1989.  
Protein samples were loaded onto a gel after 1 minute denaturation at 100 oC in an 
equal volume of 2 x loading buffer (100 mM Tris-HCl, pH 6.8, 4 % (w/v) SDS, 20 % 
(w/v) glycerol and 0.2 % (w/v) bromophenol blue dye).  Protein molecular weight 
standards (New England Biolabs) were loaded alongside protein samples to enable 
estimation of molecular weights.   
Gels were stained using Coomassie blue stain (0.2 % bromophenol blue dye, 45 % 
methanol, 10 % acetic acid) and destained in 40 % methanol, 10 % acetic acid.   
2.13. Silver Staining of SDS-PAGE gels 
Silver staining of SDS-PAGE gels was used when enhanced sensitivity of staining 
was required (Morrissey 1981).  The gel was washed twice in 50 % methanol, 10 % 
acetic acid for 15 minutes and once in 10 % ethanol, 5 % glacial acetic acid for six 
minutes.  The gel was then rinsed in distilled water and washed twice in distilled 
water for nine minutes.  Sensitisation of the gel was achieved by agitation of the gel in 
500 ml 20mg l-1 Na2S2O4 in distilled water for nine minutes.  This solution was then 
poured off and the gel was incubated on a shaker in 0.1 % AgNO3 in distilled water 
with 150 l 37 % (v/v) formaldehyde for nine minutes.   Excess AgNO3 was rinsed 
away with distilled water and 200 ml image developer (200l 37 % formaldehyde 
(v/v) in 200 ml 3 % sodium carbonate) mixed with 200 l 10 g/l sodium thiosulphate 
was added to the gel.  The gel was incubated in this solution until the desired staining 
intensity was achieved.  The developer solution was then poured off and 80 ml stop 
solution (50 g Tris, 25 ml glacial acetic acid in 1 l distilled water) was added.    
2.14.  Cell Lysis and Protein Purification 
2.14.1. Colicin E9 and colicin E3 wild-type and mutant 
proteins in complex with immunity proteins 
Cells were lysed by treatment with 5 ml Bugbuster (Novagen) at room temperature 
for 30 minutes.  The cell lysate was then centrifuged at 20,000 g for 10 minutes at 4 
 73 
ºC in a Sigma 3k30 centrifuge.  The supernatant was filtered using a 0.2 M sterile 
syringe filter (Millipore). 
Proteins were purified using HiTrap chelating HP columns (Amersham Biosciences) 
connected to a BiologicLP HPLC machine (BioRad).  Columns were equilibrated 
with 1 x PBS + 0.5 M NaCl, pH 7.4, charged with 50 mM NiSO4 and washed with 1 x 
PBS + 0.5 M NaCl, pH 7.4.  The filtered supernatant was then applied to the column 
and the column was then washed again with 1 x PBS + 0.5 M NaCl, pH 7.4 and pure 
protein was eluted using an increasing gradient of imidazole (1- 100% 1 M imidazole 
in 1 x PBS + 0.5 M NaCl, pH 7.4).  Proteins were dialysed in 5 litres potassium 
phosphate buffer (50 mM K2HPO4, 50 mM KH2PO4, pH 7) at 4 ºC for a minimum of 
16 hours.   
2.14.2. Free colicin E9 and free colicin E3 (without 
immunity proteins) 
Cells were lysed by treatment with 5 ml Bugbuster (Novagen) at room temperature 
for 30 minutes.  The cell lysate was then centrifuged at 20,000 g for 10 minutes at 4 
ºC in a Sigma 3k30 centrifuge.  The supernatant was filtered using a 0.2 M syringe 
filter (Millipore) and applied to a Hi-Trap column, equilibrated with 20 mM Tris-HCl 
pH 7.9, 5 mM imidazole, 0.5 M NaCl and charged with Nickel.  After application of 
the supernatant the column was washed with the Tris buffer.  Free colicin was then 
eluted using Tris-HCl pH 7.9, 5 mM imidazole, 0.5 M NaCl, 6 M Guanidine-HCl, 
with the polyhistidine tagged immunity protein remaining attached to the column.  
The column was then washed again with the Tris buffer and the immunity protein was 
eluted using a gradient of imidazole (0-100 % 1 M imidazole in 20 mM Tris-HCl pH 
7.9, 5 mM imidazole, 0.5 M NaCl).   
Proteins were dialysed in 5 litres potassium phosphate buffer (50 mM K2HPO4, 50 
mM KH2PO4, pH 7.4) for 16 hours at 4 ºC.  The buffer was then replaced with fresh 
potassium phosphate buffer and the proteins were dialysed for a further 8 hours.   
2.14.3. Tol proteins and Im9 
Cell pellets were resuspended in NiC buffer (10 % v/v glycerol, 25 mM NaH2PO4 pH 
7.4, 50 mM NaCl) containing a Complete EDTA-free Protease Inhibitor Cocktail 
tablet (Roche).  The cells were lysed using sonication for 40 minutes (Soniprep 150 
MSE, 20 secs on/off).  The sonicated sample was centrifuged at 15000 rpm for 30 
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minutes in a Beckman Avanti J-20 centrifuge.  Centrifugation was repeated with the 
supernatant produced.  The supernatant was filtered using a 0.2 M sterile syringe 
filter (Millipore) and applied to a Hi-trap column charged with nickel and equilibrated 
with 1 x PBS + 0.5 M NaCl pH 7.4.  Pure protein was eluted using an increasing 1M 
imidazole (in 1 x PBS + 0.5 M NaCl, pH 7.4) gradient ranging from 0-100 %.  
Proteins were dialysed in 5 litres potassium phosphate buffer (50 mM K2HPO4, 50 
mM KH2PO4, pH 7.4) at 4 ºC for a minimum of 16 hours.   
2.15. Determination of protein concentrations 
Protein concentrations were calculated using Beer’s Law: 
Abs280 = ε x path length x concentration 
Equation 2-2 Beer’s law 
Where:  
              [number of tyrosine residues x 1210) + [number of tryptophan residues x 5500] 
molecular mass of protein 
Equation 2-3 Equation used to calculate molar extinction coefficients (ε) 
Table 2.3 Table listing the molecular masses and molar extinction coefficients of purified 
proteins used in this thesis. 
Protein Molecular 
mass (Da) 
Number of 
Tyrosine 
residues 
Number of 
Tryptophan 
residues 
Molar 
extinction 
coefficient 
(cm-1/mgml-1) 
WT colicin E9/Im9 71150 9 8 0.77 
Free colicin E9 61587 6 7 0.74 
T61-DNase colicin 
E9/Im9 construct 
30873 6 6 1.30 
Free T61-DNase colicin 
E9 construct 
21291 3 5 1.46 
T & R domains of 
colicin E9 
46520 3 5 0.67 
WT colicin E3/Im3 67849 13 11 1.12 
Free colicin E3 57963 9 8 0.95 
Colicin A (1-172) 17846 5 4 1.57 
Im9 9582 3 1 0.95 
Im3 9904 4 3 2.15 
TolB 45956 13 8 1.30 
TolA (III) 12181 4 0 0.40 
TolR (II/III) 10725 2 0 0.23 
ε = 
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2.16.  Kunitz Assay 
This assay is used to test for DNase activity (Garinot-Schneider et al 1996).  The basis 
for the assay is the hyperchromic effect, whereby double-stranded DNA absorbs less 
UV light than single-stranded DNA.  Colicin E9 cleaves DNA into short pieces, 
which then degrades to single-stranded DNA and free nucleotides, causing an increase 
in absorbance at 260 nm.   
The assay was performed as described by Garinot-Schneider et al 1996.  50 g calf 
thymus DNA was suspended in 50 mM Hepes.NaOH [pH 7.5], 20 mM MgCl2 in a 
total volume of 1 ml.  10 g of test colicin (with Im9 removed) was added and the 
hyperchromic effect monitored at Abs260nm for 10 minutes using a Biomate 3 
spectrophotometer (Thermospectronic) at 25 ºC.   
2.17. DNase assay 
This assay is a qualitative test for DNase activity.  
pUC18 DNA was linearised with NdeI.  700-800 ng of colicin E9 (with Im9 removed) 
in 15 l Tris-HCl buffer (50 mM Tris-HCl [pH 8], 10 mM MgSO4) was incubated for 
30 minutes at 25 ºC.  125 ng linearised pUC18 was then added to the colicin E9 and 
this was incubated at 37 ºC for one and a half hours.  The DNA was then loaded onto 
a 1 % agarose gel and electrophoresed against untreated linearised pUC18 as a 
control.  Disappearance of the pUC18 DNA band demonstrates degradation of the 
DNA by the colicin E9.   
2.18. Gel filtration 
2.18.1. An introduction to gel filtration 
Gel filtration chromatography separates proteins on the basis of size.  A gel filtration 
column consists of two phases: a mobile phase, consisting of buffer carrying the 
solute, ie the proteins and a stationary phase, consisting of porous beads with a well-
defined range of pore sizes.  Proteins small enough to fit inside all the pores in the 
beads can be “included” inside the beads as well as having access to the mobile phase 
between beads and elute last in a gel filtration separation.  Proteins that are too large 
to fit inside any of the pores are “excluded” and, as they only have access to the 
mobile phase between the beads, they elute first in the “void volume” (Vo).  Proteins 
of intermediate size can fit inside some but not all of the pores in the beads and 
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therefore these proteins will then elute between the large, "excluded" and small, 
"included" proteins. The volume at which the intermediate proteins elute is called the 
elution volume (Ve) and depends on the partition of the molecule between the Vo and 
the volume inside the beads (Vs), which is proportional to the distribution coefficient 
(K) ie Ve = Vo + KVs. 
Both molecular weight and three dimensional shape can contribute to the degree of 
retention.  The technique can be used for purification of proteins, desalting of 
proteins, determination of molecular weight of a pure protein against standard protein 
size markers and to detect formation of complexes between proteins.   
 
 
Buffer 
flow 
 
 
 
Figure 2.4 Principle of gel filtration chromatography.  Red spheres denote “included” 
particles, yellow spheres denote partially “included” particles and green spheres denote 
“excluded” particles 
(adapted from http://www.olemiss.edu/depts/chemistry/courses/chem472_01/Expt9.pdf, accessed 
August 2004). 
2.18.2. Gel filtration methodology  
A Superdex 75 10/300 GL column with an optimum separation range of 3000 – 70000 
Da (Amersham Biosciences), attached to an ÄKTA Explorer FPLC system, was 
equilibrated with two column volumes (24 ml x 2) of 50 mM potassium phosphate 
buffer, pH 7.4 + 0.1 M NaCl (0.2 m filtered and degassed with helium) at a flow rate 
of 0.8 ml min-1. 
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100 l sample protein was then loaded onto the column at a flow rate of 0.5 ml min-1.  
The sample volume was kept as low as possible to enhance resolution.  The change in 
absorbance of the eluate at 280 nm with time was recorded.   
2.19. Atomic Force Microscopy 
2.19.1. An introduction to AFM 
The atomic force microscope (AFM), a member of the scanning probe microscope 
(SPM) family, was developed by Binnig and coworkers in 1986 (Binnig et al 1986).  
AFM is now an established technique for obtaining high resolution images of the 
surfaces of biological molecules (Dufrene 2004, Dorn et al 1999) and has also be used 
to measure inter- and intra- molecular forces in several biological systems (Rief et al 
1997a, Rief et al 1997b, Allen et al 1997, Ellis et al 1999, Willemsen et al 2000, 
Zhang et al 2002).   
2.19.2. AFM instrumentation 
The main features of an AFM are illustrated in Figure 2.5.  The first crucial part of the 
AFM is the sharp, micro-fabricated tip which actually ‘feels’ the surface.  The 
diameter of the tip, usually around 5-20 nm, is the key determinant of the resolving 
power of the microscope (Thundat et al 1992).   
 
Figure 2.5  Schematic showing the main features of the atomic force microscope 
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Attached to the tip is a cantilevered spring which allows the tip to move up and down 
as it tracks the surface topography.  The tip-cantilever assembly is usually made of 
silicon and silicon nitride due to its hard, wear-resistant properties and its capacity to 
be etched during microfabrication.  The cantilever has a very low spring constant, 
enabling the AFM to control the force between the tip and the sample with precision.  
The deflection of the tip is a measure of the forces between the tip atoms and the 
specimen atoms (usually in the pN to nN range).  Forces sensed by the cantilever are 
then transduced to generate molecular images.   
The second key feature of an AFM is the scanning mechanism, which is based around 
a piezoelectric transducer.  The transducer places the tip in close proximity to the 
sample surface.  In Figure 2.5, the scanner is placed below the sample and controls the 
motion of the sample on the nanoscale in three orthogonal directions, x, y and z.  The 
scanner can also be placed above the sample so that the piezo controls the motion of 
the tip rather than the sample.  The sample is raster scanned in the x-y direction in 
order to build up an image of the selected area of the sample, whilst the z channel 
moves the sample towards and away from the tip.   
The final aspect of the instrument is the translation of the deflection force into a 
detectable signal.  This can be achieved in several ways, but the most common 
method is the optical lever system.  A laser beam is focused directly onto the end of 
the cantilever and reflected onto a position-sensitive segmented photodiode detector.  
As the cantilever deflects, in response to the sample topography, the angle of the 
reflected laser beam changes so that the laser spot falling on the photodiode moves, 
producing changes in intensity in each of its quadrants.  The optical lever system 
amplifies the deflection signal up to 1000 fold so that deflections of less than 1 nm 
can be measured (Lal and John 1994).  Using an appropriate feedback mechanism, the 
deflection of the cantilever caused by the changes in force between the tip and sample 
can be kept constant or left to respond freely to the sensed forces.   
2.19.3. Imaging using AFM 
There are three main imaging modes available and the imaging mode used will often 
depend on the properties of the sample being investigated.   
1. Contact mode 
In contact mode, images can be generated in two ways (Morris et al 1999).  In the 
constant force mode, the feedback loop changes the height of the sample by adjusting 
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the voltage applied to the z portion of the xyz piezoelectric scanner.  The amount of 
change corresponds to the height of the sample at each point in the x-y plane.  A 
three-dimensional image can then be generated by combining the information from 
the three coordinates.    
In the alternative constant height mode, the feedback loop is open so that the 
cantilever undergoes a deflection proportional to the change in the forces between tip 
and sample and the z component of the xyz piezoelectric scanner is not actively 
adjusted.  The image is then constructed from the deflection information.   
2. Tapping mode 
In many studies of biological materials, a weak binding between the sample and 
substrate is desirable to preserve the activity and function of the sample (Möller et al 
1999).  In an attempt to reduce destructive lateral forces that can occur in contact 
mode and the contact time between the tip and the sample, tapping mode AFM has 
been developed (Hansma et al 1994).  In tapping mode AFM a relatively stiff 
cantilever is forced to oscillate above the sample at, or close to, its resonant 
frequency, so that it effectively intermittently taps the sample surface as it scans.  
Changes in the oscillation amplitude or phase, due to the sample topography, are used 
as a signal for image construction.   
The main advantage of tapping mode AFM is that it reduces the tip-sample contact 
time and the lateral forces resulting from frictional interactions which can often 
damage and displace soft, weakly immobilised samples.  However, the penalty of this 
decreased tip-sample contact time is the slight reduction in resolution, as the average 
tip-sample separation is larger in tapping mode than in contact mode.    
3. Non-contact mode 
In this mode the oscillating cantilever never actually touches the sample surface but 
remains a few nanometres above it (Morris et al 1999).  The system monitors the 
oscillation amplitude of the cantilever, which is affected by the van der Waals 
attractive forces between the tip and the sample.  A feedback circuit moves the 
scanner up and down to keep the oscillation amplitude constant.  The motion of the 
scanner can then be used to form an image of the sample surface.   
As there is no contact with the sample, the forces exerted on it in non-contact mode 
AFM are extremely low, and therefore this mode is generally used for very soft or 
elastic samples that are unsuitable for more conventional imaging.  The resolution, 
however, is lower than that for both contact mode and tapping mode AFM.    
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The AFM has been used to produce high resolution images of biomolecules such as 
proteins, DNA (Hansma et al., 1992) and cells (Hoh and Schoenenberger 1994, 
Dufrêne 2004).  Real time molecular resolution images of biomolecular interactions 
have also been achieved (Neish et al 2002).  
2.19.4. Force measurements using AFM 
In addition to topographical imaging, the AFM can also record the amount of force 
felt by the cantilever as the probe tip is brought close to a sample surface and then 
pulled away.  This allows measurement of attractive or repulsive forces between the 
probe tip and the sample surface, elucidating local chemical and mechanical 
properties including adhesive and elastic properties, and bond rupture lengths.   
AFM force measurements are made by recording the deflection of the free end of the 
AFM cantilever as the fixed end is extended towards and then retracted away from the 
sample.  Force measurements are generally performed in liquid environments in order 
to eliminate capillary forces which would otherwise mask the biomolecular 
interaction of interest (Weisenhorn et al 1989). 
 A typical force curve obtained from these force measurement experiments is shown 
in Figure 2.6 which plots force against the distance of the cantilever from the surface.   
The force sensed by the AFM tip can be determined using Hooke’s Law (Equation 
2-4). 
F = -kd                                   
Equation 2-4 Hooke’s Law, where F is force (N), k is the spring constant of the cantilever 
(N/m) and d is the displacement of the cantilever (nm).   
The spring constants of commercially available AFM cantilevers can range from 0.01 
– 1.0 Nm-1.  However, the estimated manufacturer’s spring constants can vary 
significantly from experimentally derived stiffness (Cleveland et al 1993), and it is 
therefore necessary to calibrate the spring constant of each cantilever.  There are 
several methods available for calibration of the spring constant but in this thesis, a 
thermal excitation technique was used.  This technique involves positioning the probe 
at a distance away from the sample (where the probe is not affected by long-range 
forces) so that the motion experienced is purely due to thermal fluctuations. The 
spring force constant, k, can then be determined from a measurement of the mean-
square spring displacement, using Equation 2-5. 
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kβT
q2
k =
 
Equation 2-5 Equation for measurement of the mean square spring displacement where k is 
the spring force constant, kβ is Boltzmann’s constant, T is temperature (K) and q is the 
displacement of the oscillator (spring) (m) (Hutter and Bechhoefer, 1993). 
The sensitivity of the cantilever to forces in the picoNewton range has been exploited 
to measure forces between and within individual biomolecules.  Lee et al (1994) were 
the first to demonstrate the ability of AFM to measure discrete, biologically specific 
rupture forces between molecular complexes.  They investigated the biotin-
streptavidin interaction, as it is one of the strongest non-covalent interactions in 
nature.  The rupture force required to break the interaction between biotin on the tip 
and streptavidin on the surface was measured.  The specificity of this interaction was 
demonstrated by blocking the remaining streptavidin binding sites with free biotin, 
after which no rupture forces were measured. 
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Figure 2.6  A typical force vs distance curve obtained from force measurement 
experiments.  The cantilever starts at a point above the surface (A) and is gradually brought 
closer to the surface at which point, the tip may jump into contact if it feels sufficient force 
(predominantly due to van der Waals forces) from the sample.  Once the tip is in contact with the 
surface, cantilever deflection increases (B) as the fixed end of the cantilever is brought closer to 
the sample due to overlapping of the electron orbitals of the atoms of the tip and sample (Born 
repulsion).  Once the cantilever reaches a predefined deflection level, the cantilever is then 
withdrawn from the surface but at this point the cantilever may stick to the surface due the 
adhesive interactions between the tip and the sample (C).  The adhesive interactions may be non-
specific (capillary or electrostatic) or specific between the molecule on the tip (eg a receptor) and 
the sample surface (eg a ligand).  The cantilever’s spring force is eventually enough to overcome 
the adhesion and the cantilever can then return to its original position (D).  The point at which 
the cantilever comes free from the surface can be used to measure the rupture force required to 
break the adhesion. 
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Several investigators reproduced and extended the streptavidin-biotin interaction 
experiments (Florin et al 1994) and this has been followed by the measurement of 
intra- or inter-molecular rupture forces of other biomolecules with lower affinities, 
including specific antibody-antigen interactions (Allen et al 1997), membrane 
receptor-ligand pairs (Dammer et al 1995) and flexible molecules such as titin 
(Marszalek et al 1999).   
2.19.5. Dynamic force spectroscopy 
Dynamic force spectroscopy can provide information about the molecular dynamics 
of protein-protein interactions, allowing estimation of affinity and rate constants as 
well as the position of energy barriers (Hinterdorfer et al 2002).   
In 1978, Bell proposed that the application of a mechanical force to a ligand-receptor 
bond reduces the activation energy and hence accelerates the dissociation of the bond.  
His model also predicted that the unbinding force should increase with the logarithm 
of the rate at which an external mechanical force, ie the loading rate, is applied 
towards unbinding of the complex.   
Bonds formed between complementary biomolecules have limited lifetimes and will 
spontaneously dissociate under zero force when the bond acquires sufficient energy 
(through Brownian excitation) to overcome the intermolecular potential of the 
dissociation landscape (Evans and Williams 2002).  However the retraction of the 
AFM tip from the sample surface can cause bonds to rupture at a faster rate than the 
natural lifetime of the bonds (Evans and Williams 2002).  When this occurs, the bonds 
demonstrate dynamic strength and force will be required to separate the complex.  
Over time the bond strength is reduced by thermal activation.  The off rate under 
applied force (kdiss [f]) for a single bond can be described by Equation 2-6.   
 
kdiss [f]= kdiss exp ffβ
 
Equation 2-6 Equation to determine the off rate under applied force (kdiss [f]) for an 
interaction, where kdiss is the natural rate of dissociation for the interaction, f is applied force 
and fβ is the force scale.   
 
The force scale (fβ) is defined in Equation 2-7.   
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fβ =
kB T
xβ
 
Equation 2-7 Definition of the force scale (fβ), where kB is the Boltzmann constant, T is 
temperature and xβ is the distance to the energy barrier to rupture.   
 
Application of an external force distorts the energy landscape, causing energy barriers 
to be lowered, displaced inward and narrowed, altering the kinetics (Evans and 
Williams 2002).  This distortion of the energy landscape increases the probability that 
the barrier will be overcome exponentially, and hence the probability that the bond 
will survive decreases exponentially.  Therefore, in order to overcome a single energy 
barrier along the unbinding coordinate a linear decrease in applied force is required 
with a logarithmic decrease in the rate of loading.   
 
F* = fβ[ln (loading rate) – ln (fβ kdiss)]
 
Equation 2-8 Equation describing the linear dependence of the most probable rupture force 
(F*) on the ln of the loading rate.  fβ is the force scale and kdiss is the rate of dissociation.   
  
From Equation 2-7 and Equation 2-8, a plot of peak rupture force against ln loading 
rate can be used to determine fβ (ie the gradient), the distance to the energy barrier (ie 
xβ = kBT/ fβ) and kdiss (x-intercept/gradient).  This plot is termed a dynamic force 
spectrum (DFS).   
These theoretical predictions have been confirmed experimentally using the AFM and 
the complementary approach of the biomembrane force probe (BFP), with an increase 
in loading rate causing an increase in rupture force between individual complexes of 
streptavidin/biotin (Merkel et al 1999, Yuan et al 2000).   
Merkel et al (1999) showed that the energy landscapes for the streptavidin-biotin and 
the avidin-biotin interactions comprise multiple energy barriers by plotting rupture 
force against the log of the loading rate, ie dynamic force spectra, and observing that 
two linear regimes existed in the spectrum for the streptavidin-biotin interaction, 
suggesting that dissociation of the complex proceeds via an intermediate state (see 
Figure 2.7).  Three regimes exist for the avidin-biotin interaction.  DFS analysis has 
also been used to investigate the energy landscapes of dissociation of several other 
biological complexes including antibody-antigen interactions (Strigl et al 1999) and 
protein-carbohydrate interactions (Dettmann et al 2000).   
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Figure 2.7 Dynamic force spectra for streptavidin-biotin and avidin-biotin.  The 
streptavidin-biotin bond exhibits two distinct regimes mapping the position of two different 
energy barriers along the dissociation pathway (solid). The avidin-biotin bond exhibits three 
linear regimes indicating that the dissociation pathway involves three energy barriers (dashed). 
Adapted from Merkel et al (1999). 
2.19.6. Sample preparation for AFM 
TolB was covalently immobilised onto polished silicon wafers using a method 
modified from Vinckier et al (1995) (as previously described by Allen et al 1997).  
See Figure 2.8 for the reaction pathway.   Silicon wafers were immersed in a 30% v/v 
solution of hydrogen peroxide (Sigma) in sulphuric acid (piranha solution) for 15 
minutes at room temperature.  The cleaned silicon wafers were rinsed thoroughly with 
deionised water and dried under a flow of nitrogen.  The silicon substrates were then 
oxidised in 10-2 mbar oxygen plasma for one minute at 100 W using a RF Plasma 
Barrel Etcher PT7100 (BIO-RAD Polaron Division) and then incubated in 4 % v/v 3-
aminopropyldimethylethoxysilane (3-APDES, Fluorochem) in toluene for two hours 
at room temperature, producing NH2 groups at the substrate surface.  The silanised 
substrates were rinsed in propanol, methanol and distilled water by sonication (Decon 
FS Minor, Decon Ultrasonics Ltd., UK) for one minute respectively to remove any 
loosely bound silane.  The amino functionalised substrates were then activated by 
incubation in a 10 % v/v solution of glutaraldehyde (Grade II, 25 % aqueous solution, 
Sigma) in potassium phosphate buffer (50 mM, pH 7.4) for one hour at 2-8 ºC.  The 
substrates were rinsed thoroughly in deionised water and incubated overnight in a 0.1 
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mg/ml solution of TolB.  The aldehyde groups covalently couple to the side chain ε-
amino groups of lysine residues in the protein.  Figure 2.9 shows that lysine residues 
are distributed throughout the TolB protein.  Prior to AFM analysis, the samples were 
rinsed thoroughly with deionised water to remove any non-covalently bound protein.   
In order to confirm that the modification of surface chemistry was successful and to 
optimise the concentration of TolB used, images of the silicon surfaces after the above 
procedure had been performed were obtained using a DI Multimode AFM (Digital 
Instruments, CA) in tapping mode with oxidised sharpened silicon nitride tips (Digital 
Instruments).     
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Figure 2.8  The reaction pathway for covalent immobilisation of TolB to a silanised 
silicon surface via glutaraldehyde cross-linking 
 
 
Figure 2.9  Protein sequence of TolB with lysine residues highlighted in red 
 
MKQALRVAFGFLILWASVLHAEVRIVIDSGVDSGRPIGVVPFQWAGPGAAPEDIG
GIVAADLRNSGKFNPLDRARLPQQPGSAQEVQPAAWSALGIDAVVVGQVTPNPD
GSYNVAYQLVDTGGAPGTVLAQNSYKVNKQWLRYAGHTASDEVFEKLTGIKGA
FRTRIAYVVQTNGGQFPYELRVSDYDGYNQFVVHRSPQPLMSPAWSPDGSKLAY
VTFESGRSALVIQTLANGAVRQVASFPRHNGAPAFSPDGSKLAFALSKTGSLNLY
VMDLASGQIRQVTDGRSNNTEPTWFPDSQNLAFTSDQAGRPQVYKVNINGGAPQ
RITWEGSQNQDADVSSDGKFMVMVSSNGGQQHIAKQDLATGGVQVLSSTFLDE
TPSLAPNGTMVIYSSSQGMGSVLNLVSTDGRFKARLPATDGQVKFPAWSPYL 
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2.19.7.  Imaging with AFM 
A TolB-functionalised silicon wafer was attached to a magnetic stub using double-
sided sticky tape and mounted onto a magnet located on the sample stage of the AFM 
instrument.  Topographic images of the samples were obtained in air using a DI 
Multimode AFM with a Nanoscope IIIa controller (Digital Instruments) in tapping 
mode using an “E” type scanner.  Unfunctionalised, oxidised sharpened silicon nitride 
tips (Digital Instruments) with a cantilever length of 125 m and a resonant frequency 
of 307-375 kHz were used.   
2.19.8. AFM tip functionalisation  
In order to achieve single molecular interactions between colicin E9 and TolB, colicin 
E9 was attached to the tip via the flexible polymer linker, carboxymethylamylose.  
The presence of a flexible linker is designed to reduce steric hindrance by spacing the 
colicin E9 protein away from the tip surface, allowing the colicin to freely diffuse 
around the tip and form the correct orientation for binding to TolB (Hinterdorfer et al 
2002).  In addition the linker provides a means of distinguishing between specific and 
non-specific intermolecular interactions.  When the molecule of interest is attached 
directly to the tip, it is often difficult to distinguish between intermolecular 
interactions specific to complex formation and the non-specific interactions between 
the tip and sample.  The addition of the flexible polymer to the tip produces a 
nonlinear, parabolic-like stretch characteristic in the AFM retract cycle to the point of 
bond rupture for a specific interaction between the molecule attached to the linker and 
the sample surface, whereas non-specific interactions are identified by a linear 
extension of the contact region.   
 
The following method was used to immobilise colicin E9 on the tip via a 
carboxymethylamylose linker. 
V-shaped cantilevers with silicon nitride probes (Veeco, CA) were oxidised in 10-2 
mbar oxygen plasma at 10 W for 30 seconds using a RF Plasma Barrel Etcher (BIO-
RAD Polaron Division).  The probes were then incubated in 4 % 3-APDES 
(Fluorochem) in toluene for two hours at room temperature, producing NH2 groups on 
the tip surface.  In order to remove any loosely bound silane, the probes were rinsed in 
propanol, methanol and deionised water for one minute respectively.  The amino-
functionalised tips were then incubated in 1 ml sodium phosphate buffer solution (20 
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mM, pH 7) containing 10 mg carboxymethylamylose (Sigma), 10 mg (1-ethyl-3-
dimethylamino-propyl) carbodiimide (EDC, Sigma) and 1 mg N-hydroxysuccinimide 
(NHS, Avocado Research Chemicals Ltd).  EDC is a water-soluble derivative of 
carbodiimide which catalyses the formation of amide bonds between carboxylic acids 
(on the carboxymethylamylose) and amines (on the tip) by activating carboxyl to form 
an O-urea derivative (see Figure 2.10).  NHS is used to assist the carbodiimide 
coupling by forming a more stable reactive ester that further reacts with the amine 
function to yield the amide bond.  The tips were then washed in potassium phosphate 
buffer (50 mM, pH 7.4) and incubated overnight in a 0.1 mg/ml colicin E9 protein 
solution.  The protein binds to the tip via the carboxymethylamylose linker.   
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Figure 2.10  Mechanism for EDC/NHS carbodiimide coupling of the 
carboxymethylamylose polymer linker to an AFM silicon nitride tip 
 90 
2.19.9. AFM force measurement studies  
A TolB-functionalised silicon wafer was attached to a glass microscope slide using 
double-sided sticky tape.  Approach-retract ‘force-distance’ curves were measured 
between the colicin-functionalised AFM tip and the TolB-functionalised silicon wafer 
in potassium phosphate buffer (50 mM, pH 7.4) at tip retraction rates of 10 m s-1, 1 
m s-1, 0.5 m s-1 and 0.1 m s-1 using a Molecular Force Probe instrument (MFP, 
Asylum Research, CA). 
To confirm the presence of specific TolB-colicin interactions, binding sites on TolB 
were blocked by incubation in a 1 mg ml-1 solution of colicin E9 in 50 mM potassium 
phosphate buffer, pH 7.4 at room temperature for a period of one hour.  Force 
measurements were then recorded between the colicin functionalised tip and the 
blocked surface.   
 
Figure 2.11  Schematic illustrating the experimental set-up for force measurement 
between colicin E9 and TolB 
 
Raw force data displays the cantilever deflection signal (nA) versus distance of z-
piezo movement (nm).  Plots were converted to force (nN) versus probe-sample 
distance (nm) using the cantilever spring constant which was calibrated using the 
thermal fluctuation method.  Rupture forces indicative of specific interactions were 
plotted as force versus frequency histograms.  The mode values from these histograms 
were then plotted against log of the tip retraction rate.   
 
AFM tip 
Amylose linker 
Colicin E9 
Cantilever 
TolB 
Silicon surface 
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2.20. Surface Plasmon Resonance  
2.20.1. An introduction to the SPR technique 
Surface plasmon resonance is a phenomenon which occurs when monochromatic, 
plane polarised light is reflected off thin metal films.  A fraction of the light energy at 
a specific incident angle above the critical angle can interact with delocalised 
electrons in the metal film causing a reduction in reflected light intensity at a specific 
angle.  The incident angle at which this happens, called the SPR angle, is dependent 
on the refractive index of the metal film and its immediate environment.   
The phenomenon of SPR was first observed by Turbadar (Turbadar 1959). However, 
the first commercial SPR biosensor only became available in 1990.  Since then, these 
biosensors have been used in a wide variety of fields.   
There are several SPR-based systems, but the most widely used is the BIAcore system 
(BIAcore AB, Jonsson et al 1991).  Figure 2.12 shows the set-up of a typical SPR 
BIAcore instrument.  The glass sensor chip is coated in a thin layer of gold and a 
ligand can be immobilised to this gold surface.  A flow channel allows exposure of 
the surface-bound ligand to analyte molecules and if an interaction occurs between the 
analyte and the ligand, the change in mass causes a change in the local refractive 
index of the metal film, affecting the SPR angle and in turn affecting the angle of 
reflected light with reduced intensity.  An optical detection unit measures the angle of 
reflected light with minimum intensity.  SPR response values are measured in 
resonance units (RUs), where one RU corresponds to a change in 0.0001 º in the angle 
of the intensity minimum (www.biacore.com/technology/spr_technology.lasso, 
accessed June 2004).  For most proteins this change corresponds to a change in 
concentration of about 1 pg/mm2 on the sensor surface, although the exact conversion 
factor between RU and surface concentration depends on the properties of the sensor 
surface and the interacting molecules.   
The response in RU is measured as a function of time over the course of the 
interaction, producing a sensorgram (see Figure 2.13).  The maximum response 
produced at saturation of all the ligand sites due to binding of analyte molecules, is 
termed RUmax.  The RUmax can be determined using Equation 2-9, as the amount of 
ligand bound is known.   
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RMM of analyte (kDa)
RMM of ligand (kDa)
Amount of analyte bound (RU)
Amount of ligand bound (RU)=
 
Equation 2-9 Equation describing the relationship between SPR response and relative 
molecular masses (RMM) of the ligand and analyte.  The maximum response expected if all 
ligand sites are saturated by analyte is termed RUmax and can be calculated from this equation.   
 
 
 
Figure 2.12  (from www.biacore.com, accessed June 2004).  A schematic of the set-
up of a typical SPR instrument.  The ligand, shown by a red inverted Y is attached to the thin 
gold layer of the sensor chip.  Plane polarised light is directed at the gold film and due to SPR 
there is a decrease in reflected light intensity at angle 1.  When the ligand is exposed to analyte 
molecules shown in yellow circles, the change in mass at the surface due to the interaction 
between the ligand and the analyte causes a local refractive index change at the sensor surface, 
causing a change in the angle reflected light with reduced intensity from angle 1 to angle 2.   
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Figure 2.13 (from www.biacore.com, accessed June 2004).  A typical SPR sensorgram, 
which measures response in resonance units (RUs) against time.  Starting on the left hand side, 
analyte molecules are injected across ligand molecules immobilised to a gold-coated sensor chip.  
Due to association between the analyte and the ligand, an increase in response is seen.  The 
analyte is then replaced with a continuous flow of buffer and a decrease in response is seen as the 
analyte dissociates from the ligand.  Finally the sensor surface is regenerated by removing any 
remaining analyte molecules at the surface, restoring the response to the original level and the 
sensor chip can then be re-used.  The sensorgram can be used to provide quantitative 
information on specificity, kinetics and affinity of binding.    
2.20.2. Sensor chips 
The sensor chips purchased from BIAcore AB, consist of a glass surface, coated with 
a thin layer (~50 nm) of gold.  A range of specialised surfaces are available, allowing 
the immobilisation of a variety of molecules.   
The most widely used sensor surface, consists of the gold surface modified with a 
carboxymethylated dextran matrix, 100-200 nm thick (Stenberg et al 1991, 
http://users.path.ox.ac.uk/~vdmerwe/internal/spr.pdf, accessed December 2002).   
This dextran matrix can be derivatised to allow a variety of immobilisation 
chemistries.  The dextran layer provides a hydrophilic environment to preserve 
biomolecules in a native state.  It also increases the volume of the surface increasing 
the potential level of ligand immobilisation and hence the sensitivity of the 
instrument.  
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Figure 2.14  Amine coupling TolB protein to the surface of a CM5 chip (Biacore 
AB). 
2.20.3. Amine coupling 
A widely applied immobilisation procedure of the carboxymethylated dextran matrix 
activates the carboxyl groups of the matrix using a mixture of EDC and NHS, via the 
same chemistry shown in Figure 2.10, to form esters that can react with amine groups 
on proteins, resulting in covalent immobilisation of the protein to the surface (see 
Figure 2.14).  The protein must be diluted in buffer at a pH lower than the pI value of 
the protein to allow electrostatic attraction of the protein to the negatively charged 
matrix.  Caution must be taken when using this method because the low pH used has 
the potential to denature the protein and therefore the activity of the protein should be 
measured after coupling.  Another disadvantage of this method is that the protein is 
randomly orientated on the sensor chip surface due to coupling of different lysine 
residues to the matrix, which may introduce sub-populations of accessibilities and 
reactivities (O’Shannessy et al 1992)  
A variety of other immobilisation methods have been described (O’Shannessy et al 
1992), for example, coupling by thiol/disulfide exchange [Cunningham and Wells 
1993, O’Shannessy et al 1992).  Other surfaces have also become available from 
BIAcore AB including surfaces functionalised with NTA, for capture of ligands via 
metal chelation; streptavidin, for capture of biotinylated ligands; and flat, hydrophobic 
surfaces to allow deposition of liposomes on the surface.   
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2.20.4. Microfluidics 
Biacore systems are equipped with a microfluidics system that allows analyte to pass 
over the sensor surface in a continuous, pulse-free and controlled flow 
(www.biacore.com technology brochure).  This allows the concentration at the sensor 
surface to remain constant.   
2.20.5. Reference cell 
The microfludics system allows at least two channels to be measured simultaneously.  
This allows comparison of binding between a derivatised surface and a blank 
reference surface.  Binding to the reference surface can be automatically subtracted 
from the binding measured on the derivatised surface, so that the response recorded is 
due to specific binding of the analyte to the sample surface.     
2.20.6. Regeneration 
Following an analyte injection, remaining analyte bound to the ligand must be 
removed from the sensor surface, with the ligand remaining intact, before another 
analyte injection is performed ie the surface must be regenerated.  The choice of 
regeneration conditions is dictated by the nature of the ligand-analyte interaction, the 
stability of the ligand and the type of ligand immobilisation employed.  For example 
for weak interactions, an increased speed of buffer flow may remove remaining 
analyte.  Other conditions that can be used are high or low pH (eg 10 mM glycine pH 
2, 50 mM NaOH), high salt (eg 1-2 M NaCl) or detergent (eg SDS).   The most 
frequent method used is injection of 10 mM glycine pH 1.5-2.5.  This pH change 
causes most proteins to partially unfold and become positively charged.  The protein 
binding sites will therefore repel each other, moving the ligand and analyte further 
apart.  Regeneration conditions must be optimised to ensure that the ligand remains 
intact and fully functional after the regeneration step.   
2.20.7. Applications 
SPR can be used in a number of ways to characterise biomolecular interactions.  SPR 
can provide quantitative information on affinity, kinetics, specificity and the effect of 
different conditions eg buffers, co-factors, temperature etc on complex formation.   
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2.20.7.1. Affinity 
Affinity is generally expressed as either the association constant (Ka), expressed in 
units of M-1 or the dissociation constant (Kd), which is the inverse of Ka and hence has 
units of M.   
For the interaction A + B ↔ AB,  
 
 
       
Ka and Kd can be measured directly by equilibrium binding analysis or calculated 
from the rate of association (kass) and rate of dissociation (kdiss). 
Affinity constants can be measured by using equilibrium binding analysis on the 
BIAcore instrument.  This involves injection of a series of analyte concentrations and 
measurement of the response at equilibrium.   In most cases, the data produced can 
then be fitted to the Langmuir binding model to derive affinity constants (see 
Equation 2-10).  The model assumes that the analyte is monovalent and 
homogeneous, that the ligand is homogeneous and that all events are independent.   
 
Equation 2-10 The Langmuir binding isotherm, where Req is the response measured at 
equilibrium and Rmax is the maximum response at complete saturation of immobilised binding 
sites 
 
A Scatchard plot of the same data, obtained by plotting Req/[A] against Req, can be 
used to visualise the extent to which the data fit the model (BIAevaluation Software 
Handbook).  A linear Scatchard plot is consistent with the data fitting the model.  
However, Scatchard plots alone should not be used to estimate affinity constants 
because they place inappropriate weighting on the data obtained with the lower 
concentrations of analyte, which are generally the least reliable 
(http://users.path.ox.ac.uk/~vdmerwe/internal/spr.pdf, accessed December 2002).   
2.20.7.2. Kinetic analysis 
The real-time binding data collected using SPR allows the rate constants for an 
interaction ie kass and kdiss to be determined.   
  [A] * Rmax 
[A] + Kd 
Req     = 
  [AB] 
[A] [B] 
Ka = 
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SPR measures the kinetics of binding to surface-immobilised ligand under conditions 
of continuous flow with the concentration of free analyte, [A], kept constant by 
continuous supply of new sample. The concentration of complex on the surface, [AB], 
is given by the response above baseline.  
Although the concentration of free ligand on the surface [B] is not measured directly, 
the total ligand concentration can be expressed in resonance units as the maximum 
analyte binding capacity ie Rmax and the concentration of free ligand is then Rmax – 
[AB].   
d[AB]
dt
kass[A][B] – kdiss[AB] =
 
Equation 2-11 General equation for binding kinetics 
After the sample has passed over the surface, analyte that dissociates from the 
complex is carried away by the buffer flow, so that the free analyte concentration is 
zero. The rate of dissociation is then described by Equation 2-12. 
[AB]
=
dt
- kdiss[AB]
 
Equation 2-12 
 
Therefore, the rates of association and dissociation can be determined from Equation 
2-11 and Equation 2-12.   
 
There are important limitations to kinetic analysis using SPR: 
1. Mass transport 
This effect can occur with high ligand densities where the rate at which the surface 
binds the analyte exceeds the rate at which the analyte can be delivered to the surface.  
Therefore the measured association rate (kass) is slower than the true kass.  Analyte is 
transported to the surface by diffusion and convection.  Increasing the flow rate can 
increase convection transport and diffusion limitations can be reduced by decreasing 
the amount of bound ligand and reducing the volume of the sample cell.   
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2. Rebinding of analyte 
If, following dissociation of analyte, the analyte rebinds to unoccupied ligand before 
diffusing away from the surface, the measured dissociation rate (kdiss) will be slower 
than the true kdiss.   Rebinding can be reduced by increasing the flow rate, thus 
increasing convection transport to remove the analyte at a faster rate and by 
decreasing the level of ligand immobilisation.   
These limitations mean that it is difficult to measure kass values faster than 
approximately 106 M-1 s -1 and kdiss values slower than 10-5 s-1 or faster than 1 s-1 
(http://users.path.ox.ac.uk/~vdmerwe/internal/spr.pdf, accessed December 2002). 
2.20.8. SPR Methodology 
SPR was performed using BIAcore J and BIAcore X instruments from BIAcore AB 
(Uppsala, Sweden), operating BIAcore J and BIAcore X control software 
respectively.  Operation and maintenance procedures were carried out as detailed in 
the BIAcore J and BIAcore X instrument handbooks, using BIAcore AB certified 
products.  HBS-EP running buffer (10mM Hepes [pH 7.4], 150 mM NaCl, 3 mM 
EDTA, 0.005% [v/v] surfactant P20), purchased from BIAcore AB, was used 
throughout.  All buffers and solutions used were filtered and degassed using 0.2 µm 
sterile syringe filters (Millipore) or Steritop sterile bottle-top filters (Millipore).  
Solutions filtered by syringe filter were degassed by centrifugation. 
2.20.8.1. Immobilisation of proteins on CM5 sensor chips 
The ligand was immobilised to the matrix of a newly docked CM5 sensor chip, pre-
equilibrated in HBS-EP running buffer (BIAcore AB) via amine coupling.  Medium 
flow rate (~ 35 l min-1) was used in the BIAcore J instrument and a 10 l min-1 flow 
rate was used in the BIAcore X instrument throughout ligand immobilisation.  The 
carboxymethylated matrix in both flow cells was activated using a mixture of 0.1 M 
ethyl-N-(3-diethylaminopropyl) carbodiimide (EDS, BIAcore AB) and 0.4 M N-
hydroxysuccinimide (NHS, BIAcore AB).  The protein sample was diluted in 
coupling buffer (BIAcore AB, 10 mM sodium acetate, pH 4.5) and injected in single 
channel mode across flow cell 2 until the required amount of protein was immobilised 
on the surface.  Remaining active esters in both flow cells were then deactivated using 
1M ethanolamine hydrochloride, pH 8.5.   
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The final level of immobilisation was determined after two washes with HBS-EP 
buffer.  A response of 1000 RU equates to 1 ng of protein attached to the chip 
(www.biacore.com/technology/spr_technology.lasso).   
2.20.8.2. SPR binding analysis 
Measurement of binding of proteins to the immobilised protein on the CM5 sensor 
chip was completed at 25 ºC with HBS-EP running buffer using medium flow rate 
(BIAcore J) or 30 l min -1 (BIAcore X).  Proteins to be used as analytes were diluted 
in HBS-EP buffer to the required concentration and a two minute injection of the 
diluted protein was performed.  The surface was then regenerated using a two minute 
injection of 10 mM glycine (pH 1.8).  The experiment was repeated twice for each 
concentration of protein.  
2.20.8.3. SPR data analysis 
Data from the BIAcore J instrument were analysed using BIAviewer Software 
(BIAcore AB).   
All data used for kinetic analysis were obtained using the BIAcore X instrument.  
Kinetic analysis for binding of analyte to the immobilised ligand was achieved using 
BIAevaluation software version 3.1.  Global analysis was performed employing the 
Langmuir 1:1 binding isotherm where very rapid changes in response are accounted 
for as refractive index changes.     
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3. CHAPTER 3 – Effect of mutations in and around the 
TolB box of colicin E9 on binding to TolB  
3.1. Introduction 
3.1.1. The TolB box of colicin E9 
The interaction of colicin E9 with TolB has been demonstrated using the yeast-two 
hybrid system (Carr et al 2000a).  The region of the translocation domain of colicin 
E9 involved in interacting with TolB was localised to the “TolB box” sequence 
(DGSGW), from residues 35 to 39 (Carr et al 2000a).  Mutation of residues D35, S37 
and W39 to alanine in this region abolished the cytotoxic activity of the colicin and it 
was shown, by yeast two hybrid experiments, that this was due to the loss of 
interaction with TolB (Garinot-Schneider et al 1997, Carr et al 2000a).  Mutation of 
residues S34 and S40 to alanine also caused a reduction in activity in a stab test but 
these mutants were not investigated further (Garinot-Schneider et al 1997).   
An interaction between the N-terminal domain of colicin E3 and TolB has also been 
demonstrated by cross-linking studies and this interaction is abolished if the N-
terminal domain of colicin E3 contains the S37F mutation (Bouveret et al 1997).   
3.1.2. Structure of the TolB box of colicin E9 
3.1.2.1. X-ray structures 
The crystal structures of two tol-dependent colicins, colicin N and colicin E3, have 
now been determined.  No electron density for the translocation domain (the first 66 
residues) is seen in the 3.1 Ǻ structure of colicin N, despite the domain being present 
in the initial crystal form, indicating that this region is flexible and unstructured.  This 
lack of structure in the translocation domain is consistent with CD and fluorescence 
data and the glycine/proline/serine/asparagine-rich composition of the domain (Evans 
et al 1996, Raggett et al 1998).  Residues 84-315 of the translocation domain of 
colicin E3 adopt a jellyroll structure, with three β-sheets flanked by two α-helices 
(Soelaiman et al 2001).  However, no electron density was detected for the first 83 
residues, indicating that the N-terminal region of the translocation domain is probably 
disordered, consistent with the high glycine content (43 %) within the region. 
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3.1.2.2. NMR 
Sharp signals in the 1H NMR spectra of full-length colicin E9 and the N-terminal 299 
and 349 residues have indicated that the translocation domain of colicin E9 is flexible 
(Collins et al 2002).  The narrow 1H chemical shift dispersion in the 1H-15N HSQC 
spectrum of colicin E9 is also a sign that the protein contains unstructured regions.  
The observation that this spectrum is significantly different from the spectra produced 
from the isolated DNase domain or receptor-binding domains, indicates that the 
translocation domain forms the unstructured region (Collins et al 2002).  However, 
although the consensus chemical shift index for the N-terminal region of colicin E9 
indicates that much of the region lacks secondary structure elements, differences in 
chemical shifts between colicin E9 and those of random coil values suggest that some 
residues eg S30 and D35 in the N-terminal region are not in random coil 
conformations (Collins et al 2002).  Relaxation measurements indicate that residues 
W39 to N44 and L81 to A83 of colicin E9 have more restricted mobility than the rest 
of the region (Collins et al 2002).  The restricted mobility of residue W39 suggests 
that the TolB box could be more structured than other regions of the translocation 
domain, although the mobility of D35 does not differ from that seen for the rest of the 
region and the resonances for residues 36-38 have not yet been assigned (Collins et al 
2002). 
Differing intensities of the resonances observed for residues S40, S41 and E42 in the 
NMR spectrum indicate that these residues exist in different conformational states, 
despite the homogeneity of the protein samples, confirmed with SDS-PAGE and 
chromatography (Collins et al 2002).  Collins et al (2002) suggest that these residues 
could be involved in side-chain/side-chain interactions, leading to the formation of 
clusters of interacting residues, with one cluster being involved in the interaction with 
TolB.   
 
Therefore, colicins appear to be amongst a growing number of recognised proteins 
with intrinsically disordered domains, involved in macromolecular interactions, which 
adopt folded structures upon binding to their biological targets (Dyson and Wright 
2002).  The lack of structure can be functionally advantageous, for example allowing 
the protein to bind in different conformations to several different targets in a specific 
order (Wright and Dyson 1999).    
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3.1.3. Extension of the TolB box 
The 1H-15N HSQC spectrum of colicin E9 in the presence of excess, unlabelled TolB  
shows that backbone resonances of residues 33 to 44 of colicin E9, including the TolB 
box, are perturbed on binding to TolB (Collins et al 2002).  It was therefore suggested 
that the region for binding to TolB should be extended from the recognised 
pentapeptide sequence, DGSGW, to twelve amino acids, although it could not be 
ruled out that the perturbations in resonances could be due to conformational changes 
in the region flanking the TolB box resulting from the interaction of the TolB box 
region with TolB, rather than a direct interaction between TolB and these residues.  
The backbone resonances of N10, H14, H55 and W56 were also affected by addition 
of TolB (Collins et al 2002).  However, mutation of residue W56 to alanine, located 
in a region of colicin E9 which showed homology to colicin K, did not affect the 
activity of the colicin in a stab test (Garinot-Schneider et al 1997) and constructs 
lacking residues 54-164 of colicin E9 have been shown to interact with TolB in yeast 
two hybrid experiments (Carr et al 2000a).   
Recently an alanine mutation at residue 42 has been shown to be abolish activity of 
colicin E9 and this mutant protein does not interact with TolB in SPR experiments 
(Holland, 2003).   
The three residues after the TolB box pentapeptide sequence of colicins E2-E9 and A 
are conserved (see Figure 3.1), providing further evidence that residues directly 
downstream of the TolB box may also be involved in the interaction with TolB 
(Bouveret et al 1998).  Colicin E1, which does not require TolB for translocation, 
contains a pentapeptide sequence homologous to the TolB box but the region 
immediately following this TolB box is not homologous to the endonuclease colicins, 
supporting the possibility that residues downstream of the TolB box are involved in 
the colicin-TolB interaction.  Although the TolB box of colicin A is predicted to lie 
between residues 11 and 15, a colicin A mutant with residues 16-30 deleted does not 
interact with TolB, whilst a mutant with residues 21-29 deleted does interact with 
TolB, indicating that residues between 15 and 20 could also be involved in the 
interaction of colicin A with TolB (Bouveret et al 1998).  However, no mutational 
data has been published to confirm the role of any of these six residues in binding to 
TolB.   
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Colicin E9 34 SDGSGWSSENNPW 46
Colicin E7 34 SDGSGWSSENNPW 46
Colicin E3 34 SDGSGWSSENNPW 46
Colicin E2 34 SDGSGWSSENNPW 46
Colicin E1 29 PDGSGSGGGGGKG 41
Colicin A 10 GDGTGWSSERGSG 22
Colicin K 16 MGGTGANLNQQGG 28
Colicin N 25 TSGAGSNGSASSN 37
 
Figure 3.1 Alignment of known and predicted TolB boxes (black) and flanking residues 
(red) of TolB-dependent colicins (adapted from Garinot-Schneider 1997).   
3.1.4. TolB interaction with colicin E9 
Although the region of colicin E9 involved in interacting with TolB has been 
localised to the TolB box, the region of TolB involved in interacting with colicin E9 is 
less well-defined.  As discussed in Chapter 1, the crystal structure of TolB shows that 
the protein consists of an N-terminal mixed αβ domain and a C-terminal β-propeller 
domain (Carr et al 2000a, Abergel et al 1999).   
β-propeller proteins usually use their central tunnel or the entrance to the tunnel to 
coordinate a ligand or to carry out a catalytic function that is preserved by the 
structural rigidity of the propellers.  It was therefore proposed that the translocation 
domains of colicins interact with the β-propeller domain of TolB (Carr et al 2000a).   
N-terminal and C-terminal deletions have been made in the tolb gene and the effect of 
the deletions on the TolB protein on binding to colicin E9 has been investigated using 
the yeast-two hybrid technique (Carr et al 2000a).  Deletion of the first 119 residues 
of TolB had no effect on the interaction with the translocation domain of colicin E9.  
However, deletion of residues 1-203, 205-431 or 304-431 abolished the TolB-colicin 
E9 interaction (Carr et al 2000a).  This suggests that the region of TolB involved in 
the interaction with colicin E9 is located between residues 119 and 431.  As this 
region encompasses the β-propeller domain, it has been suggested that it is the β-
propeller domain of TolB that is involved in the interaction with colicin E9 (Carr et al 
2000a).   
However, Abergel et al (1999) suggest that it is the N-terminal domain of TolB that is 
involved in interacting with colicins.  The A227V mutation in the β-propeller domain 
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of TolB does not affect the interaction with colicin, whereas insertion of two residues 
(SS) after residue P87 affected the ability of the colicin to enter cells (Abergel et al 
1999).  An E.coli tolb mutant strain, when transformed with a cloned tolb mutant 
gene, lacking most of blades V and VI of the β-propeller domain, was shown to be 
sensitive to colicins A and E1 (Bénédetti et al 1991b).   
Yeast-two hybrid experiments have shown that the translocation domain of colicin A 
does not interact directly with either the isolated β-propeller domain or N-terminal 
domain, in contrast to the yeast-two hybrid result for colicin E9, which detected an 
interaction between residues 120-413 of TolB and colicin E9 (Wallburger et al 2002, 
Carr et al 2000a).  It is suggested by Wallburger et al (2002) that the discrepancy 
could be due to differing translocation mechanisms between the pore-forming colicin 
A and the endonuclease colicin E9.   
3.1.5. Aims of this chapter 
The work described in this chapter further characterises the role of the residues in the 
recognised pentapeptide TolB box.  The technique of surface plasmon resonance has 
been used to directly compare binding of TolB to wild-type colicin E9/Im9 and to 
colicin E9/Im9 mutants with an alanine mutation in the TolB box.  The SPR technique 
has also been used to investigate the effect of mutating the three TolB box residues, 
known to abolish biological activity and TolB binding, to residues other than alanine.   
Additionally, this chapter further investigates the hypothesis that the region of the 
translocation domain of colicin E9, involved in interaction with TolB, is longer than 
the pentapeptide sequence initially proposed. 
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3.2. Results 
3.2.1. Preparation of Colicin E9 and colicin E9 TolB box 
mutants 
Wild-type colicin E9 and colicin E9 with mutations in and around the TolB box were 
expressed from the appropriate plasmid in E.coli host strains as shown in Table 1, 
using 1mM IPTG as the inducer.   
Table 3.1 List of pET21a-based plasmids used for expressing mutated colicin E9 proteins 
and the cell line used for expression.   
Mutation Plasmid E.coli host strain 
Wild-type pNP69 ER2566 
S34A pNP82 BL21 (DE3) 
D35A pNP56 ER2566 pLysS 
G36A pNP55 BL21 (DE3) 
S37A pCS9 ER2566 pLysS 
G38A pNP321 ER2566 
W39A pNP57 ER2566 pLysS 
S40A pNP84 BL21 (DE3) 
S41A pSR15 BL21 (DE3) 
E42A pLH28 BL21 (DE3) 
N43A  pSR16 BL21 (DE3) 
N44A pSR17 BL21 (DE3) 
 
The proteins were purified from harvested cells using nickel-affinity chromatography 
as detailed in Chapter 2.  The purified fractions were dialysed in 50mM potassium 
phosphate buffer, pH 7.4 and were run on a 12 % SDS-PAGE gel to check for purity 
(see Figure 3.2).   
Where appropriate, the mutants were purified free from Im9, using the method set out 
in Chapter 2.   
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Figure 3.2 12 % SDS-PAGE gels showing purified wild-type colicin E9 and purified colicin 
E9 mutant proteins.  The band around 10 kDa seen in some lanes corresponds to the immunity 
protein.   
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3.2.2. Preparation of TolB 
pRJ376, a pET21a-based plasmid containing the tolb gene, was used to transform 
E.coli BL21 (DE3) cells.  Expression of the TolB protein was induced with 1mM 
IPTG in a large scale (400 ml) culture.  The cells were lysed using sonication and the 
TolB protein was purified using nickel-affinity chromatography as detailed in Chapter 
2.  The protein was dialysed in 50 mM potassium phosphate buffer, pH 7.4 and run on 
a gel to check for purity (see Figure 3.3).   
 
47.5
25
 
Figure 3.3  12 % SDS-PAGE gel showing purified TolB protein, after dialysis.   
3.2.3. SPR  
Preliminary SPR experiments were carried out using a BIAcore J instrument, 
requiring manual injection of analyte.  The accuracy of the injection means that the 
BIAcore J is not suitable for measurement of kinetic parameters but can be used to 
rank mutants in terms of their ability to bind to TolB.     
3.2.3.1. Immobilisation of TolB onto a CM5 chip 
The BIAcore J has two flow cells, allowing derivitisation of one cell with TolB, with 
the other cell acting as a blank reference surface.  Both flow cells were activated using 
EDC/NHS as described in Chapter 2.  TolB (at a concentration of 1 M) was then 
coupled to flow cell 1 only.  Remaining active esters on both flow cells were 
deactivated using ethanolamine.  The final level of TolB immobilised was ~3000 RU 
(see section 2.20.1).     
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3.2.3.2. Binding of wild-type colicin E9/Im9 to TolB 
Two minute injections (70 l) of 2 M wild-type colicin E9/Im9 were performed 
across both flow cells.  The sensorgram produced from the underivatised flow cell 2 
was subtracted from the sensorgram produced from flow cell 1, derivatised with TolB 
protein.  This produces a corrected sensorgram, removing the response produced by 
non-specific interactions between the analyte and the sensor surface (see Figure 3.4).  
Sensorgrams shown throughout this thesis are corrected for non-specific binding in 
this way.   
Injection of 2 M colicin E9/Im9 produced a maximum response of 1705 ± 23 RU (~ 
36 % of RUmax, see section 2.20.1), demonstrating that an interaction between TolB 
and colicin E9/Im9 occurs on the sensor chip. 
3.2.4. Binding of TolB box mutants to TolB 
3.2.4.1. Colicin E9 D35A, S37A and W39A mutants 
Injection of 2 M of the D35A, S37A and W39A mutant colicin E9 proteins across 
the TolB chip produced sensorgrams shown in Figure 3.4.   
The sensorgrams in Figure 3.4 show that the D35A, S37A, W39A mutations all 
drastically reduce binding of colicin E9 to TolB, producing mean maximum responses 
of 290 ± 10 RU, 104 ± 7 RU and 48 ± 5 RU respectively (n=3).   
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Figure 3.4  SPR sensorgrams showing reduction in binding to TolB caused by 
D35A, S37A and W39A mutations in colicin E9 
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The D35A, S37A and W39A mutations in colicin E9 were expected to reduce binding 
of the colicin to TolB, as these mutations abolish the activity of the colicin and have 
been shown by yeast-two hybrid studies to abolish the TolB-colicin E9 interaction 
(Carr et al 2000a).   
3.2.4.2. G36A and G38A colicin E9 mutants 
The G36A and G38A mutations do not inactivate the biological activity of the colicin 
in a stab test and were shown by yeast-two hybrid studies to retain their interaction 
with TolB (Carr et al 2000a).  Therefore, binding of these mutants to TolB, 
comparable to wild type, was expected.  However, as can be seen from Figure 3.5, 
both mutants showed significantly reduced binding to TolB compared to wild-type 
colicin E9 at a concentration of 2 M.   
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Figure 3.5  SPR sensorgrams showing reduced binding to TolB of 2 M G36A and 
G38A colicin E9 mutants compared to 2 M wild-type colicin E9. 
 
One difference between these SPR experiments and the yeast-two hybrid experiments 
is that in the latter experiments colicin E9 was used in the absence of the immunity 
protein, whereas in this work the colicin mutant proteins had been purified in complex 
with their immunity proteins.  Therefore, the immunity protein was removed from 
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both the G36A and G38A colicin E9 mutant proteins by denaturation on a Hi-trap 
column using 6 M guanidine, as detailed in Chapter 2.   
The binding of the free colicin E9 mutant proteins to TolB was then investigated and 
the resulting sensorgrams can be seen in Figure 3.6.  Although the G36A colicin E9 
mutant binds poorly to TolB when Im9 is present, binding of the mutant to TolB when 
Im9 has been removed, is much greater, although the shape of the sensorgram 
produced is altered, suggesting that the mutation does have some effect on the binding 
site for TolB.   The binding is also enhanced compared to the binding of wild-type 
colicin E9/Im9.   
The response due to binding of the G38A colicin E9 mutant to TolB is very low for 
both the free colicin E9 protein and for the colicin E9/Im9 complex.  This contradicts 
results from yeast two hybrid data indicating that G38A colicin E9 does interact with 
TolB.  For a positive result in a yeast two hybrid screen, it is generally accepted that 
an interaction with a Kd in the micromolar range is required, yet even at 10 M the 
G38A colicin E9 mutant showed very poor binding to TolB.   
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Figure 3.6  SPR sensorgrams showing the binding of G36A and G38A colicin E9 
mutant proteins to TolB, in the presence and absence of Im9, compared to the binding of wild-
type colicin E9/Im9.   
 
A spot test was performed to check that G36A and G38A ColE9 proteins were active 
both with and without their immunity protein (see Figure 3.7).   
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Protein   Titre (nM) 
E9/Im9  30 
E9   30 
G38A E9  inactive 
G38A E9/Im9  250 
G36A E9  60 
G36A E9/Im9  60 
 
1µM 
1nM 
 E9/Im9     E9 G38A E9   G38A E9/Im9  G36A E9  G36A E9/Im9 
 
Figure 3.7  Results of a spot test to establish the activity of G36A and G38A ColE9 mutant 
proteins in the presence and absence of Im9 compared to wild type ColE9/Im9.   
 
The spot test indicates that the G36A ColE9 protein is active both with and without 
the immunity protein, although it is slightly less active than wild-type colicin E9.  
G38A is only active when Im9 is present and even then, activity is reduced compared 
to wild type.  A further spot test using higher concentrations of protein (see Figure 
3.8), indicated that the G38A mutant in the absence of Im9 was active at 
concentrations above 1 M, but confirmed that the activity was much lower than the 
activity of wild-type colicin E9.    
The colicin E9 gene in pNP321, from which G38A ColE9/Im9 was expressed, was re-
sequenced to confirm that there were no additional mutations that may be affecting 
TolB binding.   
A Kunitz assay (see section 2.16) was also performed to check that the G38A mutant 
was intact.  This assay measures the increase in absorbance at 260nm due to DNA 
degradation.  Figure 3.9 shows that the rate of DNA degradation by free G38A colicin 
E9 is comparable to that for free wild-type colicin E9, indicating that the DNase 
domain of the mutant is intact.   
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Figure 3.8 Results of a spot test to establish the activity of G38A colicin E9 protein with 
and without Im9.  Activity can be detected at 6 µM in the presence and absence of immunity 
protein.  The mutant is more active in the presence of the immunity protein but still less active 
than wild-type colicin E9.  
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Figure 3.9 Results of a Kunitz assay, comparing the DNase activity of wild-type colicin E9 
to that of the G38A colicin E9 mutant.  Results for wild-type colicin E9/Im9 are also shown as a 
control, the presence of the immunity protein preventing DNA degradation.  Lamp fluctuations 
of 0.001 AU occur over the course of the experiment, accounting for fluctuations in the traces.   
 113 
The change in binding characteristics when free G36A ColE9 binds to TolB shown by 
the shape of the SPR sensorgram does indicate that there may be a conformational 
change when residue 36 is mutated, which could cause the reduction in activity seen 
in the spot test.  The yeast-two hybrid technique only shows whether the TolB box 
mutants bind or do not bind to TolB, whereas these SPR experiments have highlighted 
a difference in binding of the G36A colicin E9 mutant to TolB compared to wild-type 
colicin E9  
The reduced activity of the G38A mutant in the spot test is consistent with the 
reduced binding to TolB, seen in the SPR experiment.  However, this is inconsistent 
with the yeast-two hybrid data, which suggested that the G38A mutation did not affect 
the binding of colicin E9 to TolB.   
3.2.5. Kinetics of binding of ColE9/Im9 to TolB 
SPR allows the direct measurement of the kinetic parameters that describe an 
interaction in real time.  The mathematical fitting of a plot of refractive index change 
with time to theoretical plots for model systems of bimolecular interactions allows 
calculation of kinetic parameters that describe the interaction. 
The BIAcore X instrument was used for all kinetic analysis presented in this thesis.  
This instrument allows continuous injection to maintain sample concentration and has 
fast buffer/sample exchange minimising sample dispersion, ensuring accurate rate 
constant determination (BIAcoreX Product Information).   
3.2.5.1. Immobilisation of TolB on a CM5 sensor chip 
In order to limit mass transfer effects (see Chapter 2), the lowest feasible level of 
ligand immobilisation should be used along with a fast flow-rate for analyte injection.   
For kinetic measurements, the maximum specific SPR response (RUmax) should be 
approximately 100 RU (BIAcore Advisor Kinetics CD).  Equation 3-1 can be used to 
calculate the amount of ligand immobilisation required for a given binding capacity.   
 
RMM of analyte (kDa)
RMM of ligand (kDa)
Amount of analyte bound (RU)
Amount of ligand bound (RU)=
 
Equation 3-1 Equation describing the relationship between SPR response and relative 
molecular masses (RMM) of the ligand and analyte.  
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Using Equation 3-1, the target level of immobilisation for the ligand ie TolB on the 
sensor chip was calculated to be ~ 160 RU, assuming a stoichiometry of 1:1 binding.  
Therefore 50nM TolB was injected across flow cell 2 of an EDC/NHS activated CM5 
chip with a contact time of 3 minutes at a flow rate of 10 l/min.    This produced a 
level of immobilisation of 300 RU, giving an Rmax of 187.5.  Although this level of 
ligand immobilisation gives a RUmax greater than 100 RU, the percentage occupancy 
of TolB binding sites is likely to be less than 100 %, and therefore this level of ligand 
immobilisation is satisfactory.  This level of immobilisation also allows the responses 
measured for partial TolB occupancy, observed with lower concentrations of colicin 
E9, to be used for kinetic analysis, by ensuring the response elicited will be above the 
level of background noise.   
3.2.5.2. Kinetic analysis of binding of colicin E9/Im9 to 
TolB 
2 minute injections of 2, 5, 10, 15 and 20 M ColE9/Im9 were performed across the 
300 RU of immobilised TolB on the CM5 chip at a flow rate of 30 l/min.  After each 
analyte injection, the sensor chip surface was regenerated using a one minute pulse of 
10 mM glycine, pH 1.8.  Following regeneration, an injection of the same 
concentration of colicin E9/Im9 produced a similar response as before, indicating that 
the TolB protein on the surface remained intact.    
Global analysis using BIAevaluation software 3.1 was used to fit corrected SPR 
responses to the theoretical 1:1 Langmuir binding model (see Figure 3.10).   
Table 3.2 lists the kinetic data obtained from fitting of the sensorgrams to this model, 
together with the residual plot comparing the experimental data to the theoretical fit.  
For a perfect fit, the residuals should be scattered around zero and reflect the noise of 
the signal (in the order of +/- 2 RU, BIAevaluation software handbook 4.1).  
However, constraining the parameters in a fit to have the same value for a set of 
curves can produce a larger scatter.  The Kd for the interaction of colicin E9/Im9 with 
TolB is 13.8 ± 0.26 M.   
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Figure 3.10 Corrected sensorgrams and residual plots for titration of 2 M (red), 5 µM 
(cyan), 10 µM (magenta), 15M (blue) and 20 M (green) ColE9/Im9 against TolB at 25oC are 
shown. The fitted kinetic data for binding are superimposed onto each sensorgram in black. 
Residual plots highlight deviation of the experimental data from the theoretical fit, the deviations 
being largest at the start and end points of the injections.  
 
Table 3.2 Kinetic data obtained from fitting of sensorgrams produced for binding of 
ColE9/Im9 to TolB to the Langmuir 1:1 binding model.  Errors for Ka and Kd were calculated by 
combining the standard errors on kass and kdiss in quadrature.   
kass (1/Ms) kdiss (1/s) Rmax (RU) Ka (1/M) Kd (M) Chi2
6130 ± 109 0.0847 ± 0.000574 286 72300 ± 1374 13.8 ± 0.26 2.06
 
Statistical parameters 
Statistical parameters, which give indications as to how good the fit is, are calculated 
as part of the BIAevaluation fitting process.  Firstly a Chi squared value is given.  The 
Chi squared test is a standard statistical measure of the closeness of fit of the 
experimental response to the theoretical model, related to the sum of squared residuals 
averaged over the number of data points.  However, as SPR sensorgrams have a large 
number of data points, the Chi squared value is not always a very sensitive measure of 
the closeness of fit.  It is generally accepted that a Chi squared value of 2 or less 
indicates a good fit (BIAevaluation manual).  The Chi squared value of 2.06 for these 
data suggests that the data closely fit the binding model.   
The second statistical parameter reported by the BIAevaluation software is the 
standard error.  This is a measure of how much the closeness of fit is affected by 
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variations in the parameter value.  A small standard error indicates that changes in the 
parameter's value have a significant effect on the fitting: in other words, confidence in 
the value is high.  The standard error for Kd can be calculated from combining the 
standard errors for kass and kdiss in quadrature.  The standard error for Kd for these data 
is 0.26, a low value, compared to the value of Kd of 13.8, giving good confidence in 
the Kd value.   
T-values can be obtained by dividing the parameter's value by the standard error, and 
thus provide a kind of normalised inverse standard error value. High T-values 
(typically above 10) indicate confidence in the parameter's value.  The T-value for kass 
is 56, the T-value for kdiss is 148, and the T-value for Ka and Kd is 53, giving good 
confidence in the values of these parameters. 
Scatchard analysis 
A Scatchard plot of the data, Max RU/[ColE9/Im9] against Max RU, which can be 
used to visualise the extent to which the data fit the model, is shown in Figure 3.11.  
The R2 value of 0.97 for a linear fit to the Scatchard plot indicates that the data fit the 
model well.   
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Figure 3.11 Scatchard plot for binding of colicin E9/Im9 to TolB.  The Kd value can be 
obtained by calculating the inverse of the gradient ie Kd = 12.2 M.   
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Mass transport 
Under the flow conditions in SPR, the rate of mass transport of analyte to the surface 
varies with the cube root of the flow rate (BIAcore Advisor Kinetics CD). In contrast, 
the rate of analyte binding to ligand is independent of the flow rate. Comparison of 
the observed binding rates at different flow rates can thus reveal whether the binding 
is limited by mass transport processes.  To investigate mass transport limitations of 
analysing the binding of colicin E9/Im9 to TolB, injections of 15 M colicin E9/Im9 
were performed at three different flow rates, 5 l/min, 15 l/min and 30 l/min.  The 
three sensorgrams produced (see Figure 3.12) show the same slope, indicating that 
mass transport limitations are negligible and thus the measured kass should be close to 
the true kass.     
 
-40
-20
0
20
40
60
80
100
120
-35 -25 -15 -5 5 15 25 35 45 55 65 75 85 95 105 115 125 135 145 155 165
Time (s)
Re
sp
o
n
se
 
(R
U)
15uM ColE9/Im9 at 30ul/min 15uM ColE9/Im9 at 15ul/min 15uM ColE9/Im9 at 5ul/min
 
Figure 3.12 Sensorgrams recorded for injections of 15 M ColE9/Im9 at three different flow 
rates in a test for mass transport effects.  If mass transport was a limiting factor, the slopes of the 
sensorgrams would be different at different flow rates.  However, as the slopes of the three 
sensorgrams are the same, it can be concluded that mass transport limitations are negligible.   
3.2.5.3. Kinetic analysis of binding of G36A mutant to 
TolB 
The same method used above, for determining kinetic parameters for binding of wild-
type colicin E9/Im9 to TolB (see section 3.2.5.2), was used to determine kinetic 
parameters for binding of the G36A colicin E9/Im9 mutant to TolB.  Global analysis 
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using BIAevaluation software 3.1 was used to fit corrected SPR responses to the 
theoretical 1:1 Langmuir binding model (see Figure 3.13).   
Higher concentrations of protein were used to investigate the kinetics of binding of 
G36A colicin E9/Im9, compared to those used for the wild-type colicin E9/Im9, due 
to the decreased binding seen for this mutant in the preliminary experiments.   
Table 3.3 lists the kinetic data obtained from fitting of the sensorgrams produced for 
binding of G36A colicin E9/Im9 to this model.  The Kd for the interaction of colicin 
E9/Im9 with TolB is 45.1 ± 1.1 M.   
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Figure 3.13 Corrected sensorgrams and residual plots for titration of 2 M (red), 5 µM 
(cyan), 10 µM (green), 20 M (magenta) and 40 M (blue) G36A ColE9/Im9 against TolB at 25oC 
are shown. The fitted kinetic data for binding are superimposed onto each sensorgram in black. 
Residual plots highlight deviation of the experimental data from the theoretical fit, the deviations 
being largest at the start and end points of the injections. 
 
Table 3.3 Kinetic data obtained from fitting of sensorgrams produced for binding of 
G36A ColE9/Im9 to TolB to the Langmuir 1:1 binding model, errors for Ka and Kd were 
calculated by combining the standard errors on kass and kdiss in quadrature.   
kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
10700 ± 437 0.481 ± 0.0119 22200 ± 550.6 45.1 ± 1.1 0.935
 
 
Sensorgrams were also recorded for injections of varying concentrations of free G36A 
colicin E9 across the TolB chip.  The sensorgrams for binding of the free G36A 
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colicin E9 to TolB produced a poor fit to the Langmuir 1:1 binding model.  Therefore, 
fitting was attempted to several other models, with the best fit obtained to a two state 
conformational change model.  This model is appropriate when the complex AB 
formed on the sensor surface undergoes a conformational change to a different form, 
AB* (see Equation 3-2).   
 
A + B  AB  AB*
 
Equation 3-2 Equation for a two-state reaction, involving a conformational change from AB 
to AB*.   
 
Kinetic parameters can be determined using the following equations: 
dB
dt
= - (kass1 [A] [B] - kdiss1 [AB])
dAB
dt
= - (kass1 [A] [B] - kdiss1 [AB]) – (kass2 [AB] – kdiss2 [AB*])
dAB*
dt
= - (kass2 [AB] – kdiss2 [AB*])
 
where kass1 is the association rate constant for formation of AB, kdiss1 is the 
dissociation rate constant for complex AB, kass2 is the rate constant for conversion of 
AB to AB* and kdiss2 is the rate constant for conversion of AB* to AB.   
For simplicity, the model assumes that the transition from AB to AB* and back can 
only occur when A and B are bound to each other ie the modified complex AB* 
cannot dissociate directly into A+B without first going through the state AB. 
 
Figure 3.14 shows the sensorgrams produced for binding of free G36A colicin E9 to 
TolB, with the fit to the two-state conformational change model superimposed in 
black.  Table 3.4 shows the kinetic parameters calculated from fitting the data to the 
two-state conformational change model.  Although the Chi squared value is higher 
than normal, the T-values for the kinetic parameters are all above 10, giving good 
confidence in the values.  The affinity constant (K, ie [kdiss1/kass1] x [kdiss2/kass2]) for 
the formation of the complex, including the conformational change, is 1.24 ± 0.12 
M.   
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Figure 3.14 Corrected sensorgrams and residual plots for titration of 0.5 M (blue), 1 µM 
(magenta), 2 µM (grey), 4 M (red) and 6 M (green) free G36A ColE9 against TolB at 25oC are 
shown. The fitted kinetic data for binding are superimposed onto each sensorgram in black. 
Residual plots highlight deviation of the experimental data from the theoretical fit. 
 
Table 3.4 Kinetic data obtained from fitting of sensorgrams produced for binding of free 
G36A ColE9 to TolB to a two-state conformational change model.  The kinetic parameters are 
kass1 (association rate constant for formation of AB), kdiss1 (dissociation rate constant for complex 
AB), kass2 (rate constant for conversion of AB to AB*) and kdiss2 (rate constant for conversion of 
AB* to AB).   
kass1 (1/Ms) kdiss1 (1/s) kass2 (1/s) kdiss2 (1/s) K (1/M) Chi2
11100 ± 337 0.0657 ± 0.0027 0.0161 ± 0.000585 0.0034 ± 0.000127 806000 25.7
 
3.2.6. TolB box revertant mutants 
Although the TolB box region of colicin E9 has been localised to residues D35 - W39 
(Carr et al 2000a, Garinot-Schneider et al 1997), there is no published information 
available as to the role of these residues in the interaction with TolB.  Mutation of 
D35, S37 and W39 residues in colicin E9 to alanine, and mutation of S37 to F in 
colicin E3 abolishes the biological activity of the colicin and the interaction of the 
colicin with TolB (Bouveret et al 1997, Carr et al 2000a).  However, it is unknown 
whether other residues could be tolerated at positions in the TolB box, without 
compromising the activity of the colicin or binding to TolB.   
Therefore, mutagenic primers were used to randomly mutate a biologically inactive 
TolB box alanine mutant to any residue and those clones with restored activity in a 
stab test were sequenced (Holland 2003).  ColE9/Im9 proteins were purified from the 
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clones with restored activity and colicin titres of these proteins were determined using 
a spot test (Holland 2003).  This mutagenic analysis was performed for residues 35, 
37 and 39.   
For residue 35, three clones were found to have restored activity.  For two of these 
clones, the residue had reverted back from alanine to the wild-type residue ie 
aspartate.  The other clone contained a serine at position 35.  The activity of the 
purified A35D and A35S proteins was shown to be the same as wild-type in a spot 
test (Holland 2003).   
For residue 37, 18 clones had restored activity and were found to contain either a 
valine, threonine or serine (wild-type) residue at position 37.  Spot tests with purified 
colicin E9 proteins from these clones, showed that the mutant proteins had similar 
activity to wild-type colicin E9 (Holland 2003).   
For residue 39, 21 clones had restored activity and were found to contain either a 
tryptophan (wild-type), phenylalanine or tyrosine residue at position 39.  Spot tests 
with the purified proteins from these clones, showed that the A39Y mutation reduced 
activity considerably, producing only a hazy zone in a spot test.  The activities of 
A39F and A39W mutants were shown to be slightly lower than that of wild-type 
colicin E9.   
3.2.6.1. Affinity of TolB box revertant mutants for TolB 
In order to relate the titres of the revertant mutants to the affinity of the mutants for 
TolB, the affinities of binding of four of the mutants with restored activity ie A35S, 
A37T, A37V and A39Y were determined by SPR.   
Kinetic parameters for the interaction between the mutant colicin E9/Im9 proteins and 
TolB were obtained in the same way as described above for wild-type colicin E9/Im9.  
Two minute injections of 2, 5, 10, 15 and 20 M of the mutants were performed 
across immobilised TolB on a CM5 chip at a flow rate of 30 l/min.  Global analysis 
using BIAevaluation software 3.1 was used to fit corrected SPR responses to the 
theoretical 1:1 Langmuir binding model.  Kd values for the mutants are shown in 
Table 3.5.  Chi squared values were less than or equal to 2 and Scatchard plots were 
linear with R2 values >0.9 (data not shown).   
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Table 3.5 Table showing comparison of Kd values for binding of TolB box revertant 
mutants to TolB, determined by SPR, to the titre for the mutants, determined by a spot test 
(Holland 2003). 
1012.2 ± 0.2S37V
Hazy zoneLow affinityW39Y
14.524.3 ± 1.2S37T
1012 ± 0.2D35S 
1013.8 ± 0.3Wild-type
Titre (nM)Kd (M)Mutation
 
 
Table 3.5 shows that a serine residue at position 35 has very little effect on the Kd for 
binding to TolB, consistent with the identical titre seen in the spot test.  Similarly the 
affinity of the A37V mutant for TolB is very similar to the affinity of wild-type 
colicin E9/Im9 for TolB, consistent with the identical titres for mutant and wild-type.  
A threonine residue at position 37 significantly decreases the affinity of the colicin for 
TolB and this is reflected in the slight increase in titre.   
It was not possible to get kinetic data for the binding of the A39Y mutant to TolB, as 
the level of binding was so low.  The reduced affinity for TolB of this mutant is 
consistent with the hazy zone seen in the spot test, indicating that the low affinity of 
the mutant for TolB, substantially reduces its activity.     
3.2.7. Extension of the TolB box 
The perturbation of the backbone resonances of residues 33 to 44 of colicin E9, in the 
1H-15N HSQC spectrum of colicin E9 in the presence of excess, unlabelled TolB are 
perturbed on binding to TolB (Collins et al 2002) has lead to the suggestion that the 
region for binding to TolB should include residues A33, S34, S40, S42, E42, N43 and 
N44, in addition to the recognised TolB box pentapeptide sequence, from residues 35-
39 (DGSGW).  Residue E42 has already been shown by SPR to be involved in 
binding to TolB (Holland 2003) and therefore this section investigates the effect of 
S34A, S40A, S41A, N43A and N44A mutations on colicin E9 activity and TolB 
binding.   
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3.2.7.1. Alanine mutagenesis of residues S41, N43 and N44 
Mutation of residues S41, N43 and N44 was achieved using a 2-step PCR method 
(Sarkar and Sommer 1990).  In the first stage pNP69 (see section 2.2) was used as the 
template along with T7 promoter primer and a mutagenic primer ie SR1, 2 or 3.  The 
megaprimer produced in the first stage was then used along with primer H52 with 
pNP69 as the template in the second stage.   
The second stage PCR product was restricted with NdeI and XhoI and cloned into 
pET21a and used to transform DH5α cells.  The purified plasmids (pSR15, 16 and 17) 
from the DH5α cells were sequenced to confirm the presence of the required mutation 
and then used to transform E.coli BL21 cells.  IPTG was used to induce expression of 
the mutated colicin E9 proteins in a 400ml culture of these BL21 cells.  Cells were 
harvested and lysed and the mutant protein was purified using nickel-affinity 
chromatography as described in Chapter 2.   
3.2.7.2. Stab tests to check activity of mutants 
E.coli BL21 cells expressing a S34A, S40A, S41A, N43A or N44A colicin E9 mutant 
were used in a stab test to test the activity of the mutant colicins (see Table 3.1 for 
appropriate plasmids).  Figure 3.15 shows that mutation of residues S34, S40 and N44 
to alanine, abolishes activity of the colicin, whereas the colicin E9 S41A and N43A 
mutants retain activity.  A slight hazy zone develops for the S34A mutant after 
incubation at 25 ºC for 24 hours but no hazy zone was observed for the S40A mutant, 
in contrast to the findings of Garinot-Schneider et al (1997).   
3.2.7.3. Spot tests to check activity of mutants 
The activity of purified S34A, S40A, S41A, E42A, N43A and N44A colicin E9 
mutant proteins was tested in a large plate spot test against wild-type colicin E9.  
Figure 3.16 shows that, consistent with the stab test, S34A and S40A mutant proteins 
are inactive along with the E42A mutant, whereas S41A and N43A proteins have 
comparable activity to wild-type colicin E9.  The N44A mutant produces a hazy zone 
at 30 M but no zone at concentrations of 5 M or less, indicating that this mutant has 
residual activity.   
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S41A S34A
N44A N43A
S40A Wild-type
 
Figure 3.15 Results of a stab test performed with E.coli BL21 cells transformed with 
plasmids encoding S34A, S40A, S41A, N43A or N44A mutant colicin E9, compared to results 
with cells transformed with wild-type colicin E9 
N44A        N43A      E42A          S41A       S40A        S34A WT
30µM
5µM
5nM
 
Figure 3.16 Results of a large plate spot test with purified S34A, S40A, S41A, E42A, N43A, 
N44A colicin E9 mutants and wild-type colicin E9. 
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3.2.7.4. Reporter assay to compare activity of mutants 
In order to obtain a more precise comparison of the activity of the purified mutant 
proteins, a luminescence reporter assay was performed, which uses an SOS-inducible 
chromosomal lux operon to detect DNA damage induced by colicin E9 
(Vankemmelbeke, unpublished data; Davidov et al 2000). 
4 l of S34A, S40A, S41A, E42A, N43A, N44A and H575A mutant colicin E9/Im9 
proteins and wild-type colicin E9/Im9, at a concentration of 10 nM, were added to 
100 l aliquots of E.coli DPD1718 cells, giving a final concentration of ~0.4 nM 
colicin.  The inactive colicin E9 H575A DNase mutant was used as a control.  Four 
replicates for each mutant and the wild-type colicin were performed.   
The mean gamma value was calculated for each mutant and the wild-type at the 50 
minute time point (see Chapter 2, Equation 3.1).  Data for each mutant are displayed 
in Figure 3.17 as the percentage of the mean wild-type gamma value and as expected, 
in addition to the control H575A mutant, the TolB box mutants (D35A, S37A and 
W39A) showed no activity.  The S34A, S40A and E42A were also inactive, 
consistent with the stab and spot tests.  The N44A mutant shows 3 % activity 
compared to wild-type, consistent with the hazy zone seen for a concentration of 30 
M of the mutant in the spot test.  The S41A mutant has 26 % of wild-type activity, 
whilst the N43A mutant has 86 % of wild-type activity.  These differences in activity 
of the S41A and N43A mutants compared to wild-type were not detected in the spot 
test.   
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Figure 3.17 Results from a reporter assay comparing the activity of TolB box mutants and 
mutants surrounding the TolB box to wild-type colicin E9/Im9.  The inactive H575A colicin 
E9/Im9 mutant was used as a control. 
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Figure 3.18 Results from a competition assay using DPD1718 reporter cells.  Addition of the 
mutant colicins in 1:1, 1:10 and 1:100 ratios to wild-type colicin, protects the reporter cells from 
DNA damage caused by the wild-type colicin.   
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3.2.7.5. Competition assay to test receptor-binding of 
mutants 
In order to check that the S34A, S40A and N44A mutants were intact proteins and 
that the mutation was not affecting the receptor-binding domain, a competition assay 
was performed on these mutants using the luminescence reporter system described 
above.  This assay tests for the ability of the mutants to bind to the BtuB receptor of 
sensitive E.coli cells, thus protecting the cells from DNase damage by wild-type 
colicin E9.   
The mutant colicin was added to cells at concentrations of 0.4 nM, 4 nM and 40 nM, 
in addition to 0.4 nM wild-type colicin E9.  The inactive H575A DNase mutant was 
used as a control.  Four replicates for each mutant were performed.   
The mean gamma value was calculated for each concentration of mutant at the 50 
minute time point (see Chapter 2, Equation 3.1).  The data for each mutant are 
displayed in Figure 3.18 as a percentage of the mean gamma value for cells treated 
with 0.4 nM wild-type colicin E9 only.  Figure 3.18 shows that when the S34A, S40A 
or N44A mutants are added to the reporter cells in a ratio of 100:1 to wild-type colicin 
E9, the percentage DNA damage compared to cells treated only with wild-type colicin 
E9, is less than 10% for all three mutants.  The protection shown is similar to that 
shown by the control H575A mutant.  This indicates that all three of these mutants are 
able to protect the cells from DNA damage by the wild-type colicin E9, indicating 
that the mutants have intact receptor-binding domains, capable of binding to BtuB.  
Therefore the loss of activity of the S34A, S40A and N44A mutants is not due to an 
inability to bind to the primary receptor, BtuB.      
3.2.7.6. Kunitz assay to test DNase activity of mutants 
In order to check that the loss of activity of the S34A, S40A and N44A mutants was 
not due to an inability to cleave DNA, a Kunitz assay was performed on the mutants.  
As the DNase activity of colicin E9 is inhibited by the presence of Im9, the immunity 
protein was removed from the mutant colicins, before the assay was carried out, by 
denaturation on a Hi-trap column using 6 M guanidine hydrochloride, as described in 
Chapter 2.   
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Figure 3.19 shows that all three mutants are able to degrade DNA to a similar extent 
to wild-type colicin E9.  Therefore the loss of activity of these mutants seen in the 
stab test, spot test and reporter assay is not due to an inability to cleave DNA.   
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Figure 3.19 Results of a Kunitz assay performed with the free S34A, S40A and N44A colicin 
E9 mutants and free wild-type colicin E9.  The increase in absorbance due to the mutant colicins 
is similar to that for wild-type colicin E9.  The presence of Im9 prevents cleavage of DNA and 
therefore there is very little increase in absorbance due to colicin E9/Im9 (blue).  Lamp 
fluctuations of the order of 0.001 occur over the time scale of this experiment, accounting for 
fluctuations in the traces.   
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Figure 3.20 SPR sensorgrams showing reduction in binding to TolB caused by S34A, S40A 
and E42A mutations in colicin E9, compared to the reduction in binding caused by the D35A 
mutation.   
3.2.7.7. SPR to test TolB binding of mutants 
The binding of the colicin E9 proteins with mutations around the TolB box to TolB 
was measured using SPR.   
 
Injections of 2 M of the S34A and S40A mutants were performed across ~3000 RU 
TolB immobilised on a CM5 chip.  Figure 3.20 shows that the binding of S34A and 
S40A mutants was drastically reduced compared to wild-type.  The sensorgram for 
the D35A mutant is also shown as a reference point and demonstrates that an alanine 
mutation at residue 34 or residue 40 reduces binding of the colicin to TolB at least as 
much as a mutation in the recognised pentapeptide TolB box region.   
 
The S41A and N43A mutants were also shown to bind to TolB, a result that was 
expected due to their biological activity (data not shown).  However, in order to 
compare the affinity of these mutants for TolB to the affinity of wild-type colicin 
E9/Im9 for TolB, SPR was used to obtain Kd values for the binding of these mutants 
to TolB.   
Figure 3.21 shows the corrected sensorgrams and residual plots for binding of the 
colicin E9 S41A mutant protein to TolB.  Table 3.6 shows that the Kd for binding of 
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this mutant to TolB is 92.3 ± 2.5 M, demonstrating that the affinity of the S41A 
mutant for TolB is significantly reduced compared to the affinity of wild-type colicin 
E9/Im9 for TolB.  This is consistent with the reduced activity (26%) of the mutant 
seen in the reporter assay (see section 3.2.7.4).  It can therefore be concluded that 
mutation of residue S41 to A, reduces biological activity of colicin E9/Im9 due to a 
reduction in affinity of this mutant for TolB.   
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Figure 3.21 Corrected sensorgrams and residual plots for titration of 2 M (green), 5 µM 
(red), 10 µM (magenta), 20 M (blue), 30 M (yellow) and 40 M (cyan) S41A ColE9/Im9 against 
TolB at 25oC are shown. The fitted kinetic data for binding are superimposed onto each 
sensorgram in black. Residual plots highlight deviation of the experimental data from the 
theoretical fit. 
 
Table 3.6 Kinetic data obtained from fitting of sensorgrams produced for binding of S41A 
ColE9/Im9 to TolB to the Langmuir 1:1 binding model, errors for Ka and Kd were calculated by 
combining the standard errors on kass and kdiss in quadrature.   
kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
5380 ± 140 0.496 ± .00438 10800 ± 297 92.3 ± 2.54 1.7
 
 
Figure 3.22 shows the corrected sensorgrams and residual plot for the binding of the 
N43A mutant to TolB.  Table 3.7 shows that the Kd for binding of the N43A mutant 
protein to TolB is 51.5 ± 1.5 M, indicating that the affinity of this mutant for TolB is 
also reduced compared to the affinity of wild-type colicin E9/Im9 for TolB, although 
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to a lesser extent than the S41A mutant.  This is consistent with the activity of 85% of 
wild-type recorded in the reporter assay for the N43A mutant (see section 3.2.7.4).  
Therefore, it can be concluded that mutation of the N43 residue to A reduces the 
biological activity of ColE9/Im9 due to a reduction in affinity for TolB.   
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Figure 3.22 Corrected sensorgrams and residual plots for titration of 2 M (red), 5 µM 
(magenta), 10 µM (green), 20 M (cyan), 30 M (yellow) and 40 M (blue) N43A ColE9/Im9 
against TolB at 25oC are shown. The fitted kinetic data for binding are superimposed onto each 
sensorgram in black. Residual plots highlight deviation of the experimental data from the 
theoretical fit. 
 
Table 3.7 Kinetic data obtained from fitting of sensorgrams produced for binding of N43A 
ColE9/Im9 to TolB to the Langmuir 1:1 binding model, errors for Ka and Kd were calculated by 
adding the standard errors on kass and kdiss in quadrature.   
kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
12600 ± 309 0.649 ± 0.0097 19400 ± 556.7 51.5 ± 1.48 0.864
 
 
The binding of the N44A colicin mutant protein to TolB was also investigated.  
Figure 3.23 shows the corrected sensorgrams and residual plot for binding of the 
N44A mutant protein to TolB.  Table 3.8 shows that the mutant binds to TolB with a 
Kd of 19.4 ± 0.2 M.  This value is very similar to the Kd value seen for the binding of 
wild-type colicin E9/Im9 to TolB ie 13.8 M (see section 3.2.5.2).  This indicates that 
the mutation of residue N44 to A in colicin E9/Im9 has very little effect on the 
binding of the colicin to TolB.   
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Figure 3.23 Corrected sensorgrams and residual plots for titration of 2 M (magenta), 5 µM 
(blue), 10 µM (cyan), 15 M (green) 20 M (red) and 30 M (yellow) N44A ColE9/Im9 against 
TolB at 25oC are shown. The fitted kinetic data for binding are superimposed onto each 
sensorgram in black. Residual plots highlight deviation of the experimental data from the 
theoretical fit. 
 
Table 3.8 Kinetic data obtained from fitting of sensorgrams produced for binding of N44A 
ColE9/Im9 to TolB to the Langmuir 1:1 binding model, errors for Ka and Kd were calculated by 
combining the standard errors on kass and kdiss in quadrature.   
kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
7210 ± 69.3 0.14 ± 0.0009 51600 ± 587.6 19.4 ± 0.22 1.58
 
 
The lack of effect of the N44A mutation on binding to TolB is a surprising result 
considering the reduction in activity to 5% of wild-type activity observed for this 
mutant in the reporter assay.  The ability of the mutant to bind to TolB as well as the 
ability to bind to BtuB and degrade DNA shown by SPR, a competition assay and a 
Kunitz assay respectively, indicates that the colicin E9 N44A mutation must be 
affecting another part of the translocation pathway, rather than the interaction between 
the colicin and TolB.   
Further sequence analysis showed that pSR17, the plasmid from which the N44A 
mutant was expressed, contained a second mutation Y561C, in the DNase domain.  
Although the Kunitz assay showed that the colicin E9 N44A mutant had comparable 
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DNase activity to wild-type colicin E9/Im9, a further assay was used to confirm the 
DNase activity of the N44A mutant.    
3.2.7.8. DNase assay with N44A mutant 
This assay assesses the ability of the N44A mutant colicin E9 to hydrolyse linear 
DNA (see Chapter 2).  Figure 3.24 shows that, in the absence of Im9, the degradation 
of DNA by the N44A mutant is equivalent to the DNA degradation by wild-type 
colicin E9.  This result confirms that the N44A mutation does not affect the DNase 
domain and that the second mutation in pSR17 is unlikely to affect the activity of the 
mutant colicin E9.   
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Figure 3.24 Results from a pUC18 DNase assay showing that N44A colicin E9 is able to fully 
degrade DNA, with equivalent efficiency to wild-type colicin E9.  Due the inhibition of DNase 
activity by Im9, this was removed from the wild-type and mutant colicin before the assay.   
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3.3. Discussion 
This study has used the technique of SPR as a rapid and sensitive method for 
quantitatively comparing the affinity of colicin E9 mutants for TolB.  It has revealed 
some interesting results concerning the role of residues in the traditional TolB box 
and the involvement of residues surrounding this box in the interaction with TolB. 
3.3.1. Affinity for binding of wild-type colicin E9 
SPR was used to determine the kinetics for binding of wild-type colicin E9/Im9 to 
TolB.  Prior to this study, the only published kinetic data on the interaction of a 
colicin with TolB was that for the interaction of the pore-forming colicin A with 
TolB.  Isothermal titration calorimetry produced a Kd value of 10.4 ± 2.6 M for the 
binding of colicin A to TolB (Gokce et al 2000).  In this study SPR was used to 
determine the kinetics of binding of wild-type colicin E9/Im9 to TolB.  SPR 
determined a Kd value for the colicin E9/Im9-TolB interaction of 13.8 ± 0.26 M.  
This Kd value determined for the binding of colicin E9/Im9 to TolB is satisfyingly 
similar to the value determined for binding of colicin A to TolB.   
3.3.2. Pentapeptide TolB box of colicin E9 
3.3.2.1. Colicin E9 D35A, S37A, W39A mutants 
As expected, from their loss of activity and yeast-two hybrid data, the D35A, S37A 
and W39A colicin E9/Im9 mutants showed very low binding to TolB in SPR analysis.   
This confirms that the D35, S37 and W39 residues are crucial for binding of colicin 
E9 to TolB.   
3.3.2.2. Colicin E9 G36A, G38A mutants 
In contrast to yeast-two hybrid data, the binding of the G36A and G38A mutants to 
TolB was also reduced in SPR experiments.  Due to the use of these colicin mutants 
in the absence of the immunity protein in the yeast-two hybrid experiments, the 
immunity protein was removed from the G36A and G38A mutants and the binding to 
TolB was re-measured by SPR.   
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G36A 
Although the binding of the colicin E9 G36A mutant to TolB was reduced compared 
to wild-type colicin E9/Im9, when the immunity protein was removed from the G36A 
mutant, enhanced binding to TolB was observed, compared to binding of G36A 
colicin E9/Im9 and binding of wild-type colicin E9/Im9.   
The shape of the sensorgram for binding of free G36A colicin E9 to TolB was altered 
compared to the binding of wild-type colicin E9/Im9 to TolB, indicating that either 
the G36A mutation or the removal of Im9, or a mixture of the two, was affecting the 
colicin E9 binding site for TolB.   
The kinetic parameters for binding of the G36A colicin E9/Im9 mutant were then 
determined.  Due to the decreased binding of the G36A mutant in the presence of Im9 
observed in the preliminary experiment, compared to wild-type colicin E9/Im9, higher 
concentrations of this mutant were injected across the TolB chip.  Fitting of the 
sensorgrams produced to the Langmuir 1:1 binding model, produced a Kd of 45.1 ± 
1.1 M.  This Kd value confirms that the affinity of G36A colicin E9/Im9 for TolB is 
lower than the affinity of wild-type colicin E9/Im9 for TolB.  Therefore, the 
sensitivity of the SPR technique has permitted the detection of a difference between 
the affinity of wild-type colicin E9/Im9 and G36A colicin E9/Im9 mutant for TolB.  
The reduction in affinity of G36A colicin E9/Im9 for TolB is consistent with the 
reduction in activity seen in the spot test for this mutant.  Previously it has been 
reported that the activity of the G36A colicin E9 mutant is the same as the activity of 
wild-type colicin E9 (Garinot-Schneider et al 1997) but it should be noted that this 
observation is only based on a relatively insensitive stab test and no spot test with the 
purified mutant protein has previously been performed.   
 
In order to investigate the effect of the immunity protein on the G36A mutant, SPR 
was used in an attempt to determine the kinetic parameters for the binding of the free 
G36A colicin E9 mutant to TolB.  However, fitting of the sensorgrams to the 
Langmuir 1:1 model produced a very poor fit, with a high Chi squared value and low 
T-values.  Therefore fitting to other, more complex, models was attempted.  The best 
fit was to a two-state conformational change model, handling a situation in which the 
ligand and analyte form a complex on the sensor surface and the complex then 
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undergoes a conformational change.  The affinity constant (K, ie [kdiss1/kass1] x 
[kdiss2/kass2]) for the formation of the complex, including the conformational change, is 
1.24 ± 0.12 M.  Therefore the affinity of the colicin E9 G36A mutant protein for 
TolB is greater in the absence of Im9 than in the presence of Im9.   
It is possible that the reduction in affinity of the colicin E9 G36A mutant for TolB 
when Im9 is present is due to the immunity protein preventing the conformational 
change, required to form a stable complex between the colicin and TolB.  The effect 
of the immunity protein on binding of colicins to TolB, is investigated further in 
Chapter 4.   
G38A 
The affinity of G38A colicin E9 for TolB was shown to be low in the presence and 
absence of Im9.  This is consistent with the reduced activity of this mutant observed 
in the spot tests.  The activity of G38A colicin E9 mutant protein in the presence of 
Im9 was significantly reduced compared to wild-type colicin E9.  Although the 
activity of wild-type colicin E9 in the spot test was not affected by the presence or 
absence of Im9, consistent with previous observations (Schaller and Nomura 1976, 
Wallis et al 1992a), the activity of the G38A mutant protein was reduced even further 
in the absence of Im9.  Previous data regarding the activity of the G38A mutant has 
been obtained using the stab test, with the expressed colicin protein attached to Im9 
(Garinot-Schneider et al 1997).  No information has been published on the activity of 
the purified mutant protein or on the comparison of the activity of the mutant in the 
presence or absence of the immunity protein.  
The ability of the free G38A mutant to degrade DNA to a similar extent to wild-type 
colicin E9, shown by the Kunitz assay, indicates that there is no gross defect in the 
three-dimensional structure of the protein.  It is possible that the immunity protein 
stabilises the G38A mutant, prior to cell entry.  A stabilising role has been proposed 
for Im3, as the activity of free colicin E3 is significantly reduced compared to the 
activity of colicin E3/Im3 (Walker et al 2003).  Although Im9 does not affect the 
activity of wild-type colicin E9, it is possible that the G38A mutation destabilises the 
colicin, introducing a requirement for the stabilising effect of the immunity protein.   
Due to the reduced binding to TolB of the G38A mutant in the presence and absence 
of Im9, it was not possible to determine kinetic parameters for the interaction.  At 
concentrations of 10 M G38A colicin E9/Im9, a small response is detected due to 
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binding of the mutant to TolB.  Therefore, although the affinity of the G38A mutant 
for TolB appears to be much lower than wild-type, the affinity may be high enough to 
enable detection of an interaction in the yeast-two hybrid screen.  It is generally 
accepted that an interaction with a Kd < 1M is required for a positive result in a 
yeast-two hybrid screen (Estojak et al 1995).  However the SPR data obtained for the 
affinity of the G36A mutant for TolB show that the Kd is much greater than 1 M and 
yet this protein still produces a positive result in the yeast-two hybrid screen.  
Therefore, it would appear that the yeast-two hybrid screen used may have the ability 
to detect interactions with a Kd greater than 1 M.  The yeast-two hybrid screen used 
the translocation domain of colicin E9 fused to the binding domain of GAL-4.  The 
use of full-length colicin E9 mutants in the SPR study should produce more accurate 
information about the in vivo interaction between colicin E9 and TolB, particularly if 
regions other than the translocation domain affect binding to TolB.  The absence of 
the receptor-binding domain, immunity protein and DNase domain in the yeast-two 
hybrid screen may increase the affinity of the colicin for TolB (see Chapter 4), with 
the binding domain of GAL-4 stabilising the conformation of the colicin domains, 
which may explain the discrepancy between the yeast-two hybrid and SPR results.   
Role of glycine residues in the TolB box 
This study is the first time that an effect on binding to TolB, of mutating glycine 
residues 36 and 38 in colicin E9 to alanine, has been observed.  However, as this 
study also presents the first quantitative method to compare the affinities of colicin E9 
mutants for TolB, this is perhaps less surprising.  The yeast-two hybrid technique is 
only able to provide a positive or negative result according to whether an interaction 
occurs or not between two proteins, whereas the SPR technique is able to 
quantitatively compare affinities of mutated colicin proteins for TolB. 
     
It is interesting to note that when the proposed and known TolB box sequences of 
TolB-dependent colicins are compared, it is the two glycine residues, at positions 36 
and 38 of colicin E9, which are most conserved (see Figure 3.1).  The N-terminal 
region of the translocation domain of colicin E9 is very rich in glycine residues, with 
the first 80 residues containing 34 glycine residues, corresponding to a glycine 
content of 43%.  Some of these glycine residues are also clustered into triple glycine 
repeats (Soelaiman et al 2001).    As discussed earlier (see section 3.1.2) the N-
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terminal regions of the translocation domain of colicin E3 and N are flexible and the 
high glycine content contributes to this flexibility.  As extensive unfolding is likely to 
occur during translocation of the colicin translocation domain across the outer 
membrane, it is reasonable to assume that the translocation domain is a flexible 
peptide when it becomes exposed to TolB.  A parallel scenario is seen for the TonB 
box of Ton-dependent receptors, which changes from a helical to an extended 
conformation upon binding of the ligand to the receptor (Locher et al 1998, Vakharia 
and Postle 2002).  Therefore it has been suggested that interaction of Ton or Tol 
domains with other proteins requires a flexible peptide (Anderluh et al 2003).  
Mutation of a glycine residue to an alanine residue, has the potential to reduce 
flexibility, as addition of the methyl group causes more steric hindrance than a 
hydrogen atom (Stryer 1995), and it is therefore possible that mutation of glycine 
residues 36 and 38 in colicin E9/Im9 to alanine reduces the flexibility of the TolB box 
region, reducing the ability of the colicin to bind to TolB.   
 
Steady-state and time resolved fluorescence resonance energy transfer (FRET) and 
NMR have demonstrated that the translocation domain of colicin N undergoes gross 
conformational changes on binding to TolA (Anderluh et al 2003).  CD, fluorescence 
and SPR have recently shown that the translocation domain of colicin N acquires 
cooperatively folded secondary and tertiary structure in the colicin N-TolA complex 
(Anderluh et al 2004).   
The broadening of resonances in the 1H-15N HSQC NMR spectrum of the 
translocation domain of colicin E9 bound to TolB, indicates that the backbone 
segmental motions of residues 40-44 could be reduced due to binding to TolB 
(Collins et al 2002).  This suggests that this region becomes less flexible on binding 
TolB, potentially due to the formation of structure, in a similar manner to that seen for 
binding of colicin N to TolA, although the structure induced would be localised to the 
TolB box region, as not all resonances in the N-terminal region of colicin E9 are 
perturbed on addition of TolB (Collins et al 2002).  The structure induced in colicin 
E9 by binding to TolB, could allow the binding of colicin E9 to other proteins of the 
Tol/Pal system such as TolA and TolR (see Chapter 5 for further discussion regarding 
interactions of colicin E9 with Tol proteins).   
It would be interesting to investigate the effect of mutating glycine residues 36 and 38 
to a residue which would reduce the flexibility of the backbone further, such as 
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proline, to supply further information on the role of these glycine residues in 
providing flexibility of the TolB box region, required for binding of colicin E9 to 
TolB.   
3.3.3. Revertant mutants 
The lack of published information on the role of the residues in the pentapeptide TolB 
box, led to mutation of residues 35, 37 and 39 from alanine to any other residue.  Stab 
tests and DNA sequencing were used to identify residues that can restore colicin 
activity (Holland 2003).  In this study, SPR has been used to investigate the direct 
effect on binding to TolB of replacing the wild-type residue with a residue that 
restores colicin activity.   
3.3.3.1. Residue 35 
The random mutagenesis experiment showed that apart from the wild-type residue 
(aspartate), serine could also be tolerated at position 35.  Mutation of residue 35 from 
alanine to serine restored the level of activity in a spot test to a comparable level to 
wild-type.  SPR kinetic analysis has shown that the Kd for binding of the A35S colicin 
E9 mutant to TolB is 12 M, a comparable value to the Kd for binding of wild-type 
colicin E9/Im9 to TolB (13.8 M).  Therefore the SPR data confirm that a serine 
residue at position 35 of colicin E9/Im9 does not affect the ability of the colicin to 
bind to TolB.   
The wild-type residue at position 35 is aspartate, a polar, acidic amino acid (see 
Figure 3.25).  Serine is also a polar residue but is uncharged and smaller than 
aspartate (see Figure 3.25).  Both aspartate and serine residues are able to form 
hydrogen bonds.   
Asparagine or threonine residues were not tolerated at position 35 (Holland 2003).  In 
asparagine and threonine, the partial negative charge of the OH group is less 
accessible than in serine and aspartate.  Therefore it has been proposed that it is the 
OH group that is important for the function of residue 35, with the orientation and the 
accessibility of the OH group being important to form a hydrogen bond, either with 
another residue of colicin E9 or with TolB (Holland 2003).   
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Figure 3.25 The structures of serine (left) and aspartate (right).  Aspartate has a pKa of 4.5 
and therefore in physiological systems does not carry the hydrogen of the carboxylic acid group.   
3.3.3.2. Residue 37 
Replacing the alanine at position 37 with serine (wild-type residue), valine or 
threonine restored the activity of the colicin (Holland 2003).  The presence of a 
threonine residue at position 37 slightly reduced the activity of the colicin in a spot 
test, compared to wild-type.  The slightly increased Kd for the binding of the A37T 
mutant to TolB (24.3 ± 1.2 M), compared to the value for wild-type colicin E9/Im9, 
is consistent with this reduction in activity.  Threonine is the residue found at the 
equivalent position of the TolB box of colicin A and this residue is the only difference 
between the TolB box of colicin A and colicin E9 (see Figure 3.1).  It is therefore 
interesting that the presence of this residue, at least in colicin E9, reduces the affinity 
of the colicin for TolB.  Chapter 5 of this thesis compares the affinity of colicin A and 
colicin E9 for TolB and shows that the affinity of colicin A for TolB is reduced 
compared to the affinity of colicin E9 for TolB.  It is therefore tempting to speculate 
that the reason for this reduced affinity is the presence of a threonine residue instead 
of a serine residue in the TolB box of colicin A (see Chapter 5 for further discussion).   
The A37V mutant had the same activity as wild-type in a spot test, consistent with a 
Kd for binding of the mutant to TolB of 12.2 ± 0.2 M, a value very similar to the Kd 
for wild-type colicin E9/Im9.  The lack of a hydroxyl group on the valine side chain 
(see Figure 3.26) suggests that the hydroxyl group of serine and threonine is not 
important for function of the residue at position 37.  The substitution of two non-
hydrogen groups at the C-β carbon in both valine and threonine, which restricts 
mobility of the protein backbone, also suggests that flexibility of the backbone is not 
important for the function of the residue at position 37 (Holland 2003).   
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Figure 3.26 Structures of serine (left), threonine (middle) and valine (right).   
3.3.3.3. Residue 39 
The residues at position 39 that restored activity were the aromatic residues, 
tryptophan (wild-type residue), phenylalanine and, to some extent, tyrosine.  The low 
affinity of the A39Y mutant for TolB seen in the SPR experiment is consistent with 
the reduced activity of this mutant in a spot test.    
Although tryptophan and phenylalanine are hydrophobic residues and are therefore 
generally found buried within proteins, tyrosine is only partially hydrophobic with a 
polar hydroxyl group (see Figure 3.27).  This reactive polar hydroxyl group may 
hinder the interaction of the colicin with TolB.   
As the only common feature of tryptophan, phenylalanine and tyrosine is the aromatic 
ring, it has been proposed that residue 39 may be involved in an interaction, involving 
stacking of π orbitals of adjacent aromatic rings (Holland 2003).  Residue 39 of 
colicin E9 may interact directly with two proline rings encircling the central channel 
of the β-propeller of TolB or with aromatic residues on the surface of TolB such as 
W208, F252 and W296 that are conserved in TolB proteins from different bacteria 
(Holland 2003).  However, mutagenic analysis of residues in TolB is required to 
investigate the role of these proline and aromatic residues in TolB. 
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Figure 3.27 Structures of tryptophan (left), phenylalanine (middle) and tyrosine (right).   
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3.3.4. TolB box extension 
Following initial analysis of the activity of the S34A and S40 colicin E9 mutants 
using a stab test (Garinot-Schneider et al 1997), this study further investigated the 
effect of the S34A and S40A mutations on the activity of colicin E9 in stab tests and 
spot tests and has shown that these mutations abolish the activity of the colicin.  The 
S34A and S40A mutant proteins were shown to have comparable receptor-binding 
and DNase activity to wild-type colicin E9.  SPR with TolB immobilised on a sensor 
chip has shown that the reason for the loss of activity of these mutants is their failure 
to bind to TolB.  This indicates that the TolB box should be extended to include at 
least one residue upstream and one residue downstream of the pentapeptide TolB box.   
The loss of activity of the E42A mutant due to loss of TolB binding (Holland 2003) is 
consistent with this proposal and indeed suggests that the TolB box should be 
extended further, at least as far as residue 42.   
Mutation of residue S41A significantly reduces the activity of colicin E9.  SPR has 
shown that the reason for this reduction in activity is a decreased ability of this mutant 
to bind to TolB, with a reduced affinity of the S41A mutant for TolB (Kd = 92.3 ± 2.5 
M) compared to the affinity of wild-type colicin E9/Im9 for TolB (Kd = 13.8 ± 0.3 
M).   
Mutation of residue N43A also partially reduces the activity of colicin E9 and SPR 
has shown that this reduction in activity is due to a decreased affinity of the mutant 
for TolB compared to wild-type colicin E9/Im9 (Kd = 51.5 ± 1.5 M vs Kd = 13.8 ± 
0.3 M).   
This indicates that residues S41 and N43 are involved in binding to TolB, but that 
they may increase the affinity of the interaction indirectly, as mutation of these 
residues does not completely abolish TolB binding.  It is possible that the side chains 
of residues S41 and N43 are involved in interacting with side chains of other residues 
in the TolB box region, creating a “structural unit” and hence increasing the affinity 
of colicin E9 for TolB.  This is consistent with the suggestion by Collins et al (2002) 
that the side-chains of residues S40, S41 and E42 interact with each other, based on 
the identification of two resonances for these residues in the 1H-15N HSQC NMR 
spectrum.  It would be interesting to perform a similar random mutagenesis analysis 
to that performed on residues 35, 37 and 39, on residues S40 – N43 to investigate the 
involvement of these residues in side-chain interactions.   
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Mutation of residue N44A abolishes activity of colicin E9, shown in a stab test and a 
spot test, and drastically reduces DNase activity, identified by the reporter assay.  The 
N44A mutant colicin E9 has been shown to be intact in its receptor-binding domain 
and in its DNase domain.  The affinity of the N44A mutant for TolB has been shown 
by SPR to be comparable to the affinity of wild-type colicin E9/Im9 for TolB (19.4 ± 
0.2 M vs 13.8 ± 0.3 M).  This shows that the drastic reduction in activity of this 
mutant is not due to a loss of binding to TolB and therefore indicates that the C-
terminal boundary of the TolB box may be formed by this residue.   
The lack of effect on binding of colicin E9/Im9 to TolB caused by the N44A 
mutation, along with the demonstration that the receptor-binding and DNase domains 
of the mutant are intact, indicates that residue N44 is involved in some other aspect of 
translocation of colicin E9.  The residue is conserved between the endonuclease 
colicins but is not conserved in pore-forming colicins, raising the possibility that the 
residue is involved in part of the translocation mechanism of endonuclease colicins 
that differs from that for pore-forming colicins.   
However, residues 43 - 45 (NNP) of colicin E9 are homologous to residues 103 – 105 
of colicin A, suggesting the possibility that these residues are important in another 
aspect of translocation.  The residues of colicin A lie just outside the region predicted 
to be involved in interacting with TolA.   
3.3.5. Use of alanine mutagenesis 
The use of site-directed mutagenesis is now widespread, providing information about 
the role of side-chain functional groups in protein structure, folding and protein-ligand 
interactions.  However, a general concern is that replacement of the wild-type residue 
with another residue can result in a structural change in the protein, rendering the 
protein inactive, without specifically affecting the protein-ligand interaction.  
Although this is possible for the mutations made in and around the TolB box, the lack 
of structure in this domain makes it unlikely.  In addition, wild-type residues have 
been mutated to alanine, which should not increase the flexibility of the protein, 
although as we have seen with the G36A and G38A mutations, a decrease in 
flexibility has the potential to alter the interaction with TolB (Morrison and Weiss 
2001).  The introduction of alanine upstream and downstream of the TolB box has no 
effect on the activity of the protein, indicating that alanine residues can be tolerated in 
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the region of interest unless a specific side chain is required (Garinot-Schneider et al 
1997, Christopher Penfold, personal communication).     
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3.4. Summary 
The work in this chapter provides further insight into the interaction between TolB 
and colicin E9.  Kinetic parameters for the interaction have been determined, 
providing a value for the Kd for the interaction of 13.8 M.   
The data presented here confirm previous observations that residues D35, S37 and 
W39 are required for binding of colicin E9 to TolB.  These residues appear to be 
required for different reasons.  The data supports the suggestion that the tryptophan 
residue at position 39 could form stacking interactions with aromatic residues in 
TolB.  The aspartate residue at position 35 may be involved in hydrogen bonding with 
another residue in colicin E9 or a residue in TolB, whilst the serine at position 37 is 
likely to be required to maintain local structure of the TolB box.   
In contrast to previous data, glycine residues at positions 36 and 38 have also been 
shown to be important for binding of colicin E9 to TolB.  These residues are likely to 
be important in maintaining flexibility of the TolB box.   
Data presented in this chapter also suggest that TolB box should be extended to 
include residues S34, S40, S41, E42 and N43.  The apparent lack of involvement of 
residue N44 in binding to TolB implies that this may be the C-terminal boundary of 
the TolB box, although mutagenic analysis of residues further downstream of residue 
44 is required to confirm this.  The N-terminal boundary of the TolB box may be 
formed by residue 34 but again further mutagenic analysis upstream of this residue is 
required to establish the N-terminus of the TolB box.    
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4. CHAPTER 4 – Effect of immunity proteins on 
binding of colicin E9 and colicin E3 to TolB 
4.1. Introduction 
4.1.1. Affinities of colicin E9 and E3 for Im9 and Im3.   
The Kd for the interaction of Im9 with the colicin E9 DNase domain of 9.3 x 10-17 M, 
makes the interaction one of the highest affinity protein-protein interactions in nature 
(Wallis et al 1995a).  The high affinity of the interaction is implied in the requirement 
for denaturation of the colicin E9/Im9 complex in order to separate the immunity 
protein from the colicin.   
The affinity of the immunity protein for the DNase domain of colicin E9 is very 
similar to the affinity of the immunity protein for full-length colicin E9 (Wallis et al 
1995).  Therefore, it has been assumed that the only region of colicin E9 that makes 
energetically important contacts with Im9 is the DNase domain.   
However, the affinity of full-length colicin E3 for Im3 is greater than the affinity of 
the RNase domain for Im3 (Walker et al 2003).  The increased affinity of the full-
length colicin for Im3 has been attributed to interactions between Im3 and the 
translocation domain of colicin E3, based on the crystal structure of the colicin 
E3/Im3 complex (Soelaiman et al 2001).   
4.1.2. Non-cognate immunity proteins 
Although each immunity protein is specific for its cognate colicin, interactions have 
been detected between colicins and non-cognate immunity proteins (Wallis et al 
1995b).  Comparison of the in vivo and in vitro cross-reactivities of colicin E9 with its 
cognate immunity protein, Im9, and the non-cognate immunity proteins, Im2, Im7 and 
Im8 (from DNase colicins) has shown that the affinities of the protein-protein 
interactions are spread over a wide range (Wallis et al 1995b).  The order of cross-
reactivity in vivo, determined by the level of protection provided by transformation of 
E.coli cells with a vector containing a cloned immunity gene, was Im9 >> Im2 > Im8 
with Im7 providing no protection (Wallis et al 1995b).  The in vitro binding affinities 
of each immunity protein for the DNase domain of colicin E9 were also determined 
and the Kd values for Im2, Im8 and Im7 were 10-8 M, 10-6 M and 10-4 M respectively, 
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corresponding to the in vivo cross-reactivity data.  The difference in Kd was shown to 
be due to increased dissociaton rates of the non-cognate immunity proteins (Wallis et 
al 1995b).  Therefore, although non-cognate immunity proteins were able to bind to 
the colicin, they were not able to make specific interactions and rapidly dissociated 
from the colicin (Kleanthous et al 1998).   
The Kd for binding of an immunity protein to a colicin must be less than 10-10 M in 
order for the immunity protein to provide complete biological protection and 
complexes with Kd values of 10-6 M or greater provide no biological protection (Li et 
al 2004).   
4.1.3. Effect of Im9 on the translocation domain of colicin E9 
The addition of Im9 did not perturb the chemical shifts or the T2 relaxation times of 
the peaks in the 1H-15N HSQC spectrum of colicin E9 (Collins et al 2002).  This 
indicates that the translocation region of colicin E9 is not affected by binding of Im9 
to the colicin.   
4.1.4. Effect of receptor-binding and cytotoxic domains on 
the translocation domain of colicins 
4.1.4.1. Binding of the translocation domain of colicin N to 
TolA 
Isothermal titration calorimetry has been used to determine a Kd for binding of colicin 
N to TolA of 18 M (Raggett et al 1998).  However, the Kd for binding of the isolated 
colicin N translocation domain to TolA was 1 M and the Kd for binding of the 
isolated translocation and receptor-binding domains was 8M.  Therefore, the affinity 
of colicin N for TolA is reduced in the presence of the pore-forming and receptor-
binding domains.  No binding of the isolated pore-forming and receptor-binding 
domains to TolA was detected.    
4.1.4.2. Binding of colicin A to TolA and TolB 
Although colicin A requires both TolA and TolB for translocation, no interaction of 
colicin A with TolA was detected by isothermal titration calorimetry (Gokce et al 
2000).  However, binding of the isolated translocation domain of colicin A to TolA 
has been detected by SPR (Derouiche et al 1997).  Gokce et al (2000) suggest that 
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this may be due to the TolA site of colicin A being masked by the rest of the protein 
in the full-length colicin A, in a similar way to the TolA site of colicin N (see above).  
The observation that colicin A translocation can be accelerated by unfolding the 
colicin with urea, also suggests that the sites for binding to Tol proteins, are partially 
occluded by the rest of the protein in the native state (Bénédetti et al 1992).   
4.1.4.3. Structure of colicin Ia 
The structure of colicin Ia, indicates that the TonB box is located at the end of an 
extended N-terminal peptide which interacts along one surface of the antiparallel 
helical sheet formed by the translocation domain (Wiener et al 1997).   This peptide is 
buried within the structure of the colicin, at the top of the receptor-binding domain, 
sandwiched between the cytotoxic and translocation domains.  The lack of electron 
density for the first 83 residues of colicin E3 prevents identification of the position of 
the TolB box of this colicin.  However, the similarity of the colicin Ia and colicin E3 
structures suggest that the TolB box could potentially be buried between the 
translocation and cytotoxic domains of colicin E3.   
4.1.5. Effect of Im9 on binding of G36A colicin E9 to TolB 
The effect of Im9 on binding of the G36A colicin E9 mutant to TolB has been 
described in the previous chapter of this thesis.  Removal of the immunity protein 
from the G36A mutant, appeared to increase the affinity of the mutant for TolB.   
Although the sensorgrams produced for the binding of G36A colicin E9/Im9 to TolB 
fitted to the simple 1:1 Langmuir binding model, the sensorgrams produced for the 
binding of the free G36A colicin E9 mutant were an altered shape and did not fit to 
simple models.  The sensorgrams did fit to a two-state conformational change model, 
indicating that removal of the immunity protein affects the conformation of the 
translocation domain, affecting the binding of the TolB box to TolB.   
4.1.6. Aims of Chapter 
The intriguing effect of the immunity protein on binding of the G36A colicin E9 
mutant to TolB, reported in the previous chapter, has led to further investigation of the 
effect of the immunity protein on binding of colicin E9 to TolB using dynamic force 
spectroscopy and surface plasmon resonance.  Unlike colicin E9, the structure of the 
colicin E3/Im3 complex is known and Im3 has been shown to interact with the 
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translocation domain as well as the translocation domain.  Therefore the effect of Im3 
on binding of colicin E3 to TolB is also investigated.   
The reason for the effect of the immunity protein on binding of these colicins to TolB 
is also explored.   
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4.2. Results 
4.2.1. Purification and verification of free colicin E9 
The presence of a polyhistidine tag at the end of Im9 allows the purification of colicin 
E9, free from Im9, by denaturation of the colicin E9/Im9 complex on a Ni-affinity 
column using 6 M guanidine hydrochloride.  This results in the elution of free colicin 
E9 with Im9 remaining bound to the column.  Following denaturation, colicin E9 was 
refolded by extensive dialysis against potassium phosphate buffer pH 7.4.  
Renaturation of free colicin E9 by dialysis has previously been shown to be effective 
by fluorescence spectroscopy and by the demonstration that the dialysed colicin 
regains full biological activity (Wallis et al 1992a).   
To ensure that the purification procedure had removed all immunity protein from the 
colicin E9 protein, the protein was run on an SDS-PAGE gel against the colicin 
E9/Im9 complex.  The gel was silver stained to increase the detection sensitivity, 
compared to staining with Coomassie blue (see Chapter 2).  Figure 4.1 shows that the 
band around 10 kDa, corresponding to Im9, is absent from the lane containing free 
colicin E9, confirming that the colicin is free from immunity protein. 
4.2.2. Purification of Im9 
Following denaturation of the colicin E9/Im9 complex and elution of free colicin E9, 
Im9 can be eluted with imidazole.  However, Figure 4.2 shows that the eluted Im9 is 
not completely pure and is contaminated with at least one other protein.  Therefore 
Im9 was cloned separately into pET21d to enable production of pure Im9 protein.  
PCR was used to amplify the Im9 gene from pNP57 (a pET21a clone containing 
colicin E9 with a W39A mutation and Im9) using primers H52 and DW22 (see 
Chapter 2).  The PCR product was restricted with XhoI and NcoI and then ligated with 
pET21d, restricted with the same restriction enzymes.  The ligation product was then 
used to transform E.coli DH5α cells.  The purified plasmid (pSR10) from the DH5α 
cells was sequenced to confirm that the plasmid encoded wild-type Im9 and then used 
to transform E.coli ER2566 cells.  IPTG was used to induce expression of the Im9 
protein in a large scale culture of the ER2566 cells (see Figure 4.3).  Cells were 
harvested by centrifugation and the mutant protein was purified using nickel affinity 
chromatography as described in Chapter 2.  The purified protein was dialysed in 50 
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mM potassium phosphate buffer, pH 7.4 and run on an SDS-PAGE gel to check for 
purity.   
As can be seen from Figure 4.4, pure protein has been produced by the nickel affinity 
chromatography, but the band on the gel corresponds to an apparent size of around 6 
kDa compared to the expected 10 kDa, although it is the same size as the Im9 band in 
the ColE9/Im9 complex sample on the same gel.   
To ensure that the purified Im9 protein was biological active, a Kunitz assay was 
performed to test whether the purified Im9 could protect DNA from being degraded 
by wild-type colicin E9.  The DNase activity of free colicin E9, colicin E9/Im9 
(purified complex) and free colicin E9 pre-incubated with purified Im9 was measured.  
Figure 4.5 shows that the purified Im9 prevents colicin E9 degrading DNA, as the 
absorbance trace for the free colicin E9 with purified Im9 added is very similar to the 
absorbance trace for colicin E9/Im9 purified as a complex.   
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Figure 4.1 Silver-stained 16 % SDS-PAGE gel comparing free ColE9 with no band at 10 
kDa to ColE9/Im9 complex with a clear band at 10 kDa.   
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Figure 4.2 Coomassie blue stained 12 % SDS-PAGE gel showing Im9 produced from 
denaturation of the colicin E9/Im9 on a Hi-trap column and then elution with imidazole.  The gel 
shows that the Im9 produced is contaminated with at least one protein.    
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Figure 4.3 16 % Coomassie-stained SDS-PAGE gel showing the expression of Im9 protein 
from pSR10. 
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Figure 4.4 16 % Coomassie-stained SDS-PAGE gel showing purified Im9.  The protein 
runs at an apparent molecular weight of approximately 6 kDa, smaller than its predicted 
molecular weight of 10 kDa.   
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Figure 4.5 Results from a Kunitz assay measuring DNA degradation activity of free colicin 
E9, colicin E9/Im9 and free colicin E9 with purified Im9 added back. 
 
4.2.3. Purification of T61-DNase 
The colicin E9 fusion protein, T61-DNase, consisting of the first 61 residues of the 
translocation domain of colicin E9 fused to the DNase domain of colicin E9, was 
expressed from BL21 (DE3) cells transformed with plasmid pNP330, a pET21a-based 
plasmid encoding the T61-DNase/Im9 construct.  The T61-DNase protein was purified 
in complex with Im9, using the same method set out for full-length colicin E9/Im9.  
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The construct was also purified free from Im9, using the denaturation method set out 
in Chapter 2.  Figure 4.6 shows the purified proteins run on a 12 % gel, following 
dialysis in 50 mM potassium phosphate buffer, pH 7.4.   
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Figure 4.6 12 % SDS-PAGE gel showing purified T61-DNase/Im9 and free T61-DNase 
proteins.  The calculated molecular weight of the T61-DNase is 20 kDa but the apparent 
molecular weight on a gel is slightly higher.   
4.2.4. Purification of Colicin E3 
Colicin E3/Im3 had been cloned in plasmid pRJ382 (a pET21a-based vector 
containing full-length colicin E3 and Im3), but an XhoI site had been introduced after 
the stop codon of Im3 so that the sequence lacked a his-tag, preventing purification of 
the protein complex via nickel affinity chromatography.  Therefore, primer W78, 
which replaces the stop codon of Im3 with an XhoI site, was used with primer Z4, 
which puts an NdeI site at the start of ColE3, in a PCR reaction with pRJ382 as a 
template.  The resulting PCR product was then restricted with NdeI and XhoI and 
ligated into pET21a restricted with the same restriction enzymes.  The ligated product 
was used to transform E.coli DH5α cells.  The colicin E3 and Im3 genes encoded by 
the purified plasmid (pSR14) obtained from the DH5α cells was sequenced to ensure 
no mutations had been introduced and pSR14 was then used to transform BL21 pLysS 
cells.  IPTG was used to induce expression of ColE3/Im3 in the transformed BL21 
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cells and crude cell lysate samples, taken before and after induction, were run on a 12 
% SDS-PAGE gel.  Figure 4.7 shows that a protein of the expected size is produced 
after induction.   Cells were harvested and lysed and the colicin E3/Im3 protein was 
then purified using nickel affinity chromatography.  The purified protein was dialysed 
in 50 mM potassium phosphate buffer, pH 7.4 and run on a gel to check for purity 
(see Figure 4.8).  Colicin E3 was also purified without Im3 using the method detailed 
in Chapter 2.  The free protein was run on an SDS-PAGE gel and silver-stained to 
check for the absence of Im3 (see Figure 4.8).  The Im3 protein, separated from 
colicin E3 by denaturation, appeared pure on an SDS-PAGE gel after dialysis (see 
Figure 4.8) and was therefore considered suitable for use in SPR analysis.   
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Figure 4.7 12 % SDS-PAGE gel showing crude cell lysate samples from BL21 DE3 cells 
transformed with pSR14, before and after induction with IPTG.  Colicin E9 was also run 
alongside these samples to check that the induced protein was of the appropriate size.  A strong 
band can be seen in the induced sample, corresponding to the size of colicin E9, indicating that 
expression of the colicin E3 protein has been achieved.    
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Figure 4.8 12 % SDS-PAGE gels showing purified colicin E3/Im3, Im3 and free colicin E3.  
The right-hand gel shows that the band corresponding to Im3 is absent from free colicin E3 and 
that the Im3 protein is free from contaminants.   
4.2.5. Effect of Im9 on binding of colicin E9 to TolB  
4.2.5.1. Preliminary SPR experiment 
A preliminary SPR experiment, using the BIAcore J instrument, involved the 
injection of 2 M free colicin E9 across TolB, immobilised to a CM5 sensor chip.  
The response produced was compared to the response produced when 2 M colicin 
E9/Im9 was injected across the TolB chip.   
Figure 4.9 shows that the response recorded for the binding of free colicin E9 to TolB 
was increased compared to the response recorded for the binding of the colicin 
E9/Im9 complex to TolB.  As the SPR response is directly proportional to changes in 
mass, the differing relative molecular masses of colicin E9 and colicin E9/Im9 must 
be taken into account.  The sensorgrams shown are therefore corrected for mass 
differences by dividing the response by the mass.   
As a further test for the effect of Im9 on binding of colicin E9 to TolB, purified Im9 
was added back to colicin E9 purified free from Im9, and this was injected across the 
TolB chip.  Figure 4.9 shows that when Im9 is added back to free colicin E9, the 
response recorded is almost exactly the same as the response recorded for colicin E9 
purified in complex with Im9.   
Therefore Im9 reduces the binding of wild-type colicin E9 to TolB in a similar way to 
the G36A colicin E9 mutant.       
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Figure 4.9 Sensorgrams (corrected for mass differences) produced from injection of colicin 
E9 in the absence of Im9, colicin E9 purified in complex with Im9 and colicin E9 pre-incubated 
with purified Im9 across a TolB chip.  A clear increase in binding can be seen for free colicin E9 
compared to colicin E9/Im9 and to colicin E9, pre-incubated with Im9.     
4.2.5.2. SPR kinetic analysis 
In order to compare the affinities of binding of colicin E9 with and without Im9 to 
TolB, the BIAcore X instrument was used to determine the kinetic parameters for 
binding of free colicin E9 to TolB.  The same method described in Chapter 3 for 
colicin E9/Im9 was used.  Injections of 0.25 M to 4 M free colicin E9 were 
performed across the same TolB chip as had been used for the colicin E9/Im9 
complex.  The sensorgrams produced were fitted to the Langmuir 1:1 binding model 
(see Figure 4.10).  The kinetic parameters produced are shown in Table 4.1.  
Scatchard analysis (see Figure 4.11), T-values and Chi squared values (see Table 4.1) 
are consistent with a good fit of the data to the model.  This is in contrast to the 
sensorgrams produced for the free G36A colicin E9 mutant, which did not fit the 
Langmuir 1:1 model (see Chapter 3).   
The Kd for binding of free colicin E9 to TolB is 1.17 ± 0.03 M.  This value is an 
order of magnitude lower than the value for binding of colicin E9/Im9 to TolB (13.8 ± 
0.3 M), confirming that the affinity of colicin E9 for TolB is reduced when the 
colicin is complexed with the immunity protein. 
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Figure 4.10 Corrected sensorgrams and residual plots for titration of 0.25 M (cyan), 0.5 
µM (magenta), 1 µM (blue), 2 M (green) and 4 M (red) free colicin E9 against TolB at 25oC are 
shown. The fitted kinetic data for binding are superimposed onto each sensorgram in black. 
Residual plots highlight deviation of the experimental data from the theoretical fit. 
 
Table 4.1 Kinetic data obtained from fitting of sensorgrams produced for binding of free 
colicin E9 to TolB to the Langmuir 1:1 binding model.  Errors for Ka and Kd were calculated by 
combining the standard errors on kass and kdiss in quadrature.   
kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
38500 ± 671 0.0451± 0.000558 854000 ± 18250 1.17 ± 0.025 4.13
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Figure 4.11 Scatchard plot of data for binding of free colicin E9 to TolB.  An R squared 
value of 0.9 is produced for a linear fit to the data indicating that the data are a good fit to the 1:1 
Langmuir binding model  
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4.2.5.3. Effect of non-cognate immunity proteins  
The effect of non-cognate immunity proteins on binding of colicin E9 to TolB, was 
used as a test for the specificity of the effect of Im9 in the reduction of binding of 
colicin E9 to TolB.  The non-cognate immunity proteins have differing but lower 
affinities for colicin E9.   
A two-minute injection of 2 M free colicin E9 across a CM5 chip, to which TolB 
had been immobilised, was performed.  Two-minute injections were then performed 
of 2 M (final concentration) free colicin E9, pre-incubated with 2 M (final 
concentration) of either the cognate immunity protein, Im9 or one of the non-cognate 
immunity proteins, Im2, Im7 or Im8 (a gift from Daniel Walker, University of York).  
Each injection was repeated three times and the mean corrected response was 
recorded.   
Figure 4.12 shows that pre-incubating free colicin E9 with the cognate immunity 
protein, Im9, significantly reduces the response, consistent with data presented earlier 
in the chapter.  Im2, with the closest affinity for colicin E9 to Im9, reduces the 
response significantly but causes less reduction in response than Im9.  Im8 also 
reduces the response, but less so than Im2 and Im9.  Im7 causes the least reduction in 
response, consistent with this immunity protein having the lowest affinity for colicin 
E9.   
The order for the reduction in response caused by the cognate and non-cognate 
immunity proteins follows the same pattern as the in vitro and in vivo immunity 
protein affinity for the colicin E9 DNase domain (Wallis et al 1995) ie 
Im9>Im2>Im8>Im7.  Therefore, this provides further evidence that the effect of the 
immunity protein in reducing binding of colicin E9 to TolB is a specific effect, 
dependent on the affinity of the immunity protein for the DNase domain.   
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Figure 4.12 Bar chart comparing the mean responses for a 2 minute injection across TolB, 
immobilised to a CM5 sensor chip, for free colicin E9 and free colicin E9 pre-incubated with Im9, 
Im2, Im8 and Im7.   
 
4.2.5.4. Effect of Im3 on binding of colicin E3 to TolB  
Although no crystal structure is available for colicin E9/Im9 or colicin E9, the crystal 
structure of the RNase colicin E3/Im3 complex shows that 83% of the Im3 surface 
area is buried in the complex and that the translocation domain forms 38% of the 
buried surface area (Soelaiman et al 2001).  Therefore, this section investigates the 
effect of Im3 on binding of colicin E3 to TolB.   
The same method for SPR kinetic analysis of the colicin E3 – TolB interaction in the 
presence and absence of Im3 was used as described in Chapter 3 for colicin E9/Im9.   
Sensorgrams produced for injection of 2 - 15 M colicin E3/Im3 across the TolB chip 
are shown in Figure 4.13, with the fit to the Langmuir 1:1 binding model 
superimposed in black.  The kinetic parameters for the interaction are shown in Table 
4.2.  Scatchard analysis (see Figure 4.15), T-values and Chi-squared values (see Table 
4.2) all show that the data fit well to the binding model.   
The Kd for the interaction between colicin E3/Im3 and TolB is 7.07 ± 0.13 M, a 
slightly lower value than obtained for the binding of colicin E9/Im9 to TolB (13.8 
M), indicating that the affinity of colicin E3 for TolB is enhanced compared to the 
affinity of colicin E9 for TolB.   
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Sensorgrams produced for injection of 0.1 – 2 M free colicin E3 across the TolB 
chip are shown in Figure 4.14, with the fit to the Langmuir 1:1 binding model 
superimposed in black.  The kinetic parameters for the interaction are shown in Table 
4.2.  Scatchard analysis (see Figure 4.15), T-values and Chi-squared values (see Table 
4.2) all show that the data fit well to the binding model.  The Kd for the interaction 
between free colicin E3 and TolB is 0.92 ± 0.02 M, a very similar value to the Kd for 
the interaction between free colicin E9 and TolB (1.2 M).  .   
Therefore, the affinity of colicin E3 for TolB is increased in the absence of Im3, in a 
similar manner to the increase in affinity already seen for free colicin E9.   
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Figure 4.13 Corrected sensorgrams and residual plots for titration of 2 M (blue), 5 µM 
(magenta), 7.5 µM (red), 10 M (cyan) and 15 M (green) colicin E3/Im3 against TolB at 25oC 
are shown. The fitted kinetic data for binding are superimposed onto each sensorgram in black. 
Residual plots highlight deviation of the experimental data from the theoretical fit. 
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Figure 4.14 Corrected sensorgrams and residual plots for titration of 0.1 M (blue), 0.25 µM 
(cyan), 0.5 µM (green), 1 M (magenta) and 2 M (red) free colicin E3 against TolB at 25oC are 
shown. The fitted kinetic data for binding are superimposed onto each sensorgram in black. 
Residual plots highlight deviation of the experimental data from the theoretical fit. 
 
Table 4.2 Kinetic data obtained from fitting of sensorgrams produced for binding of 
colicin E3/Im3 and free colicin E3 to TolB to the Langmuir 1:1 binding model.  Errors for Ka and 
Kd were calculated by combining the standard errors on kass and kdiss in quadrature.   
kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
Colicin E3/Im3 10200 ± 152 0.0719 ± 0.000698 141000 ± 2496 7.07 ± 0.13 2.17
Free colicin E3 40900 ± 578 0.0395 ± 0.000458 1030000 ± 22660 0.92 ± 0.02 5.97
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Figure 4.15 Scatchard plot for data for binding of free colicin E3 and colicin E3/Im3 to 
TolB.  The R squared values of >0.9, produced for a linear fit to the data, indicate that the data 
are a good fit to the 1:1 Langmuir binding model.  The increased gradient for free colicin E3 
compared to the colicin E3/Im3 complex, is a direct indication that the affinity of the free colicin 
is increased.  Kd values calculated from the gradients are 7.5 M for colicin E3/Im3 and 0.4 M 
for colicin E3.   
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4.2.5.5. Effect of Im9 on binding of T61-DNase domain of 
colicin E9 
One explanation for the effect of the immunity protein on binding of colicin E3 and 
E9 to TolB could be that binding of the immunity protein to the RNase or DNase 
domain of the colicin respectively, induces a conformational change that is 
transmitted to the translocation domain, via the receptor-binding domain, causing a 
reduction in affinity of the colicin for TolB.  The receptor-binding domain forms a 
helical hairpin, located between the translocation and DNase domains, providing 
scope for feeding through a conformational change from the DNase domain to the 
translocation domain.   
In order to test this hypothesis, the effect of Im9 on a truncated colicin E9 construct, 
consisting of residues 1-61 of the translocation domain linked to the DNase domain of 
colicin E9 via a thrombin cleavage site (T61-DNase) has been investigated.  If the 
theory were correct, the immunity protein should have no effect on the binding of this 
fusion protein to TolB because the receptor binding domain is not present.   
Figure 4.16 shows the mean maximum corrected responses recorded for injection of 2 
M free colicin E9, colicin E9/Im9, free T61-DNase and T61-DNase/Im9.  The binding 
of T61-DNase to TolB is significantly reduced in the presence of Im9.  This suggests 
the reduction in binding of colicin E9 to TolB due to Im9 is not due to a 
conformational change in the translocation domain fed through from the DNase 
domain via the receptor-binding domain, as the receptor binding domain is not present 
in the T61-DNase construct. 
It should be noted that the binding of the T61-DNase construct to TolB is enhanced 
compared to the binding of colicin E9 to TolB.  This indicates that the TolB box is 
perhaps more accessible in the T61-DNase construct than in full-length colicin E9.   
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Figure 4.16 Bar chart comparing the mean response (corrected for mass differences) due to 
binding to TolB of free colicin E9, colicin E9/Im9, free T61-DNase and T61-DNase/Im9.   
4.2.5.6. Effect of Im9 on binding of colicin E9 T & R 
domains to TolB 
Another possible reason for the effect of the immunity protein on binding of colicin 
E9 and E3 to TolB is that the colicin interacts with TolB via a second site in the 
DNase domain.  Binding of Im9 to the DNase domain would thus obscure the second 
site and reduce the affinity of the colicin E9-TolB interaction.   
To test this hypothesis, the binding of a truncated colicin E9, consisting of the 
translocation (T) and receptor-binding (R) domains (a gift from Mireille 
Vankemmelbeke, University of Nottingham), to TolB was investigated.   
Sensorgrams produced from injection of 0.5 – 4 M T & R domains, in the absence of 
Im9 and pre-incubated with equimolar amounts of Im9, across a TolB chip are shown 
in Figure 4.17 and Figure 4.18 respectively.  Kinetic parameters produced from fitting 
of the sensorgrams to the 1:1 Langmuir binding model are shown in Table 4.3.  
Scatchard analysis indicates that the data produced here do not fit the model as well as 
the data produced for full-length colicin E9.  However the R squared values for the 
linear fit are still within reasonable limits and the T values for kinetic parameters and 
Chi squared values for fitting are consistent with a good fit to the model.   
The Kd for binding of T & R domains of colicin E9 to TolB in the absence of Im9 is 
1.66 ± 0.03 M and the Kd for binding of T & R domains of colicin E9 to TolB in the 
presence of Im9 is 2.96 ± 0.03 M.  Therefore the affinity of the isolated T and R 
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domains of colicin E9 for TolB is very similar to the affinity of the full-length colicin 
E9 for TolB (1.66 vs 1.17 M), making the hypothesis that a site in the DNase 
domain of colicin E9 is involved in binding to TolB highly unlikely.  The immunity 
protein appears to have less effect on the affinity of the T and R domains of colicin E9 
for TolB compared to the effect on the affinity of full-length colicin E9 for TolB. 
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Figure 4.17 Corrected sensorgrams and residual plots for titration of 0.5 M (cyan), 1 µM 
(red), 2µM (blue), 3 M (green) and 4 M (magenta) T and R domains of colicin E9 against TolB 
at 25oC are shown. The fitted kinetic data for binding are superimposed onto each sensorgram in 
black. Residual plots highlight deviation of the experimental data from the theoretical fit. 
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Figure 4.18 Corrected sensorgrams and residual plots for titration of 0.5 M (cyan), 1 µM 
(magenta), 2µM (green), 3 M (red) and 4 M (blue) T and R domains of colicin E9 + Im9 
against TolB at 25oC are shown. The fitted kinetic data for binding are superimposed onto each 
sensorgram in black. Residual plots highlight deviation of the experimental data from the 
theoretical fit. 
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Table 4.3 Kinetic data obtained from fitting of sensorgrams produced for binding of the 
T&R domains of colicin E9, in the presence and absence of Im9, to TolB to the Langmuir 1:1 
binding model.  Errors for Ka and Kd were calculated by combining the standard errors on kass 
and kdiss in quadrature.   
kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
Free T&R ColE9 43600 ± 692 0.0724 ± 0.000844 602000 ± 10716 1.66 ± 0.03 2.01
T & R ColE9 + Im9 28800 ± 0.623 0.0853 ± 0.000823 338000 ± 3261 2.96 ± 0.03 1.25
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Figure 4.19 Scatchard plot for data for binding of the T & R domains of colicin E9 in the 
presence and absence of Im9 to TolB.  The R squared values produced for a linear fit to the data 
are lower than seen previously, but the T-values for kinetic parameters and the Chi squared 
value for the fitting, indicate that the data are a good fit to the 1:1 Langmuir binding model. 
4.2.6. Binding of Im9 to T & R domains 
In order to investigate whether Im9 was able to directly bind to the translocation 
domain of colicin E9, in the absence of the DNase domain, the T&R domains of 
colicin E9 were amine coupled to a CM5 chip.  A final response due to T&R domains 
of 839 RU was produced, giving an Rmax for Im9 of 180 RU.   
Concentrations of 1-20 M of Im9 were injected across the chip but no response was 
recorded indicating that Im9 does not bind to the translocation domain of colicin E9 
or if it does, it binds with a lower affinity than can be detected here, ie the Kd must be 
much higher than 20 M.  It is possible that Im9 has to bind to the DNase domain of 
colicin E9 with high affinity first, which then stabilises the lower affinity interaction 
with the T domain.  
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The activity of the T & R domains on the chip was checked by ensuring that TolB 
could bind.  A response of 339 was produced on injection of 2 M TolB (RUmax = 
812) and therefore the T & R construct on the chip was assumed to be intact.   
To check for an effect of Im9 on binding of TolB to T & R domains, the response for 
injection of 2, 5 and 10 M TolB across the chip was compared to the response due to 
injection of 2, 5 and 10 M TolB, pre-incubated for 5 minutes with equimolar 
amounts of Im9 before injection.  Figure 4.20 shows that no difference in response 
was recorded when TolB was pre-incubated with Im9 before injection across the chip, 
supporting evidence from the SPR kinetic data that Im9 does not reduce binding of 
TolB to the T & R domains of colicin E9.  The data also show that Im9 has to be 
bound to colicin E9 to exert its effect, further supporting the specificity of the 
reduction in binding.   
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Figure 4.20 Sensorgrams produced when 2, 5 and 10 M concentrations of TolB were 
injected across the T and R domains of colicin E9, immobilised to a CM5 sensor chip, in the 
presence and absence of equimolar amounts of Im9.  No difference in binding is detected when 
Im9 is present compared to when Im9 is absent.   
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4.2.7. AFM to investigate effect of Im9 on binding of colicin 
E9 to TolB 
AFM was used as an alternative method to investigate the effect of Im9 on the 
binding of colicin E9 to TolB.  This method has the advantage that it measures protein 
interactions at the single-molecule level and, as outlined in Chapter 2, is able to 
explore the energy barriers of the interaction that are difficult to investigate using 
near-equilibrium kinetics.   
4.2.7.1. AFM imaging 
A monolayer coverage of protein on the sample surface is required for force 
measurement experiments to minimise non-specific interactions, which can occur 
between the tip and underlying surface.  Therefore, in order to determine a suitable 
concentration of TolB to use for the force measurement studies, a DI Multimode AFM 
with a Nanoscope III controller (Digital Instruments), operated in tapping mode, was 
used to obtain AFM images of varying concentrations of TolB protein, covalently 
immobilised to silicon surfaces.   
Figure 4.21 shows typical AFM height images when 100 g/ml and 10 g/ml TolB 
was immobilised to silicon surfaces.  The approximate diameter of each globular 
feature is 15-20 nm.  The crystal structures of TolB (Abergel et al 1999, Carr et al 
2000a) indicate that TolB has a diameter of approximately 5nm.  However, the 
geometry of the tip can produce broadening of features and therefore, when this is 
taken into account the features observed in the images can be attributed to individual 
TolB molecules.    
The uniformity of the globular features in the image of 100 g/ml TolB shows that at 
100 g/ml TolB, a monolayer is formed and therefore this concentration was used for 
the force-measurement studies.   
4.2.7.2. Force measurement studies 
An AFM tip was functionalised with either free colicin E9 or the colicin E9/Im9 
complex.  Force measurements were recorded between the colicin E9 attached to the 
AFM tip and TolB covalently immobilised to a silicon surface at tip retraction rates of 
0.1, 1, 5 and 10 m/s using a Molecular Force Probe instrument (MFP, Asylum 
Research).  At least 1000 force-distance curves were recorded at each tip retraction 
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rate.  Example force-distance curves obtained at 1 m/s for the interaction between 
colicin E9 and TolB are shown in Figure 4.22.    
The probability of observing a specific rupture event, characterised by a non-linear 
stretching in the retract curve (see Figure 4.22), was approximately 10% in all 
experiments.  This is consistent with Poisson analysis for single molecular 
interactions, which suggests that when the probability of observing a rupture event is 
below 10%, approximately 95% of rupture events can be attributed to single 
molecular dissociation (Williams and Evans 2002).   
In order to verify that the pull-off events observed were specific to the interaction 
between colicin E9 and TolB, excess colicin E9 was added into the buffer towards the 
end of the experiment.  This reduced the probability of observing a specific event to ~ 
2 %, indicating that the interaction between the colicin E9 on the tip and TolB was 
blocked by the presence of colicin E9 in the buffer and hence the pull-off events 
observed were due to specific interactions between colicin E9 and TolB.      
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Figure 4.21 Typical AFM height images of silicon substrate functionalised with 100 g/ml 
TolB (top) and 10 g/ml TolB (bottom).  Image sizes are 500nm x 500nm and the Z-range is 5nm.   
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A distribution of rupture forces was obtained for the specific interactions at each rate 
of tip retraction.  Therefore, rupture forces indicative of specific interactions were 
plotted as force vs frequency histograms (see Figure 4.23 and Figure 4.24).  The mode 
value for each histogram, which represents the most probable rupture force, was 
calculated and is shown above each histogram, along with the mean rupture force and 
standard deviation.  For a simple bond the shape of the histogram can be predicted 
(Evans and Williams 2002), and the distribution should contain very few forces with 
values more than 1.2 times the mode. Higher forces and the subsequently wider force 
distributions are indicative of the measurement of multiple interactions.  Therefore a 
model force distribution is calculated by removing all data more than 1.2 times the 
mode, the mode of this distribution is used to estimate a force scale (fβ, from the 
curvature) and a relative zero-force dissocation rate (koff or kdiss).  These data are then 
used to predict a distribution for the event (assuming a single barrier), which is 
overlaid onto each histogram in red. The mode of the model histogram (reported in 
brackets) should be similar to the mode calculated for the experimental data unless the 
system is not a simple bond, or there are lots of multiple interactions or non-specific 
interactions included in the data.   
 
Mode values for the rupture forces recorded for the colicin E9-TolB interaction and 
the colicin E9/Im9-TolB interaction were plotted as a function of the logarithm of the 
tip retraction rate (see Figure 4.25).  The plots show that each interaction produces a 
single linear regime, with a decrease in retraction rate producing a decrease in rupture 
force (R squared values > 0.9).  This relationship is consistent with previous studies, 
measuring biotin-streptavidin interactions, antibody-antigen interactions and protein-
carbohydrate interactions (Yuan et al 2000, Strigl et al 1999, Dettmann et al 2000) 
and with theoretical models (see Chapter 2).   
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a)
b)
c)
 
Figure 4.22 Typical force-distance curves with approach traces shown in red and retract 
traces shown in blue.  a) Curve produced when no interaction occurs.   b) Curve produced when 
a non-specific interaction occurs, characterised by the continuation of the gradient of the contact 
region of the retract curve before a sharp pull-off.  c) Curve produced when a specific interaction 
occurs between colicin E9 on the tip and TolB on the surface.  Specificity is characterised by the 
non-linear stretching seen in the retract curve, before detachment of the tip from the surface.   
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0.1 m/s 1 m/s
5 m/s 10 m/s
 
Figure 4.23 Histograms produced for colicin E9/Im9 at tip retraction rates of 0.1, 1, 5 and 10 
m/s.  Blue bars show the force vs frequency data binned to the noise level, with the highest 
column centered on the predicted mode value.  The black trace shows the noise-filtered data.  
Forces from 0 up to 1.2 times the mode value are then used to determine a new histogram and the 
mode of these is used to determine a force-scale (fb, from the curvature) and relative off-rate 
(koff). These data are then used to predict a distribution for the event (assuming a single 
barrier), shown in red. 
 
0.1 m/s 1 m/s
5 m/s 10 m/s
 
Figure 4.24 Histograms produced for free colicin E9 at tip retraction rates of 0.1, 1, 5 and 10 
m/s.   
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Figure 4.25 Dynamic force spectra for the interaction between TolB and colicin E9 in the 
presence and absence of Im9.  A single linear gradient can be seen for both interactions.  The 
linear regime is extrapolated to y=0, in order to obtain the x-intercept.  The x-intercept (in log 
units) is -3.83 ± 0.27 for the colicin E9-TolB interaction and -3.07 ± 0.38 for the colicin E9/Im9-
TolB interaction.   
 
Ideally for dynamic force spectroscopy, the most probable rupture forces are plotted 
against the loading rate (tip retraction rate x spring constant of the system).  However, 
in this study the dynamic and mechanical properties of the carboxymethylamylose 
linker, used to attach the colicin E9 to the tip, are unknown.  Therefore the exact rate 
of loading cannot be determined.  An assumption can be made that at the retract 
velocities used, the polymer linker is stretched to its asymptotic regime, where it will 
become stiff, the loading rate should be linearly related to the tip retract velocity.  
Therefore the calculated gradient or force scale should be a reasonable estimate of the 
force scale of the barrier measured in this study.   
The force scale for the colicin E9/Im9-TolB interaction is 26.2 ± 3.1 pN.  The force 
scale for the colicin E9-TolB interaction is 27.5 ± 1.9 pN.  The maintenance of a 
comparable force scale for the two interactions implies that the energy barrier to 
dissociation is the same for both interactions.  If this is the case, then the decrease in 
peak rupture forces measured for the colicin E9/Im9-TolB interaction, compared to 
those measured for the colicin E9-TolB interaction, indicates a decrease in the energy 
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barrier height and hence a decrease in affinity for the colicin E9/Im9-TolB interaction.  
From the equation fβ = kBT/xβ, the position of the energy barrier from the bound state 
can be calculated as approximately 1.4 Ǻ for the colicin E9-TolB interaction and 1.6 
Ǻ for the colicin E9/Im9-TolB interaction.   
In order to determine the kdiss at zero force for the probed barrier, from Equation 4-1, 
the x-intercept, expressed as a loading rate, is required.   
F* = fβ[ln (loading rate) – ln (fβ kdiss)]
 
Equation 4-1 
The polymer linker employed, adds a second timescale to the interaction required to 
extend the polymer and apply force.  This timescale is dependent on the contour and 
persistence length of the polymer linker, values that are as yet undetermined for 
carboxymethylamylose (Williams and Evans 2002).  Therefore, it is not possible to 
determine an accurate kdiss for the interaction between colicin E9 and TolB or colicin 
E9/Im9 and TolB.   
However, as the gradients of the linear regimes plotted for the two interactions are 
very similar, a direct comparison of the x-intercept values allows a comparison of the 
kdiss values for the two interactions.  The x-intercept for the colicin E9/Im9-TolB 
interaction is 8.5 x 10-4 m/s and the x-intercept for the colicin E9-TolB interaction is 
1.5 x 10-4 m/s.  Therefore, it can be concluded that the kdiss for the colicin E9/Im9-
TolB interaction is greater than the kdiss for the colicin E9-TolB interaction.   
From the equation,  Kd = kdiss/kass, an increased kdiss for the colicin E9/Im9-TolB 
interaction compared to the kdiss for the colicin E9-TolB interaction is consistent with 
the SPR data, which shows that the Kd for the colicin E9/Im9-TolB interaction is 
greater than the Kd for the colicin E9-TolB interaction.   
4.2.8. Trypsin cleavage of ColE9 and ColE9/Im9 
The increase in affinity of colicin E9 for TolB, in the absence of Im9, suggests that 
the translocation domain could become more accessible for binding to TolB, which 
may require a conformational change.   
As a test for a change in conformation in free colicin E9, compared to the colicin 
E9/Im9 complex, a trypsin digest was performed on colicin E9 in the presence and 
absence of Im9.  A change in conformation in free colicin E9, could cause the 
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exposure of further trypsin cleavage sites, known to occur in colicin E9, increasing 
the number of fragments produced by digestion with trypsin.   
The free colicin E9 and colicin E9/Im9 proteins were dialysed overnight in 50mM 
Tris-HCl, pH 8.5.  A colicin/trypsin (Electrophoresis grade, Promega) ratio of 20 was 
used.  10% acetonitrile (v/v) was added to solubilise hydrophobic peptides generated 
during the digest.  The colicin/trypsin solution was incubated at 37°C overnight.  5µl 
glacial acetic acid was added to stop the reaction and the digests were then run on an 
SDS-PAGE gel against the undigested proteins.   The digested samples were then run 
on an SDS-PAGE gel against the undigested proteins and the gel was silver stained.   
Wallis et al (1994) showed that a trypsin digest of colicin E9/Im9 produces a 37 kDa 
fragment and a 27 kDa fragment on a gel filtration column with bands at 32 kDa, 16 
kDa and 12 kDa seen on an SDS-PAGE gel.   
A band of approximately 32kDa can be seen on the gel in Figure 4.26 for digests of 
both free colicin E9 and colicin E9/Im9.  The two smaller bands of 16 and 12 kDa 
cannot be detected on this SDS-PAGE gel.  However, the gel indicates that free 
colicin E9 is no more susceptible to protease cleavage than the colicin E9/Im9 
complex, and therefore this experiment supports NMR data suggesting that there is no 
conformational change in the T domain of colicin E9 on binding of Im9.   
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Figure 4.26  Silver-stained SDS-PAGE gel showing results of trypsin digest of colicin E9 vs 
colicin E9/Im9.  In both digests a band at around 32 kDa can be seen.  A second band can be seen 
in the colicin E9/Im9 digest at around 10 kDa corresponding to the immunity protein.   
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4.3. Discussion 
4.3.1. Effect of Im9 on binding of colicin E9 to TolB  
4.3.1.1. SPR 
A preliminary SPR experiment, performed using a BIAcore J instrument, showed that 
free colicin E9 demonstrated enhanced binding to TolB, compared to the binding of 
colicin E9/Im9.  The effect of the immunity protein was further demonstrated when 
the free colicin E9 was incubated with pure Im9 prior to injection across the TolB 
chip.  Pre-incubation of the free colicin E9 with Im9 was shown to reduce the binding 
to almost exactly the same level as had been seen for the colicin E9 purified in 
complex with Im9.  This shows that the increased binding seen for free colicin E9 is 
unlikely to be an effect of denaturation and refolding of the colicin.  Further evidence 
that the free colicin E9 protein is intact is provided by the identical activity of the free 
colicin E9 and the colicin E9/Im9 complex seen in the spot test in Figure 3.7 of 
Chapter 3.   
In order to quantitatively compare the affinities of colicin E9/Im9 and free colicin E9 
for TolB, SPR was used to determine the kinetics for binding of free colicin E9 to 
TolB.  The Kd value of 1.17 ± 0.025 M was compared to the Kd value for binding of 
the colicin E9/Im9 complex to TolB, which had been determined as 13.8 ± 0.3 M in 
Chapter 3.  The results show that the affinity of colicin E9 for TolB is reduced more 
than 10-fold when the immunity is protein is present.   
The good fit of the sensorgrams produced for binding of free colicin E9 to TolB to the 
Langmuir 1:1 binding model, suggests that the poor fit to this model seen in Chapter 3 
for binding of free G36A colicin E9 to TolB, is an effect of the G36A mutation, rather 
than the lack of immunity protein.  It is possible that the G36A mutation, increases the 
flexibility of the translocation domain and when Im9 is removed, the increased 
flexibility affects binding of the colicin to TolB.  An apparent stabilising effect of Im9 
was also seen for the G38A mutant, the activity of which was enhanced in the 
presence of Im9 (see Chapter 3).    
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4.3.1.2. AFM 
Dynamic force spectroscopy was used to probe differences in the profiles of the 
dissociation landscapes for the colicin E9- TolB interaction and the colicin E9/Im9-
TolB interaction.   
Rupture forces required to separate the colicin E9/Im9-TolB complex and the colicin 
E9-TolB complex were recorded.  In such experiments a distribution of forces is 
expected due to kinetics, but the distribution can be broadened due to experimental 
error, the most significant source of error likely to be determination of the spring 
constant of the cantilever.  The spread in rupture forces is determined by the thermal 
force scale (fβ) and therefore the widths of the force distributions should match the 
slopes of linear regimes observed in the dynamic force spectrum (Evans and Williams 
2002).   
The modal or most probable rupture forces for the dissociation of the colicin E9-TolB 
complex were found to be augmented compared to the forces recorded for the 
dissociation of the colicin E9/Im9-TolB complex.  Rupture forces were also recorded 
for both interactions at four different rates.  Analysis of the distributions of forces 
recorded for the colicin E9-TolB and colicin E9/Im9-TolB complexes over the range 
of tip retraction rates produced a logarithmic relationship between rupture force and 
dissociation rate.  This relationship is consistent with previous measurements for 
various receptor-ligand interactions, such as the streptavidin-biotin interaction (Yuan 
et al 2000).   
The most probable rupture forces were plotted as a function of the logarithm of the tip 
retraction rate to produce dynamic force spectra for both interactions.  A single linear 
regime was recorded for each interaction, which suggests that a single energy barrier 
to dissociation was probed.  The linear regimes have comparable gradients, indicating 
that the same barrier to dissociation is being measured.  The position of the energy 
barrier from the bound state has been calculated as approximately 1.5 Ǻ for both 
interactions.  The widths of the force distributions are also satisfyingly close to the 
gradients of the dynamic force spectra, hence further validating the obtained dynamic 
force spectra.   
Although only a single gradient for each interaction is seen for this data, suggesting 
that only a single energy barrier is involved in the dissociation of colicin E9 from 
TolB, measurements of force over many orders of loading rates are required in order 
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to map the complete dissociation pathway (Evans, 1998).  AFM is unable to achieve 
such a vast range of measurements, and therefore AFM can only probe barriers close 
to the bound state.  Barriers further away from the bound state require lower loading 
rates which are inaccessible by AFM.  In a landscape with more than one barrier, the 
more distant barriers are overcome first (at lower rates), and closer barriers become 
more dominant.  The biomembrane force probe (BFP) could be used to achieve a 
wider spectrum of rates, and hence to build a more complete profile of the 
dissociation pathway. 
If it is assumed that the same energy barrier is being measured for the colicin E9-TolB 
interaction and the colicin E9/Im9-TolB interaction, then the decreased rupture forces 
recorded for the colicin E9/Im9-TolB interaction are indicative of a decrease in the 
height of the energy barrier and hence a decrease in affinity of the interaction 
compared to the interaction between free colicin E9 and TolB.   
Although the use of a polymer linker with an unknown spring constant prevents the 
calculation of kdiss values for the colicin E9-TolB interaction and colicin E9/Im9-TolB 
interaction, the comparable force scales for the two interactions, allows a comparison 
of the kdiss values by comparing the x-intercept values for the extrapolated linear 
regime.  The regime for the colicin E9-TolB interaction has a lower x-intercept than 
the x-intercept of the regime for the colicin E9/Im9-TolB interaction, indicating that 
the colicin E9-TolB interaction has a lower kdiss and therefore a lower Kd than the 
colicin E9/Im9-TolB interaction.   
The reduced kdiss value for the colicin E9-TolB interaction is consistent with the 
reduced Kd value for this interaction measured by SPR, confirming the effect of Im9 
in decreasing affinity of colicin E9 for TolB and confirming that the effect of Im9 on 
TolB binding seen in SPR is not an artefact caused by, for example, non-specific 
binding to the sensor surface.   
4.3.2. Effect of Im3 on binding of colicin E3 to TolB 
The demonstration that the translocation domain of colicin E3 is involved in an 
interaction with Im3 in a thermodynamic study (Walker et al 2003), suggests that the 
immunity protein could affect binding of colicin E3 to TolB.  This possibility was 
tested by obtaining kinetics for binding of colicin E3 and colicin E3/Im3 to TolB 
using SPR.   
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The Kd values determined for binding of colicin E3 (0.92 ± 0.02 M) and colicin 
E3/Im3 (7.1 ± 0.1 M) to TolB show that the affinity of colicin E3 for TolB is 
decreased by the presence of Im3.   
A model for dissociation of Im3 from colicin E3 has been proposed in which 
translocation of at least part of the translocation domain into the periplasm allows 
binding of the translocation domain to TolB, displacing contacts between the 
translocation domain and Im3.  This weakens the colicin E3-Im3 interaction, 
significantly increasing the dissociation rate of the complex (Walker et al 2003).   
The demonstration in this study that the presence of Im3 reduces the ability of colicin 
E3 to bind to TolB, supports the idea that the colicin E3/Im3 complex could bind to 
TolB, an interaction which promotes dissociation of Im3 from the translocation 
domain, which in turn increases the affinity of the colicin E3-TolB interaction.   
 
The resolution of the colicin E3/Im3 structure does not allow detailed analysis of the 
molecular interactions between the translocation domain and Im3 (Soelaiman et al 
2001).  However, it has been noted there are relatively few electrostatic interactions 
and that the shape complementarity is lower than that for the RNase-Im3 interface 
(Walker et al 2003).  It is unclear as to whether the immunity protein directly contacts 
the TolB box region due to the lack of electron density for residues 1-83, containing 
the TolB box.  A structure of colicin E3, in the absence of Im3, is required to 
demonstrate the precise effect of Im3 on the translocation domain of the colicin, and 
to explain the effect of Im3 on binding of colicin E3 to TolB.       
As there is no structure for the colicin E9/Im9 complex it is unclear whether the 
immunity protein interacts with the translocation domain of colicin E9, in a similar 
manner to the interaction of Im3 with the translocation domain of colicin E3.  
However, thermodynamic data suggest that if an interaction does occur between Im9 
and the translocation domain, the residues must be making an energetically neutral 
contact, in contrast to the interaction of the translocation domain of colicin E3 with 
Im3 (Wallis et al 1995a, Walker et al 2003).  It is interesting to note, however, that 
the residues in the translocation domain of colicin E3 that contact the immunity 
protein are conserved in DNase and rRNase colicins, despite the immunity proteins 
being structurally unrelated (Walker et al 2003), suggesting that residues in the 
translocation domain of colicin E9 may also contact the immunity protein.  This is 
supported by the AFM and SPR data presented here, which show that the immunity 
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protein appears to affect the translocation domain of colicin E9, demonstrated by the 
effect of the immunity protein on binding of the colicin to TolB.   
4.3.3. Investigating the reason for the effect of the immunity 
protein on binding of colicins to TolB 
4.3.3.1. Effect of non-cognate immunity proteins 
In order to test the specificity of the effect of the immunity protein on binding of 
colicin E9 to TolB, the effect of non-cognate immunity proteins on the binding of 
colicin E9 to TolB was investigated.   
The immunity proteins, Im9, Im2, Im8 and Im7 bind to the DNase domain of colicin 
E9 with Kd values of 10-14 M, 10-8 M, 10-6 M and 10-4 M respectively (Wallis et al 
1995b).  Pre-incubation of colicin E9 with each of these immunity proteins before 
injection across TolB, immobilised to an SPR sensor chip, caused a relative reduction 
in binding that was related to the affinity of the immunity protein for the DNase 
domain of colicin E9.  This is consistent with the binding of the immunity protein to 
the DNase domain of colicin E9 causing a change in the translocation domain.  
However, this experiment does not rule out the possibility that the reason for reduced 
binding of colicin E9 to TolB caused by the immunity protein is due to a direct effect 
of the immunity protein on the DNase domain.   
4.3.3.2. Effect of Im9 on T & R domains of colicin E9 
A possible explanation for the reduction in binding of colicin E9 to TolB caused by 
Im9 is that TolB interacts with colicin E9, not only via the translocation domain, but 
also via a second site, perhaps in the DNase domain.  Binding of Im9 to the DNase 
domain would then obscure the second TolB binding site in this domain, reducing the 
affinity of the colicin for TolB.  The presence of a binding site for TolB in the DNase 
domain of colicin E9 was tested by investigating the binding of the isolated T and R 
domains of colicin E9 to TolB, in the presence and absence of Im9.   
The Kd values for binding of the T and R domain of colicin E9 are 1.64 M, in the 
absence of Im9, and 2.96 M in the presence of Im9.  Therefore the affinity of the T 
and R domains of colicin E9 for TolB is very similar to the affinity of the full-length 
colicin E9 for TolB (Kd = 1.2M).  This strongly suggests that the only binding site 
for TolB is located in the translocation domain of colicin E9.   
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The effect of Im9 on the affinity of the T and R domains of colicin E9 for TolB is far 
less pronounced than the effect on the affinity of full-length colicin E9 for TolB.  This 
suggests that it is the binding of Im9 to the DNase domain that is involved in reducing 
the binding of the colicin to TolB.   
4.3.3.3. Effect of Im9 on the T61-DNase colicin E9 construct 
The binding of a T61-DNase construct of colicin E9 to TolB, in the presence and 
absence of Im9 was used to investigate the hypothesis that binding of Im9 to the 
DNase domain causes a change in the helical hairpin of the receptor-binding domain 
which feeds a conformational change through to the translocation domain.  If this 
feed-through theory were correct, the immunity protein would have no effect on the 
binding of this fusion protein to TolB because the receptor binding domain is not 
present to feed-through the required conformational change.  However, SPR shows 
that the binding of the T61-DNase colicin E9 construct is reduced in the presence of 
Im9.   
This indicates that the receptor binding domain is not involved in the effect of the 
immunity protein on the translocation domain of colicin E9.  It also suggests that if 
the reason for the reduction in binding to TolB caused by Im9 is due to a direct 
binding of Im9 to the translocation domain, Im9 must bind to the first 61 residues of 
the translocation domain.  In the structure of colicin E3/Im3, the first 83 residues are 
absent but interactions between Im3 and residues downstream of the translocation 
domain can be seen to interact.  Therefore, it appears unlikely that the only interaction 
between the translocation domain of colicin E9 and Im9, occurs within the first 61 
residues of the translocation domain.   
 
Although the affinity of the T and R domains of colicin E9 for TolB is similar to the 
affinity of full-length colicin E9 for TolB, the affinity of T61-DNase colicin E9 fusion 
protein for TolB appears to be enhanced.  This suggests that residues of the 
translocation domain or receptor-binding domain, downstream of residue 61, may 
restrict access of TolB to the TolB box of colicin E9, in a similar way to the masking 
of the TolA binding site by the rest of the colicin A protein, as suggested by Gokce et 
al (2000).  
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4.3.3.4. Binding of Im9 to the translocation domain of 
colicin E9 
In an attempt to test whether the immunity protein binds directly to the translocation 
domain of colicin E9, the T and R domains of colicin E9 were covalently immobilised 
to an SPR sensor chip.  Varying concentrations of Im9 were then injected across this 
chip but no response was recorded.  The T and R domains immobilised on the chip 
were shown to be intact by the response recorded when TolB was injected across this 
chip.  In agreement with the affinity data described above for the interaction of TolB 
with the T & R domains of colicin E9, Im9 was shown to have no effect on binding of 
TolB to the immobilised T and R domains of colicin E9.   
However, this does not necessarily imply that the immunity protein does not interact 
with the translocation domain of colicin E9 in vivo.  Firstly the interaction between 
the isolated translocation domain and Im9 could be of a lower affinity than can be 
measured by SPR.  Alternatively, the binding of Im9 to the translocation domain, may 
require the initial high-affinity binding of Im9 to the DNase domain.   
4.3.3.5. Trypsin digest 
The possibility that removal of the immunity protein from colicin E9 caused a 
conformational change in the translocation domain was investigated by looking for an 
increase in trypsin cleavage of free colicin E9 compared to colicin E9/Im9.  However, 
no extra cleavage products were identified after digestion of free colicin E9 compared 
to the cleavage products produced after digestion of colicin E9/Im9.  This result is 
consistent with NMR experiments, which indicated that Im9 had no effect on the 
conformation of the translocation domain of colicin E9 (Collins et al 2002).   
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4.4. Summary  
AFM and SPR experiments have shown that there is a clear reduction in affinity for 
the interaction of colicins E9 and E3 with TolB due to the presence of their respective 
immunity proteins, indicating that the immunity protein affects the translocation 
domains of these colicins.  Although the crystal structure of colicin E3/Im3 clearly 
demonstrates that Im3 interacts with both the RNase domain and the translocation 
domain, thermodynamic experiments with colicin E9 had suggested that the only 
contacts the immunity protein had with the colicin were via the DNase domain.   
A variety of methods have been used in an attempt to elucidate the reason for the 
effect of the immunity protein on binding of colicin E9 to TolB.  No direct binding of 
the translocation domain of colicin E9 to Im9 could be detected.  The lack of change 
in conformation in the translocation domain caused by Im9, shown by a trypsin digest 
of free colicin E9 and the colicin E9/Im9 complex, and by previous NMR data, 
suggests that the reason for the decreased affinity of colicin E9/Im9 for TolB 
compared to the affinity of colicin E9 for TolB, is not a conformational change.   
A reduction in binding of the T61-DNase domain to TolB, in the presence of Im9, 
suggests that the effect does not rely on binding of Im9 to residues of the translocation 
domain, further downstream than residue 61, whereas residues downstream of the 
colicin E3 translocation domain are shown in the crystal structure to interact with 
Im3.   
It is therefore proposed that the presence of Im9 could hinder the access of TolB to 
the TolB binding site of colicin E9, without physically contacting the translocation 
domain.  This would be consistent with the requirement, proposed due to results from 
thermodynamic experiments, for any contacts between the colicin and the immunity 
protein to be energetically neutral.  The effect of Im3 on colicin E3 could be due to 
the same steric hindrance or could be due to conformational changes in the TolB box, 
caused by interactions of residues of the translocation domain further downstream 
with Im3.   
However, crystal structures of colicin E9 in the presence and absence of Im9 and of 
an endonuclease colicin in complex with TolB, are required to fully understand the 
effect of the immunity protein on binding of colicin E9 and E3 to TolB.  
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5. CHAPTER 5 – Variations in binding to Tol proteins 
between pore-forming and endonuclease colicins 
5.1. Introduction 
5.1.1. Interaction between colicins and TolB 
The interaction between colicin E3 and TolB has been observed in vivo and in vitro 
(Bouveret et al 1997) and the interaction between colicin E9 and TolB has been 
shown using the yeast-two hybrid technique (Carr et al 2000a).  Both these 
interactions have been quantified in this thesis using surface plasmon resonance (see 
Chapters 3 and 4).  An interaction between colicin A and TolB has also been 
demonstrated using in vitro cross-linking (Bouveret et al 1998).   
The regions of colicins E3, E9 and A that interact with TolB have been identified.  
Chapter 3 shows that residues S34-E42 of colicin E9 are involved in the interaction 
with TolB and, as the sequence of colicin E3 in this region is identical to colicin E9, 
the equivalent residues of colicin E3 are likely to be involved in the interaction with 
TolB.  Residues 11-20 in colicin A are predicted to be involved in interacting with 
TolB (Bouveret et al 1998).  Residues 35-42 of colicins E3 and E9 are identical to 
residues 11-18 of colicin A, with the exception that residue 37 in colicin E3 and E9 is 
a serine, whereas the equivalent residue in colicin A is a threonine.   
5.1.2. Interaction between colicins and TolA 
TolA is a three-domain protein, consisting of an N-terminal domain I (residues 1-47), 
anchoring the protein to the cytoplasmic membrane, a central domain II, which tethers 
the anchoring domain to the functional domain III (Webster 1991).   
Although an interaction has been detected between the N-terminal domain of colicins 
A and E1 with TolA by overlay Western blotting, gel-shift assays and SPR (Bénédetti 
et al 1991, Derouiche et al 1997), no interaction between TolA and the N-terminal 
domain of colicin E3 has been detected (Bouveret et al 1997, Bouveret et al 2002).  
The region of colicin A involved in interacting with TolA is between residues 52 and 
97 (Bouveret et al 1998, Journet et al 2001).  However, there is no sequence 
homology between the putative TolA binding region in colicin A and the region of 
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colicin N proposed to interact with TolA (residues 44-66, Raggett et al 1998, Gokce 
et al 2000).  This suggests that these two colicins interact with TolA in different ways.   
SPR experiments indicated that the Kd for binding of the N-terminal domains of 
colicins A and E1 to TolA domain III were between 0.2 and 0.6 M (Derouiche et al 
1997).  Similar values were obtained when domains II and III of TolA were used, and 
no interaction was seen between the colicins and domain II of TolA indicating that 
domain III of TolA is the only domain involved in binding to colicins (Derouiche et al 
1997).  Binding assays performed in varying ionic strengths indicated that the 
interaction between TolAIII and colicin A is not electrostatically driven (Deprez et al 
2002).   
The binding affinity of colicin N for TolA has also been measured, using isothermal 
titration calorimetry (ITC) and tryptophan fluorescence (Raggett et al 1998).  The 
isolated N-terminal domain of colicin N was found to have a higher affinity (Kd = 1 
M) for TolA, compared to the full-length colicin (Kd = 18 M).  It has been 
suggested that this is due to an increase in accessibility of the TolA binding site in the 
isolated N-terminal domain, which could relate to the situation when the colicin has 
bound to its primary receptor (Raggett et al 1998).  ITC was also used in an attempt to 
measure the affinity of the colicin A-TolA interaction, but this technique did not 
detect the expected binding (Gokce et al 2000).   
5.1.3. Interaction between colicins and TolR 
TolR is a 142-residue protein, consisting of three domains.  Domain I (residues 1-43) 
anchors the protein to the inner membrane by a single transmembrane segment 
(Muller et al 1993).  Domains II (44-116) and III (117-142) are located in the 
periplasm.   
The production of a recombinant TolRII in the periplasm of E.coli cells induces 
tolerance of the bacteria to colicin A (Journet et al 1999).  It has recently been shown 
by in vitro and in vivo cross-linking that this induction of tolerance is likely to be due 
to the fact that TolRII interacts with the translocation domain of colicin A (Journet et 
al 2001).   
In vitro cross-linking has also demonstrated an interaction between the translocation 
domain of colicin E3 and TolRII (Journet et al 2001).   
Deletion mutants have been used to localise the binding site for TolR to residues 7-14 
of colicin A.  This region of colicin A overlaps with the TolB box of colicin A 
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(residues 7-20), indicating that the interaction of colicin A with TolR and TolB may 
be closely related in space or time (Journet et al 2001).   
However, this putative TolR box sequence is not well conserved in other colicins.  
This is similar to the situation for TolA, where no significant homology can be found 
for the regions of colicins interacting with TolA.   
Attempts to detect the interaction between TolR and colicin A with the yeast-two 
hybrid technique and spectrofluorometric analysis have failed, indicating that this 
interaction could be weak and transient (Journet et al 2001).  It has been suggested 
that the interaction of the colicin with TolB drives the interaction of the colicin with 
TolR, despite the lower affinity of the latter interaction and less conserved sequence 
homology (Journet et al 2001).   
5.1.4. TolA-TolB interaction 
An interaction between TolA and TolB has been shown by yeast-two hybrid screening 
and was confirmed by cross-linking with the purified proteins (Wallburger et al 
2002).  Mutagenesis experiments have identified domain III of TolA as the domain 
involved in interacting with TolB (Wallburger et al 2002, Dubuisson et al 2002).  
Although the N-terminal domain of TolB was shown to be sufficient for binding to 
TolA, the C-terminal domain was suggested to strengthen the interaction (Wallburger 
et al 2002).  The identification of a suppressor mutant of tolA mutations in the tolB 
gene have provided further evidence that it is the N-terminus of TolB that interacts 
with TolA (Dubuisson et al 2002).  The D120N mutation in TolB, located in the N-
terminal domain, was able to restore colicin sensitivity to cells containing a tolA 
mutant, altered at residue F352 or Y353. 
The physiological significance of this interaction has been shown by using cells 
expressing a Y354H V409E TolAIII mutant, which retains binding to the 
translocation domain of colicin A, but is unable to bind to TolB (Wallburger et al 
2002).  These cells exhibited a tol phenotype, being sensitive to SDS and tolerant to 
colicin A.  The cells were also tolerant to colicin E3, but the sensitivity to colicin E1, 
which does not require TolB for translocation, was unaffected.  Wallburger et al 
(2002) suggest that TolB links the outer and inner membranes of the cell via 
simultaneous interactions of its C-terminal domain with Pal and its N-terminal 
domain with TolA.   
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5.1.5. Ternary complexes 
The demonstration of a ternary complex between colicin A, TolA and TolB has been 
used to suggest that colicin A can bind to TolA and TolB simultaneously (Bouveret et 
al 1998).  As the TolA and TolB boxes are reasonably far apart in the colicin A 
translocation domain, this is likely to be the case.  However, recent work showing that 
TolA binds to TolB (Wallburger et al 2002) means that although a ternary complex is 
formed between TolA, TolB and colicin A, the complex may be mediated by the 
interaction between the two Tol proteins, one of which is simultaneously interacting 
with colicin A, rather than the simultaneous interaction of colicin A with TolB and 
TolA.   
Cross-linking has shown that colicin A can also interact with TolA and TolR 
simultaneously (Journet et al 2001).   
5.1.6. Brownian ratcheting 
It has been suggested that colicin translocation could occur by Brownian ratcheting.  
This hypothesis involves the movement of the translocation domain through the 
periplasm by diffusion, with interactions between the translocation domain and Tol 
proteins, preventing the colicin from moving backwards.  Interactions between Tol 
proteins themselves may also drive the colicin through the periplasm (Journet et al 
2001).  No ATP is required for the ratcheting, consistent with the lack of ATP in the 
periplasm.   
If Brownian ratcheting were the mechanism used for colicin translocation, the 
directionality of the translocation is likely to be driven by a series of interactions with 
Tol proteins with increasing affinity.  Due to the association of TolB with the outer 
membrane via Pal, it has been suggested that TolB is the first TolB protein to interact 
with a colicin, on entering the periplasm.  The colicin could then interact with TolA, 
via the TolB-TolA or Pal-TolA interactions.  Finally the colicin would reach TolR, 
via the TolR-TolA interaction.     
This mechanism has been demonstrated for translocation inside the endoplasmic 
reticulum of Prepro-α factor by BiP (Matlack et al 1999).   
5.1.7. Pore formers vs endonucleases 
Their differing mechanisms of cytotoxicity means that pore-forming colicins only 
need to cross the outer membrane and the periplasm to reach the inner membrane and 
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form pores in it, whereas endonuclease colicins need to cross the outer membrane, the 
periplasm and then the inner membrane to access the DNA or RNA in the cytoplasm.  
The different cellular targets therefore suggest the possibility that there may be 
differences between the two types of colicins in how they use the Tol system.  This is 
supported by the observation that although colicin A interacts with TolA, no 
interaction of colicins E9 or E3 with TolA has been detected, indicating that these 
endonuclease colicins may not directly interact with TolA (Bouveret et al 2002).  
Wallburger et al (2002) also suggest that colicin A interacts with a different region of 
TolB than colicin E9.   
The interaction of colicins with TolA in particular, appears to be variable between 
colicins.  For example, two tolA mutations have been isolated which conferred 
tolerance to colicin A but not to colicins E1, E2, E3 and K, indicating that there may 
be more than one mechanism of interaction with TolA (Dubuisson et al 2002).  In 
addition, the regions of colicins N and A predicted to interact with TolA, share no 
significant sequence homology (Raggett et al 1998, Journet et al 2001).   
5.1.8. Aims of chapter 
This chapter uses surface plasmon resonance as a quantitative technique to investigate 
differences between pore-forming colicins and endonuclease colicins in their 
interaction with Tol proteins.  Much of the previous data on the interactions of 
colicins with Tol proteins has been from qualitative experimental techniques such as 
yeast-two hybrid screening and cross-linking studies.  A dataset of affinity constants 
for several different colicins with different Tol proteins is likely to provide valuable 
information on the translocation mechanism(s) of group A colicins.   
Previous chapters of this thesis have been concerned with the interaction between 
TolB and the endonuclease colicins E3 and E9.  The interactions observed here will 
initially be compared to the interaction of the pore-forming colicin A.   
The work is then extended to investigate the interactions of two other Tol proteins, 
TolA and TolR, with colicins A, E3 and E9.  The capacity of SPR to determine 
affinity data for the interactions has been exploited to investigate the validity of the 
Brownian ratcheting model.   
Finally gel filtration and SPR have been used to confirm the interaction between TolB 
and TolA, previously reported by Wallburger et al (2002), and kinetic parameters for 
this interaction have been obtained using SPR.   
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5.2. Results 
5.2.1. Production of Tol proteins 
Full-length TolB protein was prepared as described in earlier chapters.   
The association of TolA and TolR proteins with the membrane presents complications 
for the purification of these proteins.  Therefore, these proteins were purified in 
truncated form, without their membrane-associated domains.   
Mutational analysis, cross-linking and yeast-two hybrid studies have shown that TolA 
interacts with colicins via domain III (Bénédetti et al 1991b, Derouiche et al 1997, 
Wallburger et al 2002).  Previous SPR experiments investigating the interaction 
between TolA and colicins were performed with the isolated domain III of TolA and 
no interaction was detected between TolAII and colicin A (Derouiche et al 1997).  
Therefore, domain III of TolA was isolated and used in these studies.  
In vitro and in vivo studies have indicated that it is domain II of TolR that is involved 
in the interaction with colicins (Journet et al 2001).  Domain I is the only domain of 
TolR associated with the membrane and therefore domains II and III of TolR 
(residues 44-142) have been isolated and used in this study.    
5.2.1.1. TolA domain III 
TolA domain III (TolAIII) encoding DNA was prepared by digesting the plasmid 
pNP163 (Christopher Penfold), a pUC18 based plasmid containing TolA III DNA, 
with XhoI and NdeI restriction enzymes.  The digestion products were run on an 
agarose gel and the TolAIII encoding DNA was purified from the gel.  This DNA was 
then ligated into pET30c, in order to add a his-tag to the N-terminus of the encoded 
protein, and the ligated product was used to transform E.coli DH5α cells.  The 
TolAIII DNA from the purified plasmid pSR12, obtained from the E.coli DH5α cells, 
was sequenced to ensure the cloning had been successful and the plasmid was then 
used to transform E.coli BL21 (DE3) cells.  IPTG was used to express TolAIII in a 
large scale culture of these BL21 cells, with samples taken before and after induction 
and run on a 16% gel to ensure that expression had been successful (see Figure 5.1).  
Cells were harvested by centrifugation, lysed by sonication and the TolAIII protein 
was then purified using nickel affinity chromatography as described in Chapter 2.  
Following dialysis in 50 mM potassium phosphate buffer, pH 7.4, the purified 
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fractions were run on a 16 % SDS-PAGE gel to check the purity of the protein (see 
Figure 5.2).   
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Figure 5.1 16 % SDS-PAGE gel showing crude lysate samples taken from uninduced cells 
and induced cells containing pSR12.  A band of approximately 12 kDa can be seen in the lane 
containing the induced sample, indicating that induction of TolA III protein has been successful.   
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Figure 5.2 16 % SDS-PAGE gel showing purified TolR II&III (10.7 kDa) and TolAIII (12.1 
kDa) proteins 
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5.2.1.2. TolR domains II & III 
Plasmid ET1 (Elena-Stella Theophilou), a pET21a based plasmid containing domains 
II and III of TolR, was used to transform BL21 (DE3) cells.  The expression of the 
TolR II&III protein was induced using IPTG in a large scale culture of these cells.  
The cells were then harvested by centrifugation, lysed by sonication and the TolR 
II&III protein was purified using nickel-affinity chromatography as detailed in 
Chapter 2.  Following dialysis in 50 mM potassium phosphate buffer, pH 7.4, the 
purified fractions were run on a 16 % SDS-PAGE gel to ensure purity of the protein 
(see Figure 5.2).   
5.2.2. Production of colicins 
Full-length colicins E3 and E9 were purified as described in previous chapters.  
Cross-linking and SPR studies investigating the interaction of colicin A with Tol 
proteins mostly use the isolated N-terminal translocation domain of colicin A 
(Derouiche et al 1997, Bouveret et al 1998, Journet et al 2001).   
Therefore, in order to be consistent with previous studies, the isolated N-terminal 172 
residues of colicin A were also used in this study.   
DNA encoding the translocation domain of colicin A was prepared by digestion of the 
pNP200 plasmid (Christopher Penfold), a pUC18-based plasmid containing DNA 
encoding the N-terminal domain of colicin A, with NcoI and XhoI restriction 
enzymes.  The restriction digest was run on an agarose gel to separate the pUC18 
vector from the insert and the colicin A1-172 encoding digested DNA fragment was 
purified from the gel.  The colicin A1-172 DNA fragment was then ligated into 
pET21d, restricted with the same two restriction enzymes, in order to add a his-tag to 
the C-terminus of the protein, and the ligated product was used to transform E.coli 
DH5α cells.  The colicin A encoding fragment of the plasmid purified from these cells 
was first sequenced to ensure the cloning had been successful and was then used to 
transform E.coli BL21 (DE3) cells.  IPTG was used to induce expression of the 
colicin A1-172 protein in a large scale culture of the E.coli BL21 pSR12 cells, with 
samples taken before and after induction and run on an SDS-PAGE gel to ensure 
expression had been successful (see Figure 5.3).  The cells were then harvested by 
centrifugation, lysed and purified using nickel-affinity chromatography as detailed in 
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Chapter 2.  Following dialysis in 50 mM potassium phosphate buffer, pH 7.4, the 
purified protein was run on a gel to ensure purity (see Figure 5.4).   
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Figure 5.3 12% SDS-PAGE gel showing induction of colicin A1-172 protein.  A band of 
approximately 18 kDa can be seen for the induced cells, indicating that induction of colicin A1-172 
has been successful.   
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Figure 5.4 16 % SDS-PAGE gel showing purified colicin A1-172 (17.8 kDa) protein.   
5.2.3. Interactions of colicins A, E3 and E9 with TolB 
The previous two chapters of this thesis have demonstrated that an interaction can be 
detected between TolB and the endonuclease colicins E3 and E9.  The Kd for the 
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interaction between colicin E9 and TolB is 13.8 M in the presence of Im9 and 1.2 
M in the absence of Im9.   
The Kd for the interaction between colicin E3 and TolB is 7.1 M in the presence of 
Im3 and 0.9 M in the absence of Im3.  The same technique described in Chapter 3 
has been used to determine the Kd for binding of colicin A1-172 to TolB.  Injections of 
4 – 20 M colicin A1-172 were injected across the TolB chip and the sensorgrams 
produced were fitted to the Langmuir 1:1 binding model (see Figure 5.5).  The kinetic 
parameters calculated for this fit are shown in Table 5.1.  The linearity of the 
Scatchard plot (see Figure 5.6) and the low Chi squared value indicate that the data fit 
well to the model.   
The Kd for binding of colicin A1-172 to TolB was calculated as 10.5 ± 0.3 M.  
Therefore the affinity of colicin A1-172 is similar to the affinity of colicins E3 and E9 
in the presence of the immunity proteins for TolB.   
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Figure 5.5 Corrected SPR sensorgrams and residual plots for titration of 4 M (magenta), 
8 M (cyan), 10 M (red), 16 M (green) and 20 M (blue) colicin A1-172 against TolB at 25 ºC are 
shown.  The fitted kinetic data for binding are superimposed onto each sensorgram in black.  
Residual plots highlight deviation of the experimental data from the theoretical fit.   
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Table 5.1 Kinetic data obtained from fitting of sensorgrams produced for binding of 
colicin A1-172 to TolB to the Langmuir 1:1 binding model.  Errors for Ka and Kd were calculated 
by combining the standard errors on kass and kdiss in quadrature.   
kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
10100 ± 0.647 0.107 ± 0.00338 94900 ± 2998 10.5 ± 0.3 1.29
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Figure 5.6 Scatchard plot for data for binding of colicin A1-172 to TolB.  An R squared value 
of 0.9 is produced for a linear fit to the data indicating that the data fit well to the 1:1 Langmuir 
binding model.  The estimated Kd for the interaction from this plot is 16.7 M, a similar value to 
that produced for fitting of the data to the Langmuir binding model.   
5.2.4. Interactions of colicins E3, E9 and A with TolA 
Cross-linking studies have previously been used to show that colicin A interacts with 
TolA, but no interaction has been demonstrated between colicins E3 or E9 with TolA 
(Derouiche et al 1997, Bouveret et al 1997, Bouveret et al 2003, Christopher Penfold 
personal communication).  In this study, SPR has been used to investigate the 
interaction between colicins A, E3 and E9 with TolA.   
TolAIII was immobilised to a CM5 sensor chip by amine coupling as described in 
Chapter 2.  The final response produced for immobilisation of TolAIII was 875 RU, 
producing an RUmax for colicin A1-172 of ~ 1280 and an RUmax for colicins E9 and 
E3 of ~ 4500.  2-10 M colicin A1-172, colicin E9 and colicin E3 were injected across 
the sensor chip.  The sensorgrams in Figure 5.7 show that although a clear response 
was recorded on injection of 2 M colicin A, no response was recorded at even the 
highest concentration (10 M) of colicin E9 and E3.  In order to check that the 
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immunity protein was not interfering with the interaction, injections of free colicins 
E3 and E9 were performed, but still no response was recorded.   
Therefore, as expected from previous data (Derouiche et al 1997, Bouveret et al 
1998), this study confirms that colicin A binds to TolAIII.  The lack of binding of 
colicins E3 and E9 to TolAIII in the SPR experiments is consistent with the failure to 
detect an interaction between the T domain of colicin E9 and TolA III using the yeast-
two hybrid technique (Christopher Penfold, personal communication) and the inability 
to cross-link TolA with the translocation domain of colicin E3 in vitro (Bouveret et al 
1997).   
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Figure 5.7 SPR sensorgrams produced on injection of 2 M colicin A1-172, 10 M colicin E9 
and 10 M colicin E3 across TolA immobilised to a CM5 sensor chip.   
 
In order to obtain kinetic data for the interaction between colicin A1-172 and TolAIII, a 
new SPR sensor chip was used to immobilise TolAIII at a lower concentration.  The 
final response due to immobilisation of TolAIII was 61 RU, giving an RUmax for 
colicin A1-172 of 89 RU.  0.5 – 8 M colicin A1-172 was injected across the TolAIII chip 
and the sensorgrams produced were fitted to the Langmuir 1:1 binding model (see 
Figure 5.8).   
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Two previous attempts at measuring kinetic parameters for the interaction between 
colicins indicated that TolAIII on a CM5 sensor chip has heterogeneous binding sites 
(Gokce et al 2000, Derouiche et al 1997).  Therefore, the experiment was repeated in 
the opposite orientation with colicin A1-172 immobilised on the chip.  Injections of 
0.25-3 M TolAIII were performed across this chip.  The sensorgrams produced, 
along with the fit to the Langmuir 1:1 binding model are shown in Figure 5.10.  
Kinetic parameters produced from fitting of the data to the model, for both 
experiments are shown in Table 5.2.  The low Chi squared values and the high T-
values indicate that the data fit the model well.  Scatchard plots of the data also 
indicate a good fit (see Figure 5.9 and Figure 5.11).   
When TolAIII was used as a ligand, the Kd is 0.5 ± 0.008 M and when colicin A1-172 
was used as a ligand the Kd is 0.6 ± 0.002 m.  These values are very similar, giving 
good confidence that the Kd value is close to the true Kd value.   
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Figure 5.8 Corrected SPR sensorgrams and residual plots for titration of 0.5 M (blue), 1 
M (green), 2 M (cyan), 4 M (magenta) and 8 M (red) colicin A1-172 against TolAIII at 25 ºC 
are shown.  The fitted kinetic data for binding are superimposed onto each sensorgram in black.  
Residual plots highlight deviation of the experimental data from the theoretical fit.   
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Figure 5.9 Scatchard plot for data for binding of colicin A1-172 to TolA.  An R squared value 
of 0.97 is produced for a linear fit to the data indicating that the data fit well to the 1:1 Langmuir 
binding model.  The estimated Kd for the interaction from this plot is 0.75 M, a similar value to 
that produced for fitting of the data to the Langmuir 1:1 binding model.    
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Figure 5.10  Corrected SPR sensorgrams and residual plots for titration of 0.25 M 
(blue), 0.5 M (cyan), 1 M (magenta), 2 M (green) and 3 M (red) TolAIII against colicin A1-172 
at 25 ºC are shown.  The fitted kinetic data for binding are superimposed onto each sensorgram 
in black.  Residual plots highlight deviation of the experimental data from the theoretical fit.   
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Figure 5.11 Scatchard plot for data for binding of TolA to colicin A1-172.  An R squared value 
of 0.99 is produced for a linear fit to the data indicating that the data fit well to the 1:1 Langmuir 
binding model.  The estimated Kd for the interaction from this plot is 0.53 M, a similar value to 
that produced for fitting of the data to the Langmuir 1:1 binding model.    
 
Table 5.2 Kinetic data obtained from fitting of sensorgrams produced for binding of 
colicin A1-172 to TolA to the Langmuir 1:1 binding model.  Errors for Ka and Kd were calculated 
by combining the standard errors on kass and kdiss in quadrature.   
Ligand kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
TolAIII 42100 ± 611 0.0209 ± 0.000215 2020000 ± 35754 0.5 ± 0.008 1.44
Colicin A 135000 ± 3060 0.0814 ± 0.000751 1660000 ± 40620 0.603 ± 0.02 1.77
 
 
In order to confirm the lack of interaction between colicin E9 and TolA, a gel 
filtration experiment was performed to search for a colicin E9-TolA complex.   
Colicin E9 was first loaded onto a Superdex 75 gel filtration and the elution volume 
(Ve), shown by monitoring the absorbance at 280nm of the mobile phase, was 
recorded.  This was repeated with TolAIII.  Colicin E9 was then incubated for five 
minutes with equimolar amounts of TolAIII and the mixture was loaded onto the 
column.  The Ve was recorded and compared to the Ve for TolAIII alone and colicin 
E9 alone.  If a complex was formed between TolAIII and colicin E9, the complex 
would be eluted from the column earlier than the two proteins separately, ie the Ve 
would decrease, due to the increased size of the complex compared to the separate 
protein components (see Chapter 2).   
However, Figure 5.12 shows that the absorbance peaks produced for the mixture are 
at the same position as the absorbance peaks produced for each protein separately, 
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demonstrating that the Ve values for the mixture correspond to the Ve values for 
TolAIII and colicin E9, eluting as separate proteins.  This confirms the SPR work, 
indicating that there is no interaction between colicin E9 and TolAIII.   
As a control, gel filtration was performed with TolAIII and colicin A1-172.  Figure 5.13 
shows that when a TolAIII-colicin A1-172 mixture is loaded onto the column, the 
absorbance peak produced shifts to the left, indicating that the mixture elutes earlier 
than the separate proteins ie the Ve is lower for the complex than the separate 
proteins.  This shows that a complex is formed between colicin A1-172 and TolAIII, 
consistent with previous data.   
-5.00
0.00
5.00
10.00
15.00
20.00
25.00
30.00
3.7 4.5 5.3 6.1 6.9 7.7 8.5 9.3 10.1 10.9 11.7 12.5 13.3 14.1
Volume (ml)
Ab
so
rb
a
n
ce
 
(m
AU
) ColE9
ColE9-TolA
TolA
 
Figure 5.12 Gel filtration elution profiles of TolAIII alone, colicin E9 alone and TolAIII-
colicin E9 together.  The overlapping peaks indicate that there is no complex formed between 
TolAIII and colicin E9.   
 201 
-2.00
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
6.00 7.00 7.99 8.99 9.99 10.99 11.99 12.99 13.99 14.99 15.99 16.98 17.98
Volume (ml)
Ab
so
rb
a
n
ce
 
(m
AU
)
TolA
ColA
ColA-TolA
 
Figure 5.13 Gel filtration elution profiles of TolA alone, colicin A1-172 alone and TolA-colicin 
A1-172 together.  The shift in peak position to the left when TolA and colicin A1-172 are run 
together, indicates an increase in size, demonstrating that TolA and colicin A form a complex via 
the translocation domain of colicin A.   
5.2.5. Interactions of colicins E3, E9 and A with TolR 
Cross-linking studies with purified proteins have indicated that colicins A and E3 
interact with TolR (Journet et al 2001).  The sequence homology between the 
translocation domains of colicins E9 and E3 suggests that colicin E9 also interacts 
with TolR.  Therefore the binding of colicin E9 to TolR was investigated using SPR.   
TolR II&III was immobilised to a CM5 sensor chip via amine coupling.  A final 
response due to immobilisation of TolR II&III of 657 was produced giving an RUmax 
for colicin E9/Im9 of 4421 RU.  2 M colicin E9/Im9 was injected across the chip but 
no response was produced.  Therefore increasing concentrations of colicin E9 up to 50 
M were injected, but still no response was recorded.   
In order to check that the TolR II&III protein was intact on the chip, injections of 
varying concentrations of colicin A1-172 were performed.  In this case a response was 
seen (see Figure 5.15).  At 15 M colicin A1-172, the maximum response was 167 ± 2 
RU, only 15 % of the RUmax for colicin A1-172 (1092 RU).  This suggests that the 
interaction is of lower affinity than the previous interactions investigated in this 
thesis.   
In order to check that Im9 was not interfering with the interaction between colicin E9 
and TolR II&III, injections of free colicin E9 were performed but still no response 
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was produced (see Figure 5.14).  Injections of colicin E3/Im3 also produced no 
response.  This result is unexpected, as cross-linking studies had suggested that both 
colicin A
 
and colicin E3 interacted with TolR II&III.   
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Figure 5.14 SPR sensorgrams produced on injection of 10M free colicin E9, colicin E9/Im9, 
colicin E3/Im3 and 2M colicin A1-172 across TolR II&III immobilised on a CM5 sensor chip.   
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Figure 5.15 Sensorgrams produced for injection of 2, 5, 10 and 15 M colicin A1-172 across a 
TolR II&III sensor chip.   
 
To ensure that immobilisation of TolR II&III was not affecting the interaction with 
colicin E9, the above experiment was performed in reverse, with free colicin E9 being 
immobilised on the sensor chip and TolRII&III being used as the analyte.  Figure 5.16 
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shows that no response was produced on injection of 10 M TolRII&III across the 
colicin E9 chip.  TolB was injected across this chip, to check that the colicin E9 
immobilised on the chip was intact.  A response of 280 RU was produced, indicating 
that the colicin E9 translocation domain is intact and able to bind to TolB.   
 
Gel filtration was also used to investigate the interaction between colicins and 
TolRII&III.   Colicin E9 was first loaded onto a Superdex 75 gel filtration and the Ve 
was recorded.  This was repeated with TolRII&III.  Colicin E9 was then incubated for 
five minutes with equimolar amounts of TolRII&III and the mixture was loaded onto 
the column.  The Ve was recorded and compared to the Ve for TolRII&III alone and 
colicin E9 alone.  Figure 5.17 shows that the absorbance peaks produced for the 
mixture are at the same position as the absorbance peaks produced for each protein 
separately, demonstrating that the Ve values for the mixture correspond to the Ve 
values for TolRII&III and colicin E9, eluting as separate proteins.  This supports the 
SPR work, indicating that colicin E9 does not interact with TolRII&III.   
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Figure 5.16 SPR sensorgrams produced on injection of 2 M TolB and 10 M TolR II&III 
across free colicin E9 immobilised on a CM5 sensor chip.   
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Figure 5.17 Gel filtration elution profiles of colicin E9, TolR II&III and a mixture of colicin 
E9/TolR II&III.  The overlapping peaks for the mixture and separate proteins, indicate that 
colicin E9 and TolR II&III do not interact.   
 
As a control, the same gel filtration experiment was performed with colicin A1-172.  
However, Figure 5.18 shows that the peaks produced for the mixture overlap with the 
peaks produced for the individual proteins, suggesting that no complex between 
colicin A1-172 and TolR II&III is being formed.  However, this may be due to the 
apparent low affinity of the interaction suggested by the SPR data.   
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Figure 5.18 Gel filtration elution profiles of colicin A1-172, TolR II&III and a mixture of 
colicin A1-172/TolR II&III.  The overlapping peaks for the mixture and separate proteins, suggest 
that no interaction is occurring between colicin A and TolR II&III.   
 
The low responses produced in the preliminary SPR experiment for the binding of 
TolR II&III to colicin A1-172, meant that no kinetic data could be determined for the 
interaction, as the concentrations of proteins required for the analysis are too high.   
To investigate whether the binding of colicin E9 to TolAIII is dependent on binding 
of the colicin to TolR II&III or vice versa, colicin E9 was pre-incubated with 2 and 10 
M TolR II&III before being injected across a TolAIII chip.  However, pre-
incubation with TolR still produced no response.  Pre-incubation of colicin E9 with 2 
and 10 M TolAIII before being injected across a TolR II&III chip, also produced no 
response.   
5.2.6. Possible competition between TolR and TolB for 
binding to Colicin A  
Journet et al (2001) suggest that the TolR box in colicin A overlaps the TolB box.  
Therefore, it is unlikely that TolR and TolB are able to bind to colicin A at the same 
time, in which case TolR could compete with TolB for binding to colicin A or vice 
versa.  This hypothesis was tested using SPR.   
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Colicin A1-172 (2 or 4 M) was incubated with varying concentrations of TolR II&III 
(2-16 M) before being injected across a TolB chip.  The responses produced were 
compared to the responses produced with injections of 2 and 4 M colicin A1-172, 
without TolR II&III, across the TolB chip.  If colicin A1-172 and TolR II&III interact 
and are still able to bind to TolB, an increased response would be expected compared 
to injection of colicin A1-172 alone, as the TolB-colicin A1-172 complex has a greater 
mass than colicin A1-172 alone.  If colicin A1-172 could not interact with TolB, whilst it 
was interacting with TolRII&III, a decrease in response would be expected compared 
to injection of colicin A1-172 alone.  However, Figure 5.19 shows that there was no 
change in response when TolRII &III was present compared to when TolR II&III was 
absent.  No response was produced on injection of TolR II&III across the TolB chip, 
indicating that TolR II&III does not interact with TolB.  It is therefore possible that 
TolB is displacing TolR II&III for binding of colicin A1-172.  This seems plausible, as 
the affinity for binding of colicin A1-172 to TolB is much higher than the affinity for 
binding of colicin A1-172 to TolR II&III.   
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Figure 5.19 Sensorgrams produced for injection of 2 or 4 M colicin A1-172 alone and pre-
incubated with 4-16 M TolR II&III.   
5.2.7. Interaction between TolA and TolB 
Wallburger et al (2002) showed, by yeast-two hybrid screening, that TolAIII interacts 
with the N-terminal domain of TolB.  This interaction was confirmed by cross-linking 
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experiments on purified proteins.  The biological significance of this interaction was 
shown by disruption of the interaction, which caused a disruption in membrane 
integrity and a tolerance to colicin A.   
Given the significance of the interaction, this study set out to determine kinetic 
parameters for the interaction.  Initially gel filtration was used to confirm the TolAIII-
TolB interaction.  Figure 5.20 shows that when a TolAIII-TolB mixture was loaded 
onto the column, the Ve was decreased compared to the Ve for TolAIII alone and 
TolB alone, confirming that TolAIII and TolB form a complex.  This decrease in Ve 
could only be detected when concentrations of at least 15 M of TolAIII and TolB 
were used.   
SPR was then used to determine kinetic data for the interaction.  Firstly TolB was 
amine coupled to a CM5 sensor chip as described previously.  Concentrations of 
between 5 and 30 M TolAIII were injected across the TolB chip and the sensorgrams 
produced were fitted to the Langmuir 1:1 binding model, shown in Figure 5.21.  Table 
5.3 shows the kinetic parameters calculated from the fit.  The Chi squared value of <2 
and the R squared value of 0.99 for a linear fit to the Scatchard plot (shown in Figure 
5.22), indicate that the data fit the model well.  A Kd for the interaction of 15.8 ± 1.1 
M was calculated.   
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Figure 5.20 Gel filtration elution profiles for TolAIII, TolB and a TolAIII-TolB mixture.  
The shift in peak position to the left for the TolAIII-TolB mixture confirms that a complex is 
formed.   
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Figure 5.21 Corrected SPR sensorgrams and residual plots for titration of 5 M (yellow), 7.5 
M (blue), 10 M (magenta), 15 M (green), 20M (red) and 30 M (cyan) TolAIII against TolB 
at 25 ºC are shown.  The fitted kinetic data for binding are superimposed onto each sensorgram 
in black.  Residual plots highlight deviation of the experimental data from the theoretical fit.   
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Figure 5.22 Scatchard plot for binding of TolAIII as the analyte to TolB on the sensor chip.  
An R squared value of 0.99 is produced for a linear fit to the data indicating that the data fit well 
to the 1:1 Langmuir binding model.  The estimated Kd for the interaction from this plot is 17.5 
M.   
 
The experiment was then repeated in reverse, using TolAIII as the ligand and TolB as 
the analyte.  Concentrations of 2-20 M TolB were injected across the TolAIII chip 
and the sensorgrams produced were fitted to the Langmuir 1:1 binding model (see 
Figure 5.23).  The R squared value of 0.65 for a linear fit to the Scatchard plot of the 
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data, shown in Figure 5.24, suggests that the data do not fit particularly well to the 
model.  However, the low Chi squared value and the high T-values for the calculated 
parameters (see Table 5.3) indicate that the fit is reasonable.  A Kd of 15.3 ± 1.8 M is 
calculated.  This value is satisfyingly similar to the value produced when TolB is the 
ligand, giving good confidence that the calculated Kd is close to the true Kd value.   
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Figure 5.23 Corrected SPR sensorgrams and residual plots for titration of 2 M (magenta), 
5 M (green), 10 M (blue), 15 M (red),  and 20 M (cyan) TolB  against TolAIII at 25 ºC are 
shown.  The fitted kinetic data for binding are superimposed onto each sensorgram in black.  
Residual plots highlight deviation of the experimental data from the theoretical fit.   
y = -0.0577x + 3.7296
R2 = 0.6478
0
0.5
1
1.5
2
2.5
3
3.5
4
0 5 10 15 20 25 30 35
Bound analyte
Bo
u
n
d 
a
n
a
lyt
e
/c
o
n
c.
a
n
a
lyt
e
 
Figure 5.24 Scatchard plot for data for binding of TolB as the analyte to TolAIII on the 
sensor chip.  An R squared value of 0.65 is produced for a linear fit to the data.  This suggests 
that the data do not fit particularly well to the 1:1 Langmuir binding model.  However, the Chi 
squared values and T-values for the data suggest that the fit is good and the interaction has been 
shown to fit the model with TolB on the surface.  The estimated Kd for the interaction from this 
plot is 17.3 M.   
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Table 5.3 Kinetic data obtained from fitting of sensorgrams produced for binding of TolB 
(analyte) to TolAIII (ligand) and for TolAIII (analyte) to TolB (ligand) to the Langmuir 1:1 
binding model.  Errors for Ka and Kd were calculated by combining the standard errors on kass 
and kdiss in quadrature.   
Ligand kass (1/Ms) kdiss (1/s) Ka (1/M) Kd (M) Chi2
TolA 11000 ± 1210 0.169 ± 0.0078 65500 ± 7813 15.3 ± 1.8 1.25
TolB 8270 ± 515 0.131 ± 0.00422 63300 ± 4438 15.8 ± 1.1 1.54
 
5.2.8. TolAIII-TolB-Colicin E9 Ternary complex 
The formation of a ternary complex between colicin A, TolA and TolB has been 
previously demonstrated by overlay Western blotting.  To investigate whether a 
ternary complex is also formed between colicin E9, TolAIII and TolB, gel filtration 
was performed with the T61-DNase colicin E9 fusion protein, TolAIII and TolB. 
TolAIII and TolB had been shown to interact together in gel filtration (see section 
5.2.7).  An interaction between T61-DNase and TolB can also be shown by gel 
filtration (see Figure 5.25).  No interaction between T61-DNase and TolAIII was 
detected, consistent with SPR experiments.   
When a combination of T61-DNase, TolAIII, TolB was loaded onto the column, no 
shift in absorbance peak to the left was seen compared to the peaks from the TolAIII-
TolB complex and the T61DNase-TolB complex, indicating that no ternary complex is 
formed.   
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Figure 5.25 Gel filtration elution profiles of the TolAIII-TolB complex, the TolB-T61DNase 
complex and a T61DNase-TolB-TolAIII mixture.  No shift in absorbance peak to the left is seen 
for the T61DNase-TolB-TolAIII mixture, suggesting that no ternary complex is formed.   
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SPR was then used to investigate whether TolB is still able to bind to TolAIII, whilst 
bound to colicin E9.  TolB was pre-incubated with varying concentrations of colicin 
E9, prior to being injected across a TolAIII sensor chip.  The maximum responses 
produced were compared to the response produced when TolB alone was injected 
across the TolAIII chip to investigate whether the TolB remained bound to colicin E9 
when it bound to TolAIII.   
If TolB remained bound to colicin E9, an increased response would be expected 
compared to the response produced by TolB alone, due to the increased mass of the 
TolB-colicin E9 complex, compared to TolB.  However, Figure 5.26 shows that as the 
concentration of colicin E9 increased, the response produced due to binding of TolB 
to TolAIII decreased.  This suggests that colicin E9 is inhibiting the binding of TolB 
to TolAIII.   
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Figure 5.26 Maximum responses produced when 2 M TolB was injected alone across a 
TolAIII chip, and when TolB was pre-incubated with colicin E9 at 1, 2, 3 and 4 M 
concentrations before being injected across the TolAIII chip.   
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5.3. Discussion 
5.3.1. Interactions between colicins and TolB 
The Kd for binding of colicin A1-172 to TolB was found to be 10.5 ± 0.3 M.  ITC has 
previously been used to determine a Kd for the interaction of full-length colicin A 
with TolB of 10.4 ± 2.6 M.  Therefore the SPR data produced in this study appear to 
correlate very well with the ITC data.   
Table 5.4 shows the Kd values for the binding of colicins A, E3 and E9 to TolB.  The 
values from fitting the data to the Langmuir 1:1 model are similar to the values 
predicted from equilibrium analysis ie a Scatchard plot, giving good confidence in the 
parameters calculated.   
Comparison of the Kd values for binding of the three colicins to TolB shows that the 
affinity of colicin A for TolB is comparable to the affinity of colicins E3 and E9 in the 
presence of their immunity proteins.  The immunity protein for colicin A is situated in 
the inner membrane and therefore the colicin will not be in contact with the immunity 
protein, when it interacts with TolB.  However, it is as yet unknown when the 
immunity protein is lost from endonuclease colicins, on entering a cell, and therefore 
it is unclear as to whether colicins E3 and E9 are in contact with their immunity 
proteins when they interact with TolB.  A mechanism has been proposed for the loss 
of Im3 from colicin E3, in which the binding of the translocation domain to TolB, 
reduces the affinity of Im3 for colicin E3, facilitating dissociation of Im3 from the 
colicin (Walker et al 2003).  This suggests the possibility that initially the immunity 
protein is in contact with the colicin when it interacts with TolB and then the 
immunity protein is lost, increasing the affinity of the colicin for TolB.  As the 
immunity protein is not present in colicin A, it may therefore be expected that the 
affinity of colicin A for TolB is comparable to the affinity of free colicin E9 or E3 for 
TolB.  It would therefore appear that an affinity of a colicin for TolB in the region of 
10 M is sufficient for translocation and that the increase in affinity of free colicin E9 
or E3 for TolB may be part of a mechanism for release of the immunity protein.    
The only difference between the TolB box of colicin A and the TolB box of colicins 
E9 and E3 is that position 37 in colicin E9 is a serine, whereas the equivalent residue 
in colicin A is a threonine.  Chapter 3 describes a reduction on affinity for TolB due to 
mutation of S37 to T in colicin E9.  The Kd for binding of wild-type colicin E9/Im9 to 
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TolB is 13.8 M, whereas the Kd for binding of S37T colicin E9/Im9 to TolB is 24 
M.  Therefore, the reduction in affinity of free colicin A for TolB compared to the 
affinity of free colicin E9 or colicin E3 for TolB could be, at least in part, due to the 
presence of a threonine residue in colicin A, in the place of the serine residue found in 
colicins E3 and E9.   
Table 5.4 Predicted Kd values for binding of colicins A, E9 and E3 to TolB, obtained from 
fitting of sensorgrams to the Langmuir 1:1 binding model and from equilibrium analysis ie a 
Scatchard plot. 
Colicin binding 
to TolB 
Predicted Kd from 
Langmuir fitting (uM) 
Predicted Kd from 
Scatchard plot (uM) 
ColA 10.5  16.7 
ColE9 1.2  1.6 
ColE3 0.9 0.4 
ColE9/Im9 13.8  12.2 
ColE3/Im3 7.1   7.5 
 
5.3.2. Interactions between colicins and TolA 
Consistent with previous cross-linking studies, gel shift assays and SPR (Derouiche et 
al 1997, Bouveret et al 1998), this study has shown by gel filtration and SPR that the 
translocation domain of colicin A interacts with TolAIII.   
However, no interaction of colicins E3 and E9 with TolAIII could be detected by SPR 
or gel filtration.  A potential reason for this is that full-length colicins E9 and E3 were 
used, whereas only the translocation domain of colicin A was used in the experiment.  
Gokce et al (2000) were unable to detect an interaction between the full-length colicin 
A and TolA using ITC and suggested that this may be due to the TolA binding site of 
colicin A being blocked by other regions of the protein in the full-length colicin.  
However, a previous attempt to detect an interaction between the translocation 
domain of colicin E9 and TolAIII using the yeast-two hybrid technique failed 
(Christopher Penfold, personal communication) and it was not possible to cross-link 
TolA with the translocation domain of colicin E3 in vitro (Bouveret et al 1997).  
Therefore the failure to detect an interaction between colicins E3 or E9 and TolA 
using SPR and gel filtration, in combination with evidence from previous 
experiments, suggests that colicins E3 and E9 do not directly interact with TolAIII.  
These endonuclease colicins are, however, dependent on TolA for their translocation, 
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shown by their inactivity against cells containing lesions in the tolA gene (Davies and 
Reeves 1975a).   
Therefore whilst TolA is directly involved in the translocation of Group A pore-
forming colicins, TolA appears to be only indirectly involved in the translocation of 
the endonuclease colicins, perhaps by interacting with another Tol protein, such as 
TolB (see later).   
5.3.2.1. Kinetic analysis of the TolA-colicin A interaction 
Despite previous reports of a poor fit to a simple binding model, when TolAIII is 
immobilised on a CM5 sensor chip, (Gokce et al 2000, Derouiche et al 1997), in this 
SPR study the sensorgrams produced for the binding of colicin A1-172 to TolAIII 
immobilised to a CM5 sensor chip produced a good fit to the Langmuir 1:1 binding 
model, as demonstrated by the low Chi squared value (1.4) and the high R squared 
value (0.97) for a linear fit to the Scatchard plot of the data.   
Derouiche et al (1997) immobilised TolAIII to a CM5 sensor chip by amine coupling.  
Concentrations of the translocation domain of colicin A from 0.2 to 2 M were 
injected across the chip but the sensorgrams produced did not fit to the simple 
Langmuir 1:1 binding model.  The authors used a more complex model, accounting 
for heterogeneity of immobilised ligand sites.  This model produced Kd values for 
binding of the translocation domain of colicin A to TolAIII of 0.2 M and 0.6 M.   
Gokce et al (2000) used SPR to demonstrate an interaction between TolA domains II 
and III and a GST-fusion protein, consisting of GST fused to residues 40-90 of colicin 
N (GSTN40).  When GST was immobilised on a sensor chip via an anti-GST 
antibody, the sensorgrams produced on injection of varying concentrations of TolA 
II/III fitted well to the simple Langmuir 1:1 binding model producing a Kd of 0.94 
M, a kdiss of 0.085 s-1 and a kass of 9 x 104 M s-1.  However, when TolA was 
immobilised to the surface via amine coupling, the sensorgrams produced from 
injection of varying concentrations of GSTN40 across the surface, did not fit to the 
Langmuir 1:1 binding model.  Again, the authors fitted the data to a “two-site 
heterogeneous parallel-reactions model”, and suggested that GSTN40 bound 
independently to two ligand sites.  The authors suggest that immobilisation of TolAIII 
on the CM5 chip produces heterogeneous binding sites.   
In the first case, a large amount of TolAIII is immobilised on the sensor chip, 
producing responses in excess of 700 RU.  With such a high concentration of TolAIII 
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on the chip, it is possible that mass transport effects could affect the kinetics of the 
interaction due to the rate at which the translocation domain of colicin A binds to the 
TolAIII on the surface exceeding the rate at which the colicin is delivered to the 
surface (see Chapter 2).  In the current work, the RUmax for the interaction is kept 
below 100 RU, in order to reduce mass transport effects, which may account for the 
differences in the kinetic parameters.   
In the second case, although the level of TolAIII immobilisation is lower, much 
higher concentrations of the GSTN40 are required than the concentrations of colicin 
A1-172 used in the current study (12.5 – 100 M, compared to 0.5 – 8 M).  This 
indicates that the GST could be affecting the binding of TolA to the translocation 
domain of colicin N.  The GST itself may also interact with the TolAIII, which may 
explain the heterogeneity of the interaction observed.  The calculated Kd values are of 
the order of 1 M, and injections of GSTN40 at concentrations of 10-100 M are very 
high compared to this value.   
Despite the lack of agreement as to which model the interaction fits, this study 
produces a Kd value concurring with the previously calculated values (Gokce et al 
2000, Derouiche et al 1997).   The Kd for the interaction was calculated to be 0.5 M 
in this study.   Derouiche et al (1997) produced values of 0.2 M and 0.6 M whereas 
Gokce et al (2000) produced values of 0.85 M and 0.19 M when TolAIII was 
immobilised and 0.94 M when GSTN40 was immobilised.  The Kd for the 
interaction was confirmed by using colicin A1-172 as the ligand and TolAIII as the 
analyte.  In this case, the Kd was found to be 0.6 M, again a value very similar to all 
the previously determined Kd values for this interaction.  It would therefore appear 
that TolAIII is a suitable ligand, provided the surface concentration of TolAIII and the 
analyte concentrations used are low.   
The Kd for the interaction of colicin A1-172 with TolB (10.5 M) is greater than the Kd 
for the interaction of colicin A1-172 with TolAIII, indicating that the affinity of colicin 
A is greater for TolA than TolB.     
5.3.3. Interactions between colicins and TolR 
In vivo and in vitro cross-linking studies have shown that colicin A interacts with 
TolRII (Journet et al 2001).  In vitro cross-linking also detected an interaction 
between colicin E3 and TolRII (Journet et al 2001) and from the sequence homology 
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between the translocation domains of colicins E3 and E9 it was assumed that colicin 
E9 also interacts with TolR (Bouveret et al 2002).   
This SPR study detected an interaction between colicin A and TolR II&III, as 
expected, but was unable to detect an interaction between colicins E3 or E9 and TolR 
II&III.  Gel filtration experiments did not detect an interaction between TolR II&III 
and colicin A or colicin E9.   
The only previous data suggesting that colicins A and E3 interact with TolR is from 
cross-linking studies.  These studies use millimolar concentrations of protein, rather 
than the micromolar concentrations used in the SPR and gel filtration experiments.  
Journet et al (2001) state that techniques other than formaldehyde cross-linking, 
including yeast-two hybrid screening and spectrofluorometric analysis have been 
unable to detect the TolR-colicin A interaction.  The interaction between colicin A 
and TolR, detected using SPR, was much weaker than the interactions detected 
between colicin A and TolB or TolA with higher concentrations required for a 
reasonable response, and this prevented the completion of kinetic analysis.   These 
observations suggest that the TolR-colicin A interaction could be of millimolar 
affinity rather than the micromolar affinity seen for the interaction of colicin A with 
TolB and TolA.   
The detection of a colicin E3-TolRII interaction using in vitro cross-linking (Journet 
et al 2001) and the failure to detect the interaction using SPR and gel filtration raises 
the possibility that colicin E3 does interact with TolRII&III but with an even lower 
affinity than the interaction between colicin A and TolRII&III.  SPR and gel filtration 
analysis was performed with full-length colicin E3, whereas only the translocation 
domain of colicin A was used.  It is therefore possible that the region involved in 
binding to TolR in colicin E3 is less accessible in the full-length colicin, compared to 
the isolated translocation domain.  In colicin A, the region of the colicin that is 
predicted to interact with TolR overlaps the region predicted to interact with TolB.  If 
this was also the case for colicins E3 or E9, then it is unlikely that the TolR binding 
site is blocked, as the full-length colicins E3 and E9 are able to bind to TolB.  
Therefore, if a part of the full-length colicin E3 does block the TolR binding site, the 
TolR binding site must be in a different region to the TolB binding site.  Removal of 
the immunity protein did not affect the detection of an interaction between colicin E9 
or colicin E3 and TolRII&III, but did affect the affinity of the interaction between 
colicin E9 or colicin E3 and TolB.  This supports the idea that, in contrast to the TolR 
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binding site of colicin A, the TolR binding site for the endonuclease colicins is 
located at a distance from the TolB binding site.   
5.3.4. Competition between TolB and TolR for binding to 
colicin A 
The suggestion that the TolR box in colicin A overlaps the TolB box (Journet et al 
2001) led to the hypothesis that TolR may compete with TolB for binding to colicin 
A.  This was tested by incubating colicin A1-172 with varying concentrations of 
TolRII&III before injecting the colicin across a TolB chip.  As a control, TolRII&III 
was injected across the TolB chip.  There is currently no published information on an 
interaction between TolR and TolB, and no interaction between TolRII&III and TolB 
was detected in this SPR study.   
No change in response was seen, when colicin A was pre-incubated with TolRII&III, 
suggesting that TolB can compete with TolRII&III for binding to colicin A.  This is 
plausible due to the low affinity between colicin A and TolRII&III.  However, the low 
affinity of TolRII&III for colicin A, and hence the rapid dissociation rate constant, 
may mean that when TolB comes into contact with colicin A, TolRII&III has already 
dissociated from the colicin.   
5.3.5. TolA-TolB interaction 
A strong, physiologically relevant, interaction between TolA and TolB was reported 
by Wallburger et al (2002).  SPR has therefore been used to determine kinetic 
parameters for this interaction.   
The interaction between the purified proteins was initially confirmed using gel 
filtration.   Kinetic parameters were then determined for TolAIII binding to 
immobilised TolB and for TolB binding to immobilised TolAIII.  The parameters 
determined for the experiment in which TolB was the ligand, were very similar to 
those determined in the experiment in which TolAIII was the ligand.  The rate 
constants, kass and kdiss, vary slightly but the ratios of kass to kdiss are the same, so that 
the Kd for the interaction in both cases was calculated to be approximately 15 M.   
Therefore, the affinity of TolB for TolA is lower than the affinity of TolB for colicins 
A, E3 or E9.   
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5.3.6. TolA-TolB-colicin ternary complexes 
A ternary complex between colicin A, TolB and TolA has previously been shown by 
a Western blot overlay method (Bouveret et al 1998).  Therefore, gel filtration was 
used in this study to investigate whether a ternary complex is also formed between 
colicin E9, TolB and TolA.  However, no ternary complex could be detected.   
This suggests that the colicin A-TolB-TolA complex is mediated by colicin A and the 
fact that colicin E9 does not bind to TolA means that a ternary complex is unable to 
form.  Alternatively colicin E9 could affect TolB to disrupt the interaction of TolB 
with TolA.  This second hypothesis was tested by investigating the effect of 
incubating TolB with varying concentrations of colicin E9, prior to injection across a 
TolAIII sensor chip.  The presence of colicin E9 appeared to reduce the binding of 
TolB to TolAIII, supporting the possibility that colicin E9 inhibits the TolB-TolA 
interaction.  Although the N-terminal domain of TolB was shown to be sufficient to 
allow interaction with TolA by the yeast-two hybrid technique, the C-terminal domain 
strengthened the interaction.  Therefore, if colicin E9 binds to the C-terminal domain 
of TolB, it may inhibit this strengthening of the interaction, reducing the binding of 
TolB to TolA.   
5.3.7. Differences between pore-formers and endonucleases 
Several differences in the interactions between pore-forming and endonuclease 
colicins have been highlighted in this chapter.   
Firstly, the reduced affinity of the colicin A translocation domain compared to the 
affinity of free colicin E9 and colicin E3, indicates that the interactions of pore-
forming and endonuclease colicins with TolB may differ.  This is consistent with the 
suggestion by Wallburger et al (2001) that colicin A may interact differently with 
TolB than colicin E9.  This was based on the failure to detect an interaction between 
colicin A and the isolated N-terminal or C-terminal domains of TolB, in contrast to 
the detection of an interaction between the C-terminal domain of TolB and colicin E9 
(Carr et al 2000a).  The presence of a threonine residue in the TolB box of colicin A 
in place of a serine residue in the TolB box of colicin E9 may go some way to explain 
these differences.  It would be interesting to investigate whether the affinity of the 
colicin A-TolB interaction could be increased by mutation of residue T13 of colicin A 
to serine.   
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Secondly, the SPR and gel filtration experiments have confirmed the lack of a direct 
interaction between TolA and colicins E9 and E3.  This is in contrast to the direct 
interaction observed for colicin A and TolA.  Interactions between TolA and the pore-
forming colicins E1 and N have been reported (Derouiche et al 1997, Raggett et al 
1998).  Therefore, a difference in the use of TolA for translocation between 
endonuclease colicins and pore-forming colicins is emerging.   
Although an interaction between colicin A and TolR has been confirmed in this study, 
no interaction between colicins E3 and E9 and TolR could be detected.  The 
suggestion that the interaction between colicin A and TolR is transient is supported by 
the SPR and gel filtration results.  It is possible that colicins E3 and E9 also interact 
with TolR but in an even more transient way, suggesting that colicins E3 and E9 
require another factor, possibly another Tol protein to increase the affinity of their 
interaction with TolR.  A ternary complex between TolR, TolA and colicin A has 
been reported (Journet et al 2001) but a similar complex is unlikely to form for 
colicins E3 and E9, as no interaction was detected between these colicins and TolA 
and any interaction between these colicins and TolR is likely to be transient.   
The roles of YbgF, TolQ and Pal have not been considered in this study but are likely 
to be involved, either directly or indirectly, in translocation of endonuclease and/or 
pore-forming colicins.   
5.3.8. Stoichiometry and concentrations of Tol proteins 
With the possible exception of the TolR-colicin A interaction, all the interactions in 
this thesis have been of micromolar affinity.  The calculated affinity constants should 
be qualified by an approximation of the concentrations of the interacting proteins in 
the periplasmic space.  The inhibition or enhancement of interactions by other 
interacting proteins should also be considered.    
The stoichiometry of the Tol system is not well defined, as the expression levels have 
not been simultaneously measured in a given strain.  However, the number of copies 
of each Tol protein per cell has been estimated (see Table 5.5).   
Assuming that the periplasmic space has a volume of 6.5 x 10-17 litres (CyberCell 
Database, Sundararaj et al 2004), the concentrations of Tol proteins can be calculated 
from the estimations of the number of molecules of each protein per cell.   
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[A] [B]
[AB]=
Table 5.5 Concentration of proteins of the Tol system in a typical E.coli cell 
Protein Number of 
molecules per cell 
Reference Concentration 
TolA 800 Levengood et al 1991 20 M 
TolR 2000 - 3000 Muller et al 1993 51 – 76 M 
TolQ 6000 - 9000 Guihard et al 1994 153 – 230 M  
TolB 10000 - 30000 Cascales et al 2000,  
Lloubes et al 2001 
256 – 512 M 
Pal 10000 - 30000 Cascales et al 2000,  
Lloubes et al 2001 
256 – 512 M 
  
Table 5.5 shows that the concentrations of all the proteins of the Tol system are 
estimated to be at least micromolar.  From the definition of Kd for the interaction 
A  + B   AB, 
 
ie  
when the concentration of A equals the Kd, half the binding sites of B will be 
occupied, at equilibrium, in other words if the concentration of Tol proteins is above 
the Kd, more than half the colicin molecules in the cell will be bound to them.     
Therefore the micromolar concentrations of Tol proteins in the cell are consistent with 
the micromolar Kd values calculated for the interactions of these Tol proteins with 
colicins.   
5.3.9. Mechanism of translocation  
5.3.9.1. Colicin A 
Analysis of the affinity of the interactions between colicin A and three Tol proteins, 
has provided further insights into the mechanism of colicin A translocation.  The 
association of TolB with the outer membrane via Pal, suggests that on entering the 
periplasm, the translocation domain of colicin A could first interact with TolB.  The 
association of TolA with TolB and Pal, indicates that colicin A could then interact 
with TolA.  A ternary complex may form between TolA, TolB and colicin A, as 
shown by cross-linking studies (Bouveret et al 1998).  If colicin A first interacts with 
TolB and then TolA, the affinity constants calculated for the colicin A-TolB and 
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colicin A-TolA interactions are consistent with the Brownian ratcheting model, as the 
affinity of colicin A for TolA is greater than the affinity of the colicin for TolB.   
However, if colicin A then interacts with TolR, the low affinity constant for the 
colicin A-TolR interaction is inconsistent with the Brownian ratcheting model, 
although the association of TolR with TolA and the formation of a colicin A-TolA-
TolR ternary complex, may enhance the affinity of the colicin A-TolR interaction.   
5.3.9.2. Colicins E9 and E3 
In contrast to colicin A, the only interaction detected between colicin E3 and E9 with 
a Tol protein, was with TolB.  Although a ternary complex between colicin A, TolA 
and TolB has been reported, no such ternary complex has been reported for an 
endonuclease colicin.  In this study attempts to show an interaction between colicin 
E9, TolA and TolB using gel filtration did not detect a ternary complex, despite the 
detection of a TolA-TolB complex and the colicin E9-TolB complex.   In addition, 
SPR showed that incubation of TolB with colicin E9 prior to injection across a TolA 
chip partially inhibits the TolB-TolA interaction.  The affinity of the interaction 
between colicins E9 and E3 is greater than the interaction of TolB with TolA.  These 
observations suggest the possibility that binding of colicins E9 and E3 to TolB could 
displace the TolB-TolA interaction.  If the interaction between TolB and TolA is 
stabilised by the C-terminal domain of TolB, it is possible that binding of colicin E9 
or E3 to this domain of TolB, could destabilise the interaction.  The disruption of the 
TolB-TolA interaction may interfere with the Tol system stoichiometry, which has 
previously been proposed to cause a change in the cellular envelope, to trigger 
penetration of the cytotoxic domain of the colicin across the outer membrane.  Further 
studies on the precise stoichiometry of the Tol system are required to determine the 
role of the stoichiometry in colicin translocation.   
As colicins E3 and E9 only appear to directly bind to TolB, the mechanism of 
reaching the inner membrane, which they need to cross in order to enter the 
cytoplasm, remains unclear.  TolB has been proposed to act as a shuttle between the 
inner and outer membranes, as binding of colicin E3 prevents TolB from interacting 
with Pal (Clavel et al 1998, Bouveret et al 1999).  Therefore binding of colicins E9 
and E3 to TolB could disrupt the TolB-Pal and TolB-TolA interactions, allowing 
TolB to shuttle the colicin from the outer to the inner membrane.   
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5.4. Summary 
This chapter has provided further insight into the interactions between proteins of the 
Tol system and Group A colicins, and hence into the mechanisms of translocation for 
both endonuclease and pore-forming colicins.   
SPR has been used to confirm the interactions of colicin A with TolR, TolB and 
TolA.  The affinity of colicin A for TolB was shown to be decreased compared to the 
affinity of colicins E9 and E3 for TolB.  This reduction in affinity may be attributed to 
a threonine residue in colicin A in place of a serine residue in colicin E9.  The 
requirement for a higher affinity interaction between colicin E3 and TolB may reflect 
the role of the TolB-colicin E3 interaction in displacing the immunity protein from the 
colicin.  SPR was used to show that the affinity of colicin A for TolA is higher than 
the affinity of colicin A for TolB.   The transient nature of the interaction between 
colicin A and TolR was also confirmed by SPR.   
The demonstration that colicin A interacts with TolB and TolA with increasing 
affinity, supports the Brownian ratcheting model for colicin translocation.  A ternary 
complex between TolB, TolA and colicin A may increase the binding affinity further.  
However, if colicin A then interacts with TolR, the interaction must be stabilised by 
another factor in order to increase the affinity.  A ternary complex between colicin A, 
TolA and TolR may provide this extra stabilisation.   
Although colicins E3 and E9 were shown to interact with TolB with micromolar 
affinity, no interaction between these colicins and TolA was detected.  In addition, in 
contrast to previous cross-linking evidence, no interaction could be detected between 
colicins E9 or E3 and TolR.  This indicates that if colicins E9 and E3 do interact with 
TolR, the interaction is particularly transient and may require stabilisation by another 
Tol protein.  In contrast to colicin A, no ternary complex could be detected between 
colicin E9, TolB and TolA, suggesting that there is a difference in the translocation 
mechanism between pore-forming and endonuclease colicins.  It is proposed that 
binding of colicin E9 to the C-terminal domain of TolB could destabilise the TolA-
TolB interaction and the TolB-Pal interaction, allowing the cytotoxic domain to 
penetrate the inner membrane and shuttling of the colicin or from the outer membrane 
to the inner membrane by TolB.    
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6. CHAPTER 6 – General Discussion 
6.1. Introduction 
Colicins are multi-domain proteins, which exhibit several fundamental biological 
properties and they have therefore been exploited in several ways to address 
fundamental biological questions.  The mechanism by which colicins kill cells is a 
rare example of uptake of polypeptides into bacterial cells.  Colicins initially bind to 
at least one outer membrane receptor.  The translocation domain of the colicin then 
traverses the outer membrane and the periplasm, a process which allows translocation 
of the cytotoxic domain across the outer membrane and, for endonuclease colicins, the 
inner membrane.  The mechanisms used for entry of colicins into cells, share 
similarities with the mechanisms used by the cell for uptake of essential metabolites.  
Therefore a detailed understanding of this process has potential for delivery of 
recombinant polypeptides into bacterial cells and for development of new antibiotics.   
Colicins are also emerging as an interesting example of a protein with an intrinsically 
disordered region ie the N-terminus of the translocation domain, which is functionally 
important and which adopts a folded structure upon binding to its biological target.   
In addition, the combination of high binding affinities between a colicin and its 
cognate immunity protein, together with the relatively low affinities between the 
colicin and non-cognate immunity proteins, makes it an attractive system for 
investigating molecular recognition events between proteins.   
 
The work presented in this thesis has focussed on the process of translocation of 
Group A colicins across the periplasm, which requires interactions between the 
translocation domain of the colicin with the periplasmic and membrane-bound 
proteins of the Tol system.  Although there is now a substantial amount of published 
information about the translocation process, a number of important details remain 
unresolved.   
One of the best characterised interactions involved in colicin translocation is the 
interaction between endonuclease colicins, particularly colicin E9, and TolB.  
However, several issues regarding this interaction remained unresolved such as the 
region of TolB involved in the interaction with colicins, the possibility that an 
extended region of colicin E9 could be involved in the interaction with TolB and the 
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suggestion that binding of the translocation domain to colicin E9 could induce 
structure in this disordered region of the colicin.  This thesis set out to further 
characterise the interaction of colicin E9 with TolB, in an attempt to resolve some of 
these issues.      
 
There have now been a number of studies on the interactions of several colicins with 
various Tol proteins and it is tempting to apply information obtained for one colicin to 
another colicin.  However, recent evidence suggests that different Group A colicins, 
may use the Tol system in different ways in order to access their site of cytotoxic 
action. There is currently a lack of quantitative analysis of interactions of Tol proteins 
with endonuclease and pore-forming colicins, measured under the same experimental 
conditions.  Therefore this thesis has investigated differences in the interactions with 
Tol proteins between the Group A pore-forming colicin A and the endonuclease 
colicins E9 and E3.   
6.2. TolB  
Yeast-two hybrid experiments and mutagenesis experiments identified a pentapeptide 
sequence, DGSGW, from residues 35-39 of colicin E9 that interacts with TolB (Carr 
et al 2000a, Garinot-Schneider et al 1997).  By sequence homology and mutagenesis 
experiments, the same sequence in colicin E3 had also been shown to interact with 
TolB (Bouveret et al 1997).  An interaction between colicin A and TolB has also been 
demonstrated using in vitro cross-linking with residues 11-20 of colicin A predicted to 
be involved in the interaction (Bouveret et al 1998).   
6.2.1. Roles of residues of the established TolB box 
Chapter 3 of this thesis confirms that residues D35, S37 and W39 of colicin E9, and, 
by homology, of colicin E3, are crucial for the interaction with TolB.  Revertant 
mutations of these three essential residues showed that at least one other residue could 
be tolerated in these positions without substantial loss of activity or loss of TolB 
binding.  The chemical nature of the tolerated residues suggests that the roles of 
residues at positions 35, 37 and 39 differ.  It is speculated that residue D35 is involved 
in hydrogen bonding with another residue in colicin E9 or a residue in TolB.  Residue 
S37 may be involved in maintaining local structure of the TolB box and residue W39 
may form stacking interactions with aromatic residues in TolB.   
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In addition to these three essential residues, this study has shown for the first time that 
G36 and G38 also play a role in binding of colicin E9 to TolB.  It is suggested that 
these glycine residues may be important in maintaining flexibility of the TolB box 
and it would be interesting to investigate the role of other glycine residues in the 
glycine-rich translocation domain.   
6.2.2. Extension of the TolB box 
Consistent with previous evidence, including NMR data and mutagenesis studies 
(Collins et al 2002, Holland 2003), the region of colicin E9 involved in interacting 
with TolB has been shown in this study to be larger than the previously identified 
pentapeptide sequence.  Mutation of residues S34, S40, S41, E42 and N43 abolish 
activity and significantly reduce binding of colicin E9 to TolB.  Therefore the TolB 
box extends at least from residue S34 to N43.  Further mutagenesis is required to 
investigate whether the TolB box extends further upstream of residue S34 and further 
downstream of residue N43, although residue N44 appears not to be involved in the 
interaction with TolB and may therefore form the C-terminal boundary of the TolB 
box.  Residues 34 – 42 are conserved in all endonuclease colicins, suggesting that the 
TolB box defined for colicin E9 is also applicable to other endonuclease colicins.  
6.2.3. Differences between pore-forming and endonuclease 
colicins in interacting with TolB 
Residues 35-42 of colicin E9 are also conserved in colicin A, with the exception of a 
threonine residue in colicin A, in place of a serine residue at position 37 in colicin E9.  
Mutation of residue S37 to a threonine residue in colicin E9, has been shown in this 
study to significantly reduce binding of colicin E9 to TolB.  The affinity of colicin A 
for TolB is lower than the affinity of endonuclease colicins for TolB, suggesting that 
the presence of the threonine residue in colicin A could be at least partially 
responsible for the reduction in affinity of colicin A for TolB, compared to the affinity 
of colicin E9 for TolB.  Colicin K also contains a threonine residue at this position of 
the TolB box and it would be interesting to compare the affinity of colicin K for TolB 
to the affinities of colicins A, E3 and E9 for TolB.   
However, the presence of an alanine residue at the fifth position of the TolB box of 
colicin K, instead of a tryptophan residue in colicin E9, indicates that this colicin may 
interact differently with TolB than colicin E9, as mutation of the tryptophan residue to 
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alanine in colicin E9 has been shown previously, by yeast-two hybrid studies, and in 
this study, by SPR, to abolish binding of colicin E9 to TolB.  Residues S34, S40, S41 
and E42 of colicin E9, which are proposed to also be involved in the interaction with 
TolB, are conserved in other colicins known to interact with TolB, such as colicins 
E2, E3, E6, E7, colicin A and colicin U but are not conserved in colicin K, providing 
further evidence that the interaction between colicin K and TolB is different to the 
interaction between other TolB-dependent colicins with TolB.   
Colicins A and K are pore-forming colicins, indicating that the proposed difference in 
the interactions of colicin K with TolB and colicin A with TolB are not due to a 
difference in cytotoxic target.   
The increased affinity of endonuclease colicins for TolB compared to the affinity of 
pore-forming colicins for TolB may reflect a crucial role of TolB in allowing the 
cytotoxic domain of endonuclease colicins to cross the cytoplasmic membrane.  This 
increased affinity for TolB would not be required for pore-forming colicins, as they 
could firstly bind to TolB and then to TolA, releasing TolB.   
6.3. TolA 
This study has confirmed the interaction between colicin A and domain III of TolA, 
and determined a Kd for the interaction of 0.5 M, a value very similar to the values 
determined in previous studies.  The data presented here also supports evidence from 
yeast-two hybrid and cross-linking experiments that colicins E9 and E3 do not 
directly interact with TolA.  This suggests a possible difference between pore-forming 
colicins and endonuclease colicins in their use of the Tol system.   
6.4. TolR 
The interaction between colicin A and TolR has also been confirmed in this study.  
However, the interaction was the weakest interaction measured for colicin A with a 
Tol protein.   
Despite a previous cross-linking study that suggested colicin E3 interacted with TolR, 
no interaction of colicin E3 with TolR could be detected by gel filtration or SPR 
(Journet et al 2001).  These results suggest that the interaction of colicins with TolR is 
transient.  High concentrations, ie millimolar concentrations, used in in vitro cross-
linking studies, of colicin E3 or TolR may be required to detect an interaction 
between colicin E3, and by homology colicin E9, with TolR.  This suggests that in 
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vivo, TolR may be recruited at a specific site, to increase the apparent local 
concentration of TolR.  This may be achieved by binding of colicin A to TolA, and 
binding of TolA to TolR, consistent with the detection of a TolA-TolR-colicin A 
ternary complex (Journet et al 2001).    
6.5. Mechanisms of translocation 
6.5.1. Colicins E9 and E3 
The only interaction between colicin E9 and the Tol system that has been detected in 
this study and previous studies is the interaction with TolB.  However, despite the 
lack of a direct interaction between colicins E9 or E3 with TolA or TolR, these Tol 
proteins are still required for translocation of these colicins.  This suggests that 
binding of colicin E9 to TolB triggers a set of events, involving interactions between 
Tol proteins that allows translocation of colicin E9 across the periplasm.  It has been 
suggested that intermittent contact of TolB with Pal could allow TolB to act as a 
shuttle between the outer and inner membranes.  The region of TolB, involved in 
binding Pal has been localised to the β-propeller domain (Ray et al 2000, Abergel et 
al 1999).  The same domain of TolB is proposed to be involved in interacting with 
colicin E9 (Carr et al 2000a), and the binding of colicin E3 to TolB has been shown to 
prevent the interaction of TolB with Pal (Bouveret et al 1997) suggesting the 
possibility that binding of colicin E9 to TolB, disrupts the TolB-Pal interaction, 
allowing the colicin E9-TolB complex to move across the periplasm towards the inner 
membrane.   
 
This study has also confirmed the interaction between TolA and TolB and has 
provided kinetic parameters for the interaction.  The Kd for the interaction was 
determined as 15 M, indicating that the affinity of TolB for TolA is lower than the 
affinity of TolB for colicins.   
Although a ternary complex for colicin A, TolB and TolA has been reported, no such 
complex has been reported for colicin E9, and attempts to detect a colicin E9-TolB-
TolA complex in this study, using gel filtration, failed.  The binding of colicin E9 to 
TolB, was also shown to inhibit the TolB-TolA interaction.  These observations have 
lead to the proposal that binding of colicin E9 or E3 to TolB could displace the TolB-
TolA interaction, altering the stoichiometry of the Tol/Pal complex and possibly 
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disrupting the outer membrane integrity, to allow penetration of the cytotoxic domain 
of the colicin.   
6.5.1.1. Immunity proteins for endonuclease colicins 
An unexpected reduction in binding of colicins E9 and E3 to TolB, caused by the 
immunity protein, has been demonstrated by SPR and AFM.   
The immunity protein of endonuclease colicins must be lost during entrance of the 
colicin to a susceptible cell, to allow the C-terminal domain to exert its cytotoxic 
action.  However, the affinity of the immunity protein for the colicin is one of the 
highest ever measured and there is little information available as to how this high 
affinity interaction may be overcome to allow loss of the immunity protein.   
The immunity protein of colicin E3 has been shown to interact with the cytotoxic 
domain and the translocation domain by thermodynamic and structural analysis 
(Walker et al 2003, Soelaiman et al 2001).  With the contacts that Im3 makes with the 
translocation domain of colicin E3, an effect of Im3 on this domain to reduce binding 
of the colicin to TolB is conceivable.  It has been suggested that the binding of the 
translocation domain of colicin E3 to TolB, could allow dissociation of Im3 from the 
translocation domain, reducing the affinity of Im3 for the colicin and promoting 
dissociation of the immunity protein (Walker et al 2003).  The increase in affinity of 
colicin E3 for TolB, when the immunity protein is removed, is consistent with this 
hypothesis.   
However, it has been suggested that the immunity protein of colicin E9 only interacts 
with the cytotoxic domain of the colicin, and, if contacts did occur between the 
immunity protein and the translocation domain, they must be energetically neutral 
(Walker et al 2003).  Therefore the effect of the immunity protein on the translocation 
domain of colicin E9, reducing binding of the colicin to TolB, is more puzzling.  It is 
suggested, that rather than directly contacting the translocation domain of colicin, Im9 
may sterically hinder the translocation domain, partially inhibiting the binding of 
colicin E9 to TolB.   
Structures of colicin E9 in complex with Im9 and colicin E3 and E9 in the absence of 
their respective immunity proteins and an in vivo assay to confirm the stage at which 
the immunity protein is lost, would allow a more detailed understanding of the effect 
of immunity proteins on the translocation domains of endonuclease colicins and on 
their binding to Tol proteins.     
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6.5.2. Colicin A 
It has been proposed that colicin A translocation could occur via Brownian ratcheting.  
This mechanism requires each interaction between the colicin and a Tol protein, to be 
of a higher affinity than the previous interaction, to prevent the colicin from moving 
backwards.  This study has shown that the affinity of the interaction between colicin 
A and TolB is lower than the affinity of the interaction between colicin A and TolA, 
consistent with the ratcheting model, assuming that colicin A first interacts with TolB, 
associated with the outer membrane, and then TolA.  This assumption was based on 
the localisation of TolB to the outer membrane via its interaction with Pal.  However, 
it has recently been shown that TolA also interacts with Pal (Cascales et al 2000), 
indicating that the C-terminus of TolA is also linked to the outer membrane.  The 
binding of colicin A to TolAIII has been shown to cause an increase in flexibility of 
this domain, possibly disrupting the TolA-Pal interaction, affecting the integrity of the 
outer membrane and allowing the cytotoxic domain to traverse the outer membrane.   
The demonstration in this study that the colicin A-TolR interaction is of low affinity, 
is, ostensibly, inconsistent with the ratcheting model.  However, the suggestion that 
colicins interact with one protein at a time is likely to be an over-simplification of the 
in vivo situation.  The identification of a TolA-TolB-colicin A ternary complex and a 
TolA-TolR-colicin A ternary complex, suggests that the colicin recruits a Tol protein 
and then interactions between different Tol proteins occur, facilitating another 
interaction of the colicin with a different Tol protein and, in effect, pulling the colicin 
across the periplasm.   
6.6. Comparison of translocation mechanisms 
A summary of the proposed mechanisms for translocation of endonuclease and pore-
forming colicins is shown in Figure 6.1 and Figure 6.2.   
The two major requirements for colicin translocation are translocation of the cytotoxic 
domain across the outer membrane and movement of the colicin across the periplasm.  
The proposed systems that endonuclease and pore-forming colicins use in order to 
fulfil these requirements are given below.     
1. Translocation of the cytotoxic domain across the outer membrane  
For colicin A, it is proposed that this occurs by the interaction of the colicin with 
TolA, which disrupts the TolA-Pal interaction, disrupting the integrity of the outer 
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membrane.  For colicin E9/E3, it is proposed that binding of the colicin to TolB 
disrupts the TolB-TolA and the TolB-Pal interactions, again causing a disruption of 
the outer membrane.   
2. Transport of the translocation and cytotoxic domains across the periplasm.   
For colicin E9 and E3 it is proposed that TolB, initially tethered to the outer 
membrane via its interaction with Pal, shuttles the colicin from the outer membrane to 
the inner membrane due to disruption of the Pal-TolB interaction on binding of the 
colicin to TolB.  For colicin A, it is proposed that colicin A binds to TolB and then 
forms a complex with TolB and TolA.  The association of TolA with TolR via domain 
III of TolR, then allows an interaction between colicin A and domain II of TolR, 
effectively pulling the colicin towards the inner membrane.     
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C
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TolB box TolB box
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Im Im
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1. Receptor binding domain 
binds to BtuB, allowing the 
translocation domain to thread 
through OmpF into the 
periplasm.  
2. Binding of the TolB box to TolB 
causes the loss of TolB-Pal and 
TolB-TolA interactions and also 
dissociation of the immunity protein 
(Im) from the translocation domain.
3. Loss of TolB-Pal and TolB-TolA
interactions causes disruption of outer 
membrane, allowing the cytotoxic domain to 
traverse the outer membrane and causing 
the loss of the immunity protein from the 
cytotoxic domain, increasing the affinity of 
the colicin for TolB.
14 M 1 M
 
Figure 6.1 Suggested mechanism for translocation of endonuclease colicins.   
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4.  Disruption of the TolA-Pal interaction 
causes disruption of the outer membrane, 
allowing the cytotoxic domain to traverse the 
outer membrane.  The colicin dissociates from 
TolB and binds to TolR, pulling the colicin 
across the periplasm.
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TolB.  This disrupts the TolA-Pal 
interaction.  
 
Figure 6.2 Proposed mechanism for translocation of pore-forming colicins. 
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6.7. Future directions 
The models proposed above are still incomplete and further work is required to 
modify and validate the models.   
Although it is useful to obtain affinity constants for the interactions between colicins 
and Tol proteins, it is, in general, likely to be too simplistic to consider individual 
interactions between a single Tol protein and the colicin.  Rather, a situation in which 
interactions between a colicin and a Tol protein promote varying and transient 
interactions between different protein partners.  Information on the stoichiometry of 
the Tol system in the presence and absence of colicins may prove invaluable in 
understanding how colicins use the Tol system for translocation.  Further information 
on the cellular role of the Tol/Pal system may also provide clues as to why colicins 
have parasitized the system for purposes of translocation and hence clarify the role of 
the Tol proteins in colicin translocation.    
The proposal that at least part of the translocation domain is unfolded to allow it to 
enter the periplasm via OmpF (Kurisu et al 2003) together with the possibility that 
partial folding occurs on binding of the translocation domain to TolB and TolA 
(Collins et al 2002, Anderluh et al 2003, 2004), suggests that the colicin may be in 
different states of folding, when it interacts with each Tol protein.  This may help 
direct the colicin through the periplasm.  NMR studies on the conformation of colicins 
in complex with varying Tol proteins may provide further information on the role that 
different conformations of the colicin play in the translocation process.    In vivo 
localisation of TolB in the presence and absence of colicin, using confocal 
microscopy for example, may help to verify whether TolB can act as a shuttle, to 
transport endonuclease colicins from the outer to the inner membrane.   
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